PART II

POLICIES AND PROCEDURES

for

EARLY AND PERIODIC SCREENING,
DIAGNOSTIC AND TREATMENT (EPSDT)
SERVICES – Health Check Program (COS 600)

GEORGIA DEPARTMENT OF COMMUNITY HEALTH

DIVISION OF MEDICAID

Revised: October 1, 2019
## Policy Revisions Record

**Part II Policies and Procedures Manual for EPSDT Services (Health Check)**

2019

<table>
<thead>
<tr>
<th>REVISION DATE</th>
<th>SECTION &amp; PAGE</th>
<th>REVISION DESCRIPTION</th>
<th>REVISION TYPE</th>
<th>CITATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/2019</td>
<td>902.2, E.4., p. IX-14</td>
<td>4. Tobacco, Alcohol, or Drug Use Assessment – updated hyperlink to access CRAFFT screening tool</td>
<td>M</td>
<td>DCH</td>
</tr>
<tr>
<td>10/2019</td>
<td>902.2, G.5., p. IX-20</td>
<td>5. Tuberculin Risk Assessment and Test – updated hyperlinks to access info o DPH TB and forms</td>
<td>M</td>
<td>DCH/DPH</td>
</tr>
<tr>
<td>10/2019</td>
<td>908, p. IX-44</td>
<td>Oral Health and Dental Services - Added guidance - Periodicity of Examination, Preventive Dental Services, Anticiptory Guidance/Counseling, and Oral Treatment for Infants, Children, and Adolescents</td>
<td>A</td>
<td>DCH</td>
</tr>
<tr>
<td>10/2019</td>
<td>908, p. IX-45</td>
<td>Oral Health and Dental Services - Replaced the Recommendations for Pediatric Oral Health Assessment, Preventive Services, and Anticipatory Guidance/Counseling</td>
<td>M</td>
<td>DCH</td>
</tr>
<tr>
<td>10/2019</td>
<td>Appendix A, p. A-2</td>
<td>“Lead Screening Requirements and Medical Management Recommendations for Children” – Updated table to reflect blood lead level of 5 µg/dL or greater requires further testing and monitoring.</td>
<td>M</td>
<td>DPH</td>
</tr>
</tbody>
</table>
# Policy Revisions Record

**Part II Policies and Procedures Manual for EPSDT Services (Health Check)**

**2019**

<table>
<thead>
<tr>
<th>REVISION DATE</th>
<th>SECTION &amp; PAGE</th>
<th>REVISION DESCRIPTION</th>
<th>REVISION TYPE</th>
<th>CITATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/2019</td>
<td>Appendix A, p. A-15 - A-18</td>
<td>Georgia Childhood Lead Poisoning Prevention Program Case Management Guidelines - updated guidelines to reflect blood lead level of 5 µg/dL or greater requires further testing and monitoring. - updated Regional Lead Coordinator (RLC) title to Regional Healthy Homes Coordinator (RHHC) - removed the specific number of coordinators.</td>
<td>M</td>
<td>DPH</td>
</tr>
<tr>
<td>10/2019</td>
<td>Appendix A, p. A-19</td>
<td>Georgia Public Health Laboratory (GPHL) - updated locations, removed Albany location</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10/2019</td>
<td>Appendix C-4 p. C-10, C-11</td>
<td>Blood Lead Level Testing Procedure Codes - Clarifications to billing guidance</td>
<td>M</td>
<td>DCH</td>
</tr>
<tr>
<td>REVISION DATE</td>
<td>SECTION &amp; PAGE</td>
<td>REVISION DESCRIPTION</td>
<td>REVISION TYPE</td>
<td>CITATION</td>
</tr>
<tr>
<td>---------------</td>
<td>----------------</td>
<td>---------------------</td>
<td>---------------</td>
<td>----------</td>
</tr>
</tbody>
</table>
| 07/2019       | Appendix C-1 p. C-3 | ICD 10 diagnosis code Z23.0 was added as a reportable diagnosis with the applicable vaccine administration code.  
- May report diagnosis code Z00.121 or Z00.129 or Z23.0 with each of the vaccine administration codes ONLY when vaccines are administered during EPSDT preventive health visits for members through age 17 years.  
- May report diagnosis code Z00.00 or Z00.01 or Z23.0 with the applicable vaccine administration code ONLY when vaccines are administered during EPSDT preventive health visits for members age 15 years through 20 years | A | DCH |
**Revised description:** Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier, (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use | M | American Medical Association (AMA) – Jan. 1, 2019 released to AMA website Eff. July 1, 2019 Updated 12/19/18 CPT – Publication CPT® 2020 |
# Policy Revisions Record

## Part II Policies and Procedures Manual for EPSDT Services (Health Check)

### 2019

<table>
<thead>
<tr>
<th>REVISION DATE</th>
<th>SECTION &amp; PAGE</th>
<th>REVISION DESCRIPTION</th>
<th>REVISION TYPE</th>
<th>CITATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>04/2019</td>
<td>902, p. IX-1</td>
<td>Notification – effective July 1, 2019 DCH will adopt the updated 2019 AAP Bright Futures Periodicity Schedule</td>
<td>M</td>
<td>AAP/ BF</td>
</tr>
<tr>
<td>04/2019</td>
<td>905, p. IX-37-41</td>
<td>2019 CDC Immunization Schedules posted</td>
<td>A</td>
<td>CDC/ACIP</td>
</tr>
<tr>
<td>04/2019</td>
<td>1003, p. X-3-6 #6-10</td>
<td>Clarifications – (1) the appropriate ICD-10 diagnosis code may be either preventive or non-preventive; (2) the examples of the ICD-10 diagnosis codes listed are preventive</td>
<td>M</td>
<td>DCH</td>
</tr>
<tr>
<td>04/2019</td>
<td>Appendix Q</td>
<td>2019 AAP Bright Futures Periodicity Schedule - summary of changes</td>
<td>A</td>
<td>AAP/ BF</td>
</tr>
<tr>
<td>04/2019</td>
<td>Appendix T</td>
<td>2019 CDC Immunization Schedules – summary of changes</td>
<td>A</td>
<td>CDC/ACIP</td>
</tr>
<tr>
<td>01/2019</td>
<td>Appendix C-2</td>
<td>90713 – added Poliovirus (IPV) added for high risk members, ages 19-20 yrs</td>
<td>A</td>
<td>DCH</td>
</tr>
<tr>
<td>01/2019</td>
<td>Appendix C-2</td>
<td>90630 – removed Influenza virus vaccine, quadrivalent (IIV4), no preservative, for intradermal use</td>
<td>D</td>
<td>CDC/DCH</td>
</tr>
<tr>
<td>01/2019</td>
<td>Appendix C-2</td>
<td>90672 - added Influenza virus vaccine (FluMist), quadrivalent, live (LAIV4), for intranasal use (&gt;2 years)</td>
<td>A</td>
<td>CDC</td>
</tr>
<tr>
<td>01/2019</td>
<td>Appendix</td>
<td>Performance Measures Appendix – removed</td>
<td>D</td>
<td>DCH</td>
</tr>
</tbody>
</table>
CONTENTS

INTRODUCTION
The Early and Periodic Screening Components of EPSDT
The Diagnostic and Treatment Components of EPSDT
The Medically Fragile Child

CHAPTER 600 SPECIAL CONDITIONS OF PARTICIPATION................................. VI
601 Enrollment
602 Special Conditions of Participation

CHAPTER 700 SPECIAL ELIGIBILITY CONDITIONS ........................................ VII

CHAPTER 800 PRIOR APPROVAL/AUTHORIZATION........................................... VIII

CHAPTER 900 SCOPE OF SERVICES ................................................................. IX
901 General
902 AAP Periodicity Schedule and
   Minimum Standards for Screening Components
903 Required Equipment and Required Location Where Services are to be Provided
904 Periodic, Catch-Up and Interperiodic Screening
905 Immunizations
906 Diagnosis, Treatment, and Referral
907 Lead Risk Assessment and Screening
908 Oral Health and Dental Services
909 Other Related Medicaid Programs
910 Summary of Non-Covered Services
911 Health Check Profile (Appointment Tracking System)
912 EPSDT HIPAA Referral Codes
913 Access to Mental Health Services
914 Services for Foster Care Children

CHAPTER 1000 BASIS FOR REIMBURSEMENT............................................... X
1001 Fee For Service Reimbursement Methodology
1002 Vaccine for Children
1003 Billing Tips
APPENDIX A  Guidelines in Screening and Reporting Elevated Blood Lead Levels

APPENDIX B  Guidelines in Screening and Reporting TB Disease and Infection

APPENDIX C-1  Vaccine Administration Codes
APPENDIX C-2  Vaccine Procedure and Diagnosis Codes
APPENDIX C-3  TB Skin Test Procedure Codes
APPENDIX C-4  Blood Lead Level Testing Procedure Codes

APPENDIX D  Children’s Intervention Services

APPENDIX E  Medicaid Non-Emergency Transportation

APPENDIX F  Childhood Obesity – Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents

APPENDIX G  Health Check Required Equipment Form

APPENDIX H  Georgia Families

APPENDIX I  Georgia Families 360°

APPENDIX J  Preventive Oral Health: Fluoride Varnish

APPENDIX K  EPSDT HIPAA Referral Code Examples

APPENDIX L  Health Insurance Claim Form (CMS-1500)

APPENDIX M  Resources for Children in Georgia

APPENDIX N  General Claims Submission Policy for Ordering, Prescribing, or Referring (OPR) Providers

APPENDIX O  Screening Tools

APPENDIX P  2016-2018 Policy Revisions Record

APPENDIX Q  2019 AAP Bright Futures Periodicity Schedule – summary of changes

APPENDIX R  2017 AAP Bright Futures Periodicity Schedule- summary of changes

APPENDIX S  2018 CDC Immunization Schedules – summary of changes

APPENDIX T  2019 CDC Immunization Schedules – summary of changes
INTRODUCTION
The Early and Periodic Screening, Diagnostic, and Treatment (EPSDT) benefit includes a comprehensive array of preventive, diagnostic, and treatment services for Medicaid eligible infants, children and adolescents under age 21, as specified in Section 1905(r) of the Social Security Act (the Act). The EPSDT benefit is also available to PeachCare for Kids® members up to 19 years of age. The EPSDT benefit is designed to assure that children receive early detection and care, so that health problems are averted or diagnosed and treated as early as possible. The goal of the EPSDT benefit is to assure that individual children get the health care they need when they need it. The EPSDT benefit also covers medically necessary diagnostic services. When a screening examination indicates the need for further evaluation of a child’s health, the child should be appropriately referred for diagnosis without delay. States are required to arrange for and cover under the EPSDT benefit any Medicaid covered service listed in Section 1905(a) of the Act if that treatment or service is determined to be medically necessary to correct or ameliorate defects and physical and mental illnesses or conditions. This includes physician, nurse practitioner and hospital services; physical, speech/language, and occupational therapies; home health services, including medical equipment, supplies, and appliances; treatment for mental health and substance use disorders; treatment for vision, hearing and dental diseases and disorders, and much more. This broad coverage requirement results in a comprehensive, high-quality health benefit for children under age 21 enrolled in Medicaid.

The Health Check Program provides reimbursement for preventive health services, interperiodic visits, developmental screenings, brief emotional/behavioral assessments, hearing and vision screenings, and immunizations under the EPSDT benefit. This manual provides information pertaining to the required screening components of the EPSDT program which should be performed in accordance with the American Academy of Pediatrics (AAP) Bright Futures recommendations for preventive health/well-child check-ups. Diagnostic and Treatment (DT) services available under the EPSDT benefit are reimbursed under other program areas within the Georgia Medicaid and PeachCare for Kids® programs.

The Early and Periodic Screening Components of EPSDT
All screening components for the preventive exam should be provided as outlined in this manual. The required screening components include: a comprehensive unclothed physical examination (unclothed means to the extent necessary to conduct a full, age-appropriate examination); a comprehensive health and developmental history; developmental appraisal (including mental, emotional and behavioral health components); anticipatory guidance and health education; measurements; dental/oral health assessment; vision and hearing tests; certain laboratory procedures; lead risk assessments, and immunizations. Immunizations as needed should be given at the time of the preventive health visit as appropriate. All of the age appropriate components per the periodicity schedule and this manual must be completed and documented for each screening as appropriate. All preventive/well-child services must be provided under the EPSDT benefit following the policies and procedures as outlined in this manual.
The Diagnostic and Treatment Components of EPSDT

The Diagnostic and Treatment policies, procedures, and billing for the EPSDT benefit are found under other Georgia Medicaid programs. However, the Health Check provider may address a medical condition at the time of the preventive health visit or during an interperiodic visit. Under these circumstances, the Health Check provider bills for the office visit associated with the medical condition.

Provider Manuals relevant to the EPSDT benefit include, but may not be limited to:

- Advanced Nurse Practitioner Services
- Children’s Intervention Services (CIS)
- Children’s Intervention School Services (CISS)
- Dental Services
- Diagnostic Screening and Preventive Services (DSPS)
- Durable Medical Equipment (DME) Services
- Federally Qualified Health Center (FQHC) Services
- Georgia Pediatric Program (GAPP)
- Hospice Services
- Hospital Services
- Medicaid/PeachCare for Kids® Provider Billing Manuals
- Nurse Midwifery Services
- Orthotic and Prosthetic Services
- Pharmacy Services
- Physician Assistant Services
- Physician Services
- Rural Health Clinic (RHC) Services
- Vision Care Services

Provider Manuals are available for downloading. Contact DXC Technology (DXC) at 1-800-766-4456 or visit the website at www.mmis.georgia.gov for more information.

The Medically Fragile Child

Many medically fragile children are under the care of medical specialists. The child’s primary care provider may request Diagnostic and Treatment services for the child by documenting the medical necessity for the proposed medical service. The practitioner must state the medical reason for the requested service as it relates to the child’s medical condition or diagnosis. These providers should refer to their applicable Medicaid programs’ policies and procedures manual for policy guidelines. See Appendix M for resources available to children in Georgia and Appendix D for an explanation of services provided under the Children’s Intervention Services program.
PART II - CHAPTER 600
Special Conditions of Participation

601. Enrollment

Physicians (pediatricians, family practitioners, general practitioners, internists, and OB/GYN specialists), Advanced Nurse Practitioners (pediatric, OB/GYN, family medicine or adult medicine), Certified Nurse Midwives, Local Education Agencies (LEAs) [school districts], hospitals, Local Boards of Health (county health departments), Rural Health Centers (RHCs) or Federally Qualified Health Centers (FQHCs) may enroll in the Health Check Program to provide EPSDT services. Physician sponsored advanced nurse practitioners (pediatric, OB/GYN, family medicine or adult medicine) and physician’s assistants may also enroll in the Health Check program but must maintain current written protocols and physician sponsorship. These non-physician providers must submit an official letter from their physician sponsor as proof of physician sponsorship at the time of enrollment and at the time their physician sponsorship changes. Providers who wish to provide Diagnostic and Treatment services should enroll in their respective Medicaid program, such as Physician Services, Advanced Nurse Practitioner Services, etc. Physicians, nurse practitioners and nurse midwives may enroll in the Health Check Program to provide EPSDT services and their respective programs to provide diagnostic and treatment services by completing only one provider data form.

Local Education Agencies, hospitals, Local Boards of Health, RHCs or FQHCs must enroll as an entity, as opposed to each provider that will be providing services enrolling individually. The enrolling entity must ensure that only staff members who meet the qualifications listed in Section 602 of this manual are providing services.

Application Process

Providers who wish to enroll in the Health Check program are required to:

- Meet the Conditions of Participation in Medicaid’s Part I Policies and Procedures for Medicaid and PeachCare for Kids® Manual (Part I Manual) and the special conditions listed in Section 602;

- Read the EPSDT Benefit Policy Manual prior to signing enrollment forms and;

- Complete and sign the Health Check Required Equipment form in Appendix G

In addition, it is strongly encouraged that providers submit an application for enrollment into the Vaccines For Children (VFC) Program – see Section 905.3 for more information.
The Department of Community Health contracts with DXC to provide an electronic health care administration system for its contracted providers. The DXC field representatives are responsible for assisting Medicaid and PeachCare for Kids® providers with claims adjudication, the web portal and technical support. Contact DXC at 1-800-766-4456 for more information.

602. Special Conditions of Participation

In addition to the general Conditions of Participation contained in Part I Policies and Procedures for Medicaid and PeachCare for Kids®, providers in the Health Check program must meet the following requirements:

A. Physicians, including those employed or contracted by an LEA, must be currently licensed to practice medicine. (Refer to the Physician Services Manual)

B. Nurse Practitioners, including those employed or contracted by an LEA, must maintain a current registered nurse license for the State of Georgia and current specialty certification by the appropriate certifying agent of the American Nurses Association. (Refer to the Advanced Nurse Practitioners Manual)

C. Nurse Midwives, including those employed or contracted by an LEA, must maintain a current registered nurse license and current certification as a nurse-midwife by the American College of Nurse-Midwives (ACNW). A copy of the national certification must be on file with the Division of Medicaid. (Refer to the Nurse Midwifery Manual)

D. Physician-sponsored providers, including those employed or contracted by an LEA, must be currently licensed to practice and must submit a copy of their license with the application. They must also maintain current written protocols, physician sponsorship and submit an official letter from their physician sponsor as proof of physician sponsorship. These providers include:

- Certified pediatric, OB/GYN, family, general or adult nurse practitioners. A recent graduate of a Nurse Practitioner Program may enroll as a Nurse Practitioner once he/she passes the Specialty Certification exam.

- Physician assistants must be licensed by the Georgia Board of Medical Examiners and be associated with one or more sponsoring physician(s) on file with the Composite State Board of Medical Examiners. (Refer to the Physician Assistant Services Manual)

- Public Health registered nurses, affiliated with a Georgia local board of health, who have successfully completed the required training for expanded role nurses.
602.1 Health Check providers **must** provide immunizations. It is recommended the provider enroll in the VFC program and submit a VFC Provider Enrollment Letter with their Health Check Provider Enrollment Application. This is encouraged because the vaccine administration fee is the only reimbursement a provider will receive for administering vaccines otherwise available through the VFC program. (The VFC vaccines may only be used by certain populations. See Section 905.3.) For members nineteen (19) years of age through twenty (20) years of age, VFC stock is not available. Providers must use their own stock of vaccines for these Medicaid eligible members and the Division will reimburse for the vaccine product and for vaccine administration.

602.2 Health Check providers must submit documentation verifying they possess the necessary equipment to perform all components of the periodic screening (See Chapter 900, Section 903 for the equipment list.)

602.3 Health Check providers must determine whether members requesting a preventive health visit have already received that periodic screening. Periodic screenings for foster children in state custody are an exception to this requirement.

602.4 Health Check providers must perform, at the time of the member’s preventive health visit, all of the EPSDT required components for that visit as listed below, along with those identified in the Bright Futures Periodicity Schedule (see Section 902.1). The EPSDT required components include:

   A. A comprehensive health and developmental history, developmental appraisal (including mental, emotional and behavioral)
   
   B. A comprehensive unclothed physical examination (unclothed means to the extent necessary to conduct a full, age-appropriate examination) including measurements
   
   C. Health education and anticipatory guidance for both the child and caregiver
   
   D. Dental/oral health assessment
   
   E. Vision and hearing assessments
   
   F. Laboratory testing (including blood lead screening appropriate for age and risk factors)
   
   G. Appropriate immunizations, in accordance with the pediatric and adult schedules for vaccines established by the Advisory Committee on Immunization Practices
The Health Check provider must:

A. Use Place of Service (POS) code 99 for all preventive health services and interperiodic visits. Public Health providers – see Section 1003.11 for additional information;

B. Document, in the member’s health record, all services provided during the preventive health visit;

C. Make available for on-site audits by the Division or its agents all records related to EPSDT services. Providers must submit plans for corrective action when requested;

D. Refer the member to other ancillary service providers for services that are not covered under the Medicaid or PeachCare for Kids® programs;

E. Provide services in a manner consistent with the policies, procedures and requirements outlined in this manual;

F. If performing the required laboratory testing, be in compliance with the Clinical Laboratory Improvement Amendment. Providers seeking information concerning laboratory services should contact:

   Office of Health Care Facilities Regulations at (404) 657-5700

G. Maintain an office, clinic, or other similar physical facility, which complies with local business and building license ordinances;

H. Provide immunizations as needed at the time of the preventive health visit. Providers not enrolled in the VFC program will not be reimbursed for the cost of the vaccine they administer to Medicaid members if those vaccines can be provided under the VFC program. They will only be reimbursed the vaccine administration fee. To enroll in the Vaccines For Children Program, please call 1-800-848-3868. For members nineteen (19) years of age through twenty (20) years of age, VFC stock is not available. Providers must use their own stock of vaccines for these Medicaid eligible members and the Division will reimburse for the vaccine product and for vaccine administration.

I. Maintain legible, accurate, and complete medical records in order to support and justify the services provided. A Medical record is a summary of essential medical information on an individual patient including dated reports supporting claims submitted to the Division for services provided in an office, hospital, outpatient, or other place of service. Records of service shall be entered in chronological order by the practitioner who rendered the service.
602.6 All documentation in the medical record shall be legible and shall include but not be limited to:

1. Date(s) of service
2. Patient's name and date of birth
3. Name and title of person performing the service
4. Pertinent medical history; immunizations
5. Pertinent findings on examination
6. Medications, equipment or supplies prescribed/provided
7. Recommendations for additional treatment, procedures, or consultations
8. Tests and results
9. Plan of treatment/care and outcomes
10. Refusal of care documented with signed form by responsible person for member
11. The signature of the person performing the service. The original handwritten personal signature (electronic or fax signatures are acceptable only if these documents are legible) of the person performing the service must be on each document contained in the patient's medical record. When a fax document or signature is included in the medical record, the document with the original signature must be retrievable from the original source. This includes but is not limited to progress notes and lab reports for each date of service billed.

**NOTE:** Electronic signature is defined as "an electronic or digital method executed or adopted by a party with the intent to be bound by or to authenticate a record, which is unique to the person using it, is capable of verification, is under the sole control of the person using it, and is linked to the data in such a manner that if the data are changed the signature is invalidated." O.C.G.A. 10-12-3. (1) (1997)

12. All documents contained in the medical record must be written in Standard English Language. Records must be available to the Georgia Division of Medicaid or its agents and to the U.S. Department of Health and Human Services upon request. Documentation must be timely, complete, and consistent with the by-laws and medical policies of the office or facility where the services are provided.
PART II - CHAPTER 700

Special Eligibility Conditions

All persons eligible for Medicaid who are less than twenty-one (21) years of age are eligible for the EPSDT benefit with the exception of women aged eighteen to twenty-one (18 to 21) who are enrolled in the Planning for Healthy Babies Program (P4HB®). P4HB participants are not eligible for the EPSDT benefit. All persons eligible for the PeachCare for Kids® program are eligible for the EPSDT benefit.
PART II - CHAPTER 800

Prior Approval/Authorization

801. The Health Check provider must provide all of the required EPSDT preventive health services, as identified by the periodicity schedule and this manual, during the preventive visit in order to be reimbursed at the Health Check visit rate. If additional service needs are identified, through the screening process, that are outside the scope of practice of the EPSDT primary care provider (PCP), the member must be referred to a provider who can address those needs.

If the provider is not the member’s EPSDT PCP, the provider must notify the member’s PCP of the preventive health/interperiodic visit and any additional service needs identified during that visit. The member’s PCP must make the appropriate referral(s).

Some EPSDT services provided to Medicaid and PeachCare for Kids® members may require prior authorization and/or a referral if the member has a PCP/medical home and the member’s PCP/medical home does not perform those additional services.

Documentation of care rendered outside of the PCP or the medical home (such as medical records and immunization charting) must be sent to the PCP or the medical home as identified by the member within five (5) business days of the provision of those services.

802. Prior authorization may be required for services rendered by Diagnostic and Treatment providers. These providers should refer to their applicable Medicaid policy and procedure manuals for a listing of the services that require prior approval.
PART II - CHAPTER 900
Scope of Services

901. General
The Health Check Program provides reimbursement for preventive health and interperiodic visits and other services provided during those visits.

The Diagnostic and Treatment components of the EPSDT benefit are covered under other Georgia Medicaid programs as described previously in this manual. Those programmatic policies and procedures should be followed as specified in the appropriate related manuals (i.e., Physician Services program, etc.). Diagnostic and Treatment services are provided for identified suspicious or abnormal conditions by either the Health Check provider, if qualified to perform those services, or upon referral to an appropriate service provider of the member’s choice.

902. AAP Periodicity Schedule and Georgia Minimum Standards for Screening Components
Effective July 1, 2019, the Georgia Division of Medical Assistance Plans will adopt the AAP 2019 Bright Futures “Recommendations for Pediatric Health Care” Periodicity Schedule as the periodicity schedule for EPSDT visits and services. The schedule is available at https://www.aap.org/en-us/Documents/periodicity_schedule.pdf. The updated 2019 schedule consists of revisions to footnote 6 (blood pressure), footnote 24 (anemia) and footnote 25 (lead). A copy of the summary of changes is displayed in Appendix Q.

902.1 Periodicity Schedule and Screening Sequence
The periodic intervals for screening for all Medicaid and PeachCare for Kids® Health Check providers, as shown on the following page, are based on the American Academy of Pediatrics’ recommendations.

NOTE: The updated 2019 Periodicity Schedule will be used for all EPSDT preventive health visits completed on or after July 1, 2019. Exception: the prenatal visit and over 21 years of age visit as listed on the schedule are not covered under the Health Check Category of Service (COS) 600.
Effective July 1, 2019, the GA Division of Medicaid adopted the updated AAP Bright Futures “Recommendations for Pediatric Health Care” Periodicity Schedule as the periodicity schedule for EPSDT preventive health visits and services.

### Recommendations for Preventive Pediatric Health Care

#### Bright Futures/American Academy of Pediatrics

Each child and family is unique; therefore, these Recommendations for Preventive Pediatric Health Care are designed for the care of children who are receiving competent primary care. They focus on the prevention and early detection of nine important health problems, and are growing and evolving in conjunction with developmental, psychosocial, and ethical changes. For children and adults, early detection and treatment is essential from preventive care visits. Additional visits may become necessary if a timeframe is established over the normal period.

<table>
<thead>
<tr>
<th>Age</th>
<th>Physical Development</th>
<th>Mental Development</th>
<th>Social Development</th>
<th>Family Health</th>
<th>School Health</th>
<th>Other Health</th>
<th>Total</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-6 mo</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>6-12 mo</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>1-2 years</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>2-3 years</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

These recommendations represent a consensus by the American Academy of Pediatrics (AAP) and Bright Futures. The AAP continues to emphasize the growth importance of continuity of care in comprehensive health supervision and the need to ensure that children, including those with special health care needs, receive care.

The recommendations in this document do not include an exclusive series of treatments or standards for medical care. Therefore, taking into account individual circumstances, may be appropriate. Copyright © 2019 by the American Academy of Pediatrics, updated 03/2019.

---

**Access**

- [American Academy of Pediatrics](https://www.aap.org)
- [Bright Futures](https://www.brightfutures.org)

---

**References**

1. [AAP Bright Futures Periodicity Schedule](https://www.aap.org/en-us/practice-tools/bright-futures/Pages/Periodicity-Schedule.aspx)
2. [Health Maintenance Organizations](https://www.aap.org/en-us/practice-tools/bright-futures/Pages/Health-Maintenance-Organizations.aspx)

---

**Copyright © 2019 by the American Academy of Pediatrics, updated 03/2019**
Summary of Changes Made to the
Bright Futures/AAP Recommendations for Preventive Pediatric Health Care
(Periodicity Schedule)

This schedule reflects changes approved in December 2018 and published in March 2019. For updates and a list of previous changes made, visit www.aap.org/periodicitieschedule.

CHANGES MADE IN DECEMBER 2018

BLOOD PRESSURE
- Footnote 6 has been updated to read as follows: “Screening should occur per Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents” (http://pediatrics.aappublications.org/content/140/1/e20171854). Blood pressure measurement in infants and children with specific risk conditions should be performed at visits before age 3 years.”

ANEMIA
- Footnote 24 has been updated to read as follows: “Perform risk assessment or screening, as appropriate, per recommendations in the current edition of the AAP Pediatric Nutrition Policy of the American Academy of Pediatrics (from chapter).”

LEAD
- Footnote 35 has been updated to read as follows: “For children at risk of lead exposure, screen for Prevention of Childhood Lead Toxicity” (http://pediatrics.aappublications.org/content/138/3/e2016493) and “Low Level Lead Exposure Harm Children: A Renewed Call for Primary Prevention” (https://www.cdc.gov/hcb/lead/ACCPFinal_document86712/pdf).”
KEY

• = to be performed
* = risk assessment to be performed, with appropriate action follow, if positive
← • → = range during which a service may be provided, with the symbol indicating the preferred age.

FOOTNOTES

1. If a child comes under care for the first time at any point on the schedule, or if any items are not accomplished at the suggested age, the schedule should be brought up-to-date at the earliest possible time.

2. A prenatal visit is recommended for parents who are at high risk, for first-time parents, and for those who request a conference. The prenatal visit should include anticipatory guidance, pertinent medical history, and a discussion of benefits of breastfeeding and planned method of feeding, per “The Prenatal Visit” (http://pediatrics.aappublications.org/content/124/4/1227.full).

3. Newborns should have an evaluation after birth, and breastfeeding should be encouraged (and instruction and support should be offered).

4. Newborns should have an evaluation within 3 to 5 days of birth and within 48 to 72 hours after discharge from the hospital to include evaluation for feeding and jaundice. Breastfeeding newborns should receive formal breastfeeding evaluation, and their mothers should receive encouragement and instruction, as recommended in “Breastfeeding and the Use of Human Milk” (http://pediatrics.aappublications.org/content/129/3/e827.full). Newborns discharged less than 48 hours after delivery must be examined within 48 hours of discharge, per “Hospital Stay for Healthy Term Newborns” (http://pediatrics.aappublications.org/content/125/2/405.full).


6. Screening should occur per “Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents” (http://pediatrics.aappublications.org/content/140/3/e20171904). Blood pressure measurement in infants and children with specific risk conditions should be performed at visits before age 3 years.
7. A visual acuity screen is recommended at ages 4 and 5 years, as well as in cooperative 3-year-olds. Instrument-based screening may be used to assess risk at ages 12 and 24 months, in addition to the well visits at 3 through 5 years of age. See “Visual System Assessment in Infants, Children, and Young Adults by Pediatricians” (http://pediatrics.aappublications.org/content/137/1/e20153596) and “Procedures for the Evaluation of the Visual System by Pediatricians” (http://pediatrics.aappublications.org/content/137/1/e20153597).

8. Confirm initial screen was completed, verify results, and follow up, as appropriate. Newborns should be screened, per “Year 2007 Position Statement: Principles and Guidelines for Early Hearing Detection and Intervention Programs” (http://pediatrics.aappublications.org/content/120/4/898.full).

9. Verify results as soon as possible, and follow up, as appropriate.

10. Screen with audiometry including 6,000 and 8,000 Hz high frequencies once between 11 and 14 years, once between 15 and 17 years, and once between 18 and 21 years. See “The Sensitivity of Adolescent Hearing Screens Significantly Improves by Adding High Frequencies” http://www.jahonline.org/article/S1054-139X(16)00048-3/fulltext

11. See “Identifying Infants and Young Children With Developmental Disorders in the Medical Home: An Algorithm for Developmental Surveillance and Screening” (http://pediatrics.aappublications.org/content/118/1/405.full).

12. Screening should occur per “Identification and Evaluation of Children With Autism Spectrum Disorders” (http://pediatrics.aappublications.org/content/120/5/1183.full).

13. This assessment should be family centered and may include an assessment of child social-emotional health, caregiver depression, and social determinants of health. See “Promoting Optimal Development: Screening for Behavioral and Emotional Problems” (http://pediatrics.aappublications.org/content/135/2/384) and “Poverty and Child Health in the United States” (http://pediatrics.aappublications.org/content/137/4/e20160339).


16. Screening should occur per “Incorporating Recognition and Management of Perinatal and Postpartum Depression Into Pediatric Practice” (http://pediatrics.aappublications.org/content/126/5/1032).

17. At each visit, age-appropriate physical examination is essential, with infant totally unclothed and older children undressed and suitably draped. See “Use of Chaperones During the Physical Examination of the Pediatric Patient” (http://pediatrics.aappublications.org/content/127/5/991.full).
18. These may be modified, depending on entry point into schedule and individual need.

19. Confirm initial screen was accomplished, verify results, and follow up, as appropriate. The Recommended Uniform Newborn Screening Panel [https://www.hrsa.gov/advisory-committees/heritable-disorders/rusp/index.html](https://www.hrsa.gov/advisory-committees/heritable-disorders/rusp/index.html) as determined by The Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children, and state newborn screening laws/regulations ([http://genes-r-us.uthscsa.edu/home](http://genes-r-us.uthscsa.edu/home)) establish the criteria for and coverage of newborn screening procedures and programs.

20. Verify results as soon as possible, and follow up, as appropriate.

21. Confirm initial screening was accomplished, verify results, and follow up, as appropriate. See “Hyperbilirubinemia in the Newborn Infant ≥35 Weeks’ Gestation: An Update With Clarifications” [http://pediatrics.aappublications.org/content/124/4/1193](http://pediatrics.aappublications.org/content/124/4/1193)

22. Screening for critical congenital heart disease using pulse oximetry should be performed in newborns, after 24 hours of age, before discharge from the hospital, per “Endorsement of Health and Human Services Recommendation for Pulse Oximetry Screening for Critical Congenital Heart Disease” [http://pediatrics.aappublications.org/content/129/1/190.full](http://pediatrics.aappublications.org/content/129/1/190.full)

23. Schedules, per the AAP Committee on Infectious Diseases, are available at [http://redbook.solutions.aap.org/SS/Immunization_Schedules.aspx](http://redbook.solutions.aap.org/SS/Immunization_Schedules.aspx) Every visit should be an opportunity to update and complete a child’s immunizations.


25. For children at risk of lead exposure, see “Prevention of Childhood Lead Toxicity” ([http://pediatrics.aappublications.org/content/138/1/e20161493](http://pediatrics.aappublications.org/content/138/1/e20161493)) and Low Level Lead Exposure Harms Children: A Renewed Call for Primary Prevention” ([http://www.cdc.gov/nceh/lead/ACCLPP/Final_Document_030712.pdf](http://www.cdc.gov/nceh/lead/ACCLPP/Final_Document_030712.pdf))

26. Perform risk assessments or screenings as appropriate, based on universal screening requirements for patients with Medicaid or in high prevalence areas.

27. Tuberculosis testing per recommendations of the AAP Committee on Infectious Diseases, published in the current edition of the AAP Red Book: Report of the Committee on Infectious Diseases. Testing should be performed on recognition of high-risk factors.


29. Adolescents should be screened for sexually transmitted infections (STIs) per recommendations in the current edition of the AAP Red Book: Report of the Committee on Infectious Diseases.
30. Adolescents should be screened for HIV according to the USPSTF recommendations http://www.uspreventiveservicestaskforce.org/uspstf/uspshivi.htm once between the ages of 15 and 18, making every effort to preserve confidentiality of the adolescent. Those at increased risk of HIV infection, including those who are sexually active, participate in injection drug use, or are being tested for other STIs, should be tested for HIV and reassessed annually.


34. See USPSTF recommendations https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/dental-caries-in-children-from-birth-through-age-5-years-screening Once teeth are present, fluoride varnish may be applied to all children every 3–6 months in the primary care or dental office. Indications for fluoride use are noted in “Fluoride Use in Caries Prevention in the Primary Care Setting” (http://pediatrics.aappublications.org/content/134/3/626).

35. If primary water source is deficient in fluoride, consider oral fluoride supplementation. See “Fluoride Use in Caries Prevention in the Primary Care Setting” (http://pediatrics.aappublications.org/content/134/3/626).
902.2 Minimum Standards for Screening Components during the Preventive Health Visits

Required Components are specified here and in the chart and footnotes of the American Academy of Pediatrics Recommendations for Preventive Pediatric Health Care (AAP Periodicity Schedule).

Visit Components:
Every periodic health supervision (well-child) visit must include:
1. A comprehensive health, psycho-social and developmental history;
2. Documentation of vital signs;
3. An unclothed comprehensive physical examination (unclothed means to the extent necessary to conduct a full, age-appropriate examination);
4. Assessment of growth and nutritional status;
5. Assessment of immunization status and provision of appropriate immunizations. (Use the Advisory Committee on Immunization Practices (ACIP) schedules);
6. Screening for vision, hearing, and development, as per AAP guidance;
7. Laboratory testing where appropriate to age and exam findings, and in line with AAP guidance. (Some testing, if not bundled, may be covered under other programs i.e. Physician Services, DSPS, etc. Please follow those programs’ guidelines for reimbursement.);
8. Oral health screening, preventive counseling, and referral to a dentist for ongoing dental care;
9. Screening for and if suspected, reporting of child abuse and neglect;
10. Anticipatory guidance (Health Education); and
11. Referrals /follow-ups where appropriate based on history and exam findings.

Helpful materials:
https://brightfutures.aap.org

CDC Positive Parenting Tips (handouts English and Spanish to download for families) at:
http://www.cdc.gov/ncbddd/child/infants.htm

Immunization schedule (Recommended Immunization Schedule, 0-18 years)
http://aapredbook.aappublications.org/site/resources/izschedules.xhtml

A. Age
Calculate the child’s age. If a child comes under care for the first time at any point on the schedule, or if any items were not accomplished at the suggested age, the member’s visit should be brought up to date.

B. History

Initial history: All ages: The history may be obtained at the time of the visit from the parent/guardian or it may be obtained through a form or checklist sent to the parent/guardian prior to the visit for completion.
History must contain, but is not limited to:
1. Present health status and past health history of member;
2. Developmental information;
3. Allergies and immunization history - allergies must be clearly and easily found in records;
4. Family history;
5. Dietary (nutrition) history;
6. Risk assessment of lead exposure; and
7. Refusal of Care documentation form (as necessary).

**Documentation:** Initial health history is recorded in the medical record.

**Interval history:** All ages: For known patients, the age-specific history may be confined to the interval since the previous evaluation. The provider must review and supplement these histories at the time of the patient's examination. Include nutrition history.

**Documentation:** Evidence of review.

C. Measurements

1. **Assessment of Growth:**

   **All ages:** Growth must be measured, plotted on a graph, and recorded as outlined below.

   **Children younger than 2 years:** Age, weight, length, and head circumference are required. Measurements should be plotted on the appropriate World Health Organization (WHO) growth chart(s).

   **Children 2 years of age and older:** Age, weight, height, and BMI are required. Measurements must be plotted on the appropriate Centers for Disease Control and Prevention (CDC) growth chart(s). The BMI number must be plotted on the BMI-for-age growth chart to obtain a BMI percentile ranking.

   The CDC and WHO growth charts are available at the following website: [http://www.cdc.gov/growthcharts/](http://www.cdc.gov/growthcharts/)

   **Documentation:** All measurements in numerical values must be recorded and plotted as indicated. All measurements outside of normal range must have an intervention. Interventions following assessments, as suggested by the CDC, are also acceptable. Please refer to Appendix F for the correct BMI diagnosis codes to be recorded on the claim. The diagnosis code must align with the BMI percentile plotted on the growth chart.

   Fee For Service (FFS) EPSDT providers should not link the preventive health visit code to the BMI percentile diagnosis code on the claim.
2. **Blood Pressure Assessment:**

**Children younger than 3 years:** Infants and children with specific risk conditions need a blood pressure assessment. See the Bright Futures Guidance (BFG).

**Children 3 years and older:** Blood pressure assessment is performed at every visit.

**Documentation:** All measurements in numerical values must be recorded. All measurements outside of the normal range must have an intervention.

*NOTE:* Definitions for High Blood Pressure must follow the range published by the National High Blood Pressure Education Program in “The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents.”


The article, “Simple Table to Identify Children and Adolescents Needing Further Evaluation of Blood Pressure,” can be found in Pediatrics 2009; 123; e972-e974; David C. Kaelber and Frieda Pickett

http://pediatrics.aappublications.org/cgi/reprint/123/6/e972

---

**D. Sensory Screening**

1. **Vision Procedure:**

**Children from birth to 3 years of age:** A Vision Risk Assessment is needed at every visit. This risk assessment includes: ocular history, vision assessment, external inspection of the eyes and lids, ocular motility assessment, pupil and red reflex examination.

If the risk assessment is positive, refer to an ophthalmologist.

**Children 3 years and older:** A Vision Screening is required at the 3, 4, 5, 6, 8, 10, 12, and 15 year old visits. (The routine screening at age 18 has been changed to a risk assessment). A Vision Risk Assessment should be performed at all other visits. Patients uncooperative with screening and with no history, nor signs/symptoms of problems, should be re-screened within 6 months. To test visual acuity, use age appropriate tests. BFG suggests the Snellen letter or Symbol E charts. The use of alternative tests (HOTV or Matching Symbol, Faye Symbol, Allen Pictures) should be considered for preschoolers.

If the risk assessment is positive, conduct a vision screening. If the vision screening is positive, refer to an ophthalmologist.

Reminder: If a child wears eyeglasses, assessment regarding the need for referral for optometric re-evaluation must be made based on screening with eyeglasses and the length of time since the last evaluation.
**Documentation:** Sensory Screening documentation consists of an age appropriate assessment, assessment results (normal or abnormal) and examinations performed and results (pass/fail) data. Appropriate follow up or referral is needed for results outside of the normal range.

2. **Hearing Procedure:**

**Newborns:** All newborns should receive a newborn hearing screening per the AAP “Year 2007 Position Statement: Principles and Guidelines for Early Hearing Detection and Intervention Programs” ([http://pediatrics.aappublications.org/content/120/4/898.full](http://pediatrics.aappublications.org/content/120/4/898.full))

If the newborn does not pass the hearing screening, refer for a follow-up outpatient rescreening within one month. For newborns who do not pass the rescreening, refer to an audiologist.

Georgia’s [Early Hearing Detection and Intervention (EHDI) Program](http://dph.georgia.gov/EHDI) is housed in the Georgia Department of Public Health along with the Newborn Metabolic Screening Program and the [Children 1st Program](http://www.children1stprogram.org). These three programs maintain and support a comprehensive, coordinated, statewide public health screening and referral system. EHDI includes:

- Screening for hearing loss in the birthing hospital;
- Referral of newborns who do not pass the hospital screening for rescreening;
- Referral of newborns who do not pass the rescreening for diagnostic audiological evaluation; and
- Linkage to appropriate intervention for those babies diagnosed with hearing loss.

Refer to the [Georgia EHDI Program](http://dph.georgia.gov/EHDI) for further guidance.

**Infants and toddlers under age 2 years:** These children should be monitored for auditory skills, middle ear status, and developmental milestones (surveillance).

**Infancy and Early Childhood visits:** Conduct a risk assessment at each preventive visit during the Infancy and Early Childhood years (from the three to five days visit through the 3 year old visit). If the risk assessment is positive, refer to an audiologist.

**Middle Childhood and Adolescent visits:** Conduct a risk assessment during the preventive visit at ages 7 years and 9 years. If the risk assessment is positive, refer to an audiologist.
At the 4, 5, 6, 8 and 10 year visits: Appropriate universal hearing screening (objective) is required.

At the 11 years through 20 years visits: Screen with audiometry including 6,000 and 8,000 Hz high frequencies once between 11 and 14 years, once between 15 and 17 years, and once between 18 and 20 years. See “The Sensitivity of Adolescent Hearing Screens Significantly Improves by Adding High Frequencies” https://www.jahonline.org/article/S1054-139X(16)00048-3/fulltext

Additional Guidance for Hearing Assessment Visits
Concerns identified during surveillance for children less than 2 years of age should be followed by performance of screening using a validated global screening tool (ASQ, PEDS, etc.). Those who do not pass the speech-language portion of the global screen or who have a caregiver concern should be referred immediately for further evaluation. Children with persistent middle ear effusions should be referred for otologic evaluation.

Older children who fail the risk assessment tool or screening should have appropriate intervention. Older children with persistent middle ear effusions should be referred for otologic evaluation.

Documentation: Sensory Screening documentation consists of an age appropriate assessment, assessment results (normal or abnormal) and examinations performed and results (pass/fail) data. Appropriate follow up or referral is needed for results outside of the normal range.

Patients uncooperative with screening and with no history, nor signs/symptoms of problems, should be re-screened within 6 months. This time frame is not appropriate for newborns.

E. Psychosocial/Behavioral Assessment and Developmental Surveillance

1. Surveillance:

Required for all ages: This assessment should occur with each clinical encounter with the child or adolescent. Comprehensive childhood surveillance of development includes activities that will document social, emotional, communication, cognitive, and physical development concerns (this content is listed at each health supervision visit in BFG under Surveillance of Development). Psychosocial/behavioral surveillance will encourage activities and interventions to promote mental health and emotional well-being. See BFG Chapter 3.

Documentation: Evidence of surveillance.
2. Developmental Screening:

Required at ages 9 months, 18 months, and 30 months: This screening **must** be accomplished using one or more of the following recommended standardized developmental screening tools:

- Ages and Stages Questionnaire (ASQ) - 2 months to 5 years
- Ages and Stages Questionnaire - 3rd Edition (ASQ-3)
- Battelle Developmental Inventory Screening Tool (BDI-ST) – Birth to 95 months
- Bayley Infant Neuro-developmental Screen (BINS) - 3 months to 2 yrs
- Brigance Screens-II – Birth to 90 months
- Child Development Inventory (CDI) - 18 months to 6 years
- Infant Development Inventory – Birth to 18 months
- Parents’ Evaluation of Developmental Status (PEDS) – Birth to 8 years
- Parents’ Evaluation of Developmental Status - Developmental Milestones (PEDS-DM)

**NOTE:** Screening tools not included in the list are not acceptable. *It is important to note that standardized tools specifically focused on one domain of development [e.g. child’s socio-emotional development (ASQ-SE) or autism (M-CHAT)] are not included in the list. The screening is anchored to recommendations related to global developmental screening using tools that identify risk for developmental, behavioral and social delays.*

**Documentation:** Evidence of the screening. Documentation in the medical record must include all of the following: a note indicating the date on which the screening was performed; a copy of the completed standardized tool used; and documented evidence of a screening result or screening score. If indicated, document the follow-up assessment, therapeutic interventions used, referrals made, and treatments received.

3. Autism Screening:

**Required at ages 18 months and 24 months or any time parents raise a concern:** The screening should be performed with an autism-specific screening tool. The Modified Checklist For Autism in Toddlers (MCHAT) is the recommended tool and downloadable at [https://m-chat.org](https://m-chat.org). The M-CHAT is a validated developmental screening tool for toddlers between 16 and 30 months of age, and should not be used for children younger than 16 months of age. The M-CHAT is designed to identify children who may benefit from a more thorough developmental and autism evaluation. The M-CHAT can be administered and scored as part of the preventive health visit, and also can be used by specialists or other professionals to screen for developmental delay and autism. The M-CHAT on-line version features the latest scoring system, Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F), making the results more sensitive in detecting developmental concerns.
**Documentation:** Evidence of the screening. Documentation in the medical record must include a note indicating the date on which the screening was performed; a copy of the screening tool used; and documented evidence of a screening result or screening score. If indicated, document the follow-up assessment, therapeutic interventions used, referrals made, and treatments received.

4. **Tobacco, Alcohol, or Drug Use Assessment:**
   **Required at 11 years through 20 years of age:** At all adolescent (11-20 years) visits, pre-teens and teens should be asked about substance use. The screening should be performed and documented or the child referred for care at any encounter when a parent raises a concern. AAP recommends using the CRAFFT screening tool (available at http://www.crafft.org) for this assessment. A copy of the CRAFFT Screening Interview is available in Appendix P.

   **Documentation:** Evidence of assessment. Screening tool must be standardized and scorable. Document the screening tool used and the screening results (i.e., CRAFFT score). If indicated, document the follow-up assessment, therapeutic intervention used, referrals made, and treatments received.

5. **Depression Screening:**
   **Required at 12 years through 20 years of age:** At all adolescent (12-20 years) visits, pre-teens and teens should be asked about depression.

   AAP recommends using the Patient Health Questionnaire (PHQ)-2 (see Appendix P) http://www.cqaimh.org/pdf/tool_phq2.pdf or other tools available in the GLAD-PC toolkit. The Bright Futures instructions for use of the PHQ 2 Questionnaire are available at https://brightfutures.aap.org.

   **Documentation:** Evidence of assessment. Document the screening tool used and the screening results in the medical record. If indicated, document the follow-up assessment, therapeutic intervention used, referrals made, and treatments received.

   Fee For Service EPSDT providers should link the depression screening procedure code (96127) to the applicable preventive health visit ICD-10 diagnosis code. The providers should not link a depression screening diagnosis code to the preventive health visit procedure code.
6. Maternal Depression Screening:

**Required at the 1, 2, 4 and 6 month visits:** At all visits (1, 2, 4, and 6 months), the mothers of newborn children should be asked about depression.

The relevant AAP guidance, in concert with Bright Futures recommendations (http://brightfutures.aap.org), references screening mothers with one of the two methods endorsed by the US Preventive Task Force: (1) the Edinburgh Postnatal Depression Scale (EPDS) or (2) the Patient Health Questionnaire-2 (PHQ-2), the two-question screening, administered at 1, 2, 4 and 6 months postpartum, with follow up referral for resources and treatment.

A copy of the EPDS and instructions can be found at the following link: https://psychology-tools.com/epds/

A copy of the PHQ2 is available at http://www.cqaimh.org/pdf/tool_phq2.pdf

**NOTE:** Per the BF guidance, “Screening should occur per “Incorporating Recognition and Management of Perinatal and Postpartum Depression Into Pediatric Practice” http://pediatrics.aappublications.org/content/early/2010/10/25/peds.2010-2348

**Documentation:** Evidence of assessment. Screening tool must be standardized and scorable. Document the screening tool used and the screening results in the medical record. If indicated, document the follow-up assessment, therapeutic intervention used, referrals made, and treatments received.

If evidence of depression is documented, EPSDT providers may refer the mother to the Georgia Crisis and Access Line (GCAL). GCAL, a statewide toll free crisis hotline, provides access to resources and services to individuals in need of crisis management for mental health, addictive disease, and crisis services. GCAL can be reached 24 hours a day, 7 days per week at 1-800-715-4225 (GCAL) or accessed on the web at www.mygcal.com.

F. Physical Exam

1. Physical Exam:

**All children:** A comprehensive physical exam is required for periodic and catch-up visits. The physical examination is the cornerstone of pediatric evaluation. Per the Federal EPSDT policy guidelines, the physical examination must be an unclothed physical inspection (unclothed means to the extent necessary to conduct a full, age-appropriate examination) that checks the general appearance of the child to determine overall health status. This process can pick up obvious physical defects, including orthopedic disorders, hernias, skin diseases, genital abnormalities and oral health needs. Physical inspection includes an examination of all organ systems such as pulmonary, cardiac, and gastrointestinal.

**Documentation:** Findings on all organ systems must be documented in the medical record. A checklist type form allowing documentation of normal/abnormal findings may be utilized for recording the different organ systems. Abnormal findings require further evaluation, follow-up or parental counseling.
2. Nutrition:

The Federal EPSDT policy guidelines mandate assessment of nutritional status but state it can be accomplished during many different parts of the exam. “Accurate measurements of height and weight...are among the most important indices of nutritional status.” “If information suggests dietary inadequacy, obesity or other nutritional problems, further assessment is indicated.”

**Documentation:** Evidence of the assessment.

G. Procedures

1. Newborn Screenings

   a. Newborn Blood Screening

   All infants under 4 months: Georgia law requires that every live born infant receive a metabolic screening for selective inherited disorders. The Georgia Newborn Screening (NBS) Program ensures that every newborn in Georgia is screened for 31 heritable disorders for prompt identification and treatment.

   If the infant is discharged before twenty-four (24) hours after birth, a blood specimen shall be collected prior to discharge. In this case a second specimen shall be collected prior to 7 days of age.

   Refer to the Georgia NBS Program for further guidance.

   **Documentation:** All infants whose test results are unavailable at the time of the 3-5 day preventive visit must have a specimen collected immediately during this visit unless the results are pending due to processing.

   The Newborn Blood Screening process may not be complete with results available before the first scheduled preventive health visit; however, these results should be actively tracked to completion and documented as soon as possible. If the results are outside the normal limits for a newborn screening disorder, the provider should ensure that the child receives prompt appropriate retesting and/or make a referral to an appropriate sub specialist.

   Providers may access newborn screening results online through the State Electronic Notification Surveillance System (SendSS). Results are also available through the Georgia Public Health Laboratory’s Newborn Screening eReports web portal.
Information regarding the SendSS registration process is available at:

https://sendss.state.ga.us/sendss/login.screen

Providers may register as a user of the Georgia Department of Public Health Laboratory’s Newborn Screening eReports electronic portal by completing the Newborn Screening eReports Web Portal Registration Form. The form is available at http://dph.georgia.gov/sites/dph.georgia.gov/files/NBS%20eReports%20Web%20Portal%20Registration%20form.pdf

NOTE

Newborn Bilirubin: The screening for bilirubin concentration at the newborn visit has been added. See “Hyperbilirubinemia in the Newborn Infant > 35 Weeks’ Gestation: An Update With Clarifications” http://pediatrics.aappublications.org/content/124/4/1193

b. **Critical Congenital Heart Defect (CCHD) Screening**

Screening for critical congenital heart disease using pulse oximetry should be performed in newborns, after 24 hours of age, before discharge from the hospital, per the 2011 AAP statement, “Endorsement of Health and Human Services Recommendation for Pulse Oximetry Screening for Critical Congenital Heart Disease” http://pediatrics.aappublications.org/content/129/1/190.full

CCHD was added to the Georgia newborn screening panel in 2014. In accordance with the Georgia Newborn Screening Program’s Policy and Procedure Manual, hospitals and birthing centers shall be equipped to conduct a critical congenital heart defect (CCHD) screening test on newborns using pulse oximetry. This screening can detect 14 common congenital heart defects in newborns which could result in disability and death. The CCHD screening should be performed in newborns before discharge from the hospital.

*Documentation:* Refer to the Georgia Newborn Screening Program for further guidance and documentation requirements.

2. **Immunizations**

All children: An immunization assessment is required for all children. This is a key element of preventive health services. Immunizations, if needed and appropriate, shall be given at the time of the preventive health visit. The Federal EPSDT policy guidelines mandate the use of the current ACIP schedule at http://www.cdc.gov/vaccines
**Documentation:** All immunizations (historic and current) must be documented in the medical record and recorded in the [Georgia Registry of Immunization Transactions and Services (GRITS)](https://dph.georgia.gov/immunization). Refusals must be documented with a signed document.

3. **Anemia Screening (Hematocrit and Hemoglobin)**

   **Anemia Screening Procedure:**

   - **At 12 months:** Screening must be performed on all members with documentation of a hemoglobin or hematocrit measurement.
   - **At 4 months:** Selective screening may be performed on all preterm, low birth weight infants and those not on iron fortified formula.

   **Anemia Risk Assessment:** An anemia risk assessment is required at the 4, 15, 18, 24, and 30 months visits, and annually starting at 3 years.

   **Documentation:** Evidence of screening, if required, and/or test results as well as any further evaluation, treatment or counseling for results outside of the normal limits. Evidence of a risk assessment performed at the 4, 15, 18, 24, and 30 months visits, and annually thereafter starting at 3 years. This can be part of the nutrition assessment.

4. **Lead Screening**

   **Blood Lead Risk Assessment:**

   The Blood Lead Risk Assessment is required at 6, 9 and 18 months and 3 to 6 years per the BFG periodicity schedule. A questionnaire, based on currently accepted public health guidelines, should be administered to determine if the child is at risk for lead poisoning. A recommended tool is the Georgia Healthy Homes and Lead Poisoning Prevention Program (GHHLPPP) Blood Lead Risk Assessment Questionnaire which can be found at [https://dph.georgia.gov/lead-screening-guidelines-children](https://dph.georgia.gov/lead-screening-guidelines-children).

   When using the questionnaire, a blood lead test should be done immediately if the child is at high risk (one or more “yes” or “I don’t know” answers on the lead risk assessment questionnaire) for lead exposure. Completing this questionnaire does not count as a blood lead screening.

   Note: Assessment questions are not needed if a Blood Lead Level (BLL) screening (test) will be done at the visit.

   **Documentation:** Risk assessment findings per the Bright Futures periodicity schedule with selective BLL screening (test) if there is a positive response or a change in risk.
**Blood Lead Level (BLL) Screen:**
A BLL screening (test) is required at 12 and 24 months.

**Children between the ages of 36 months and 72 months:** All children in this age range must receive one BLL screening **IF** they have not previously been tested for lead exposure.

ALL *venous* sample lead screening tests conducted using any Magellan Diagnostic lead testing system should be laboratory analyzed by a properly accredited laboratory.

**Documentation:** Test results as well as any further evaluation, treatment or counseling for results outside of the normal limits must be documented in the medical record.

Note: Completing a lead risk assessment questionnaire **DOES NOT** count as a blood lead level screening and does not meet Medicaid requirements.

**NOTE:** The Georgia Healthy Homes and Lead Poisoning Prevention Program (GHHLPPP) at 404-657-6534 has a Lead Risk Assessment Questionnaire that the provider may choose to use at [https://dph.georgia.gov/lead-screening-guidelines-children](https://dph.georgia.gov/lead-screening-guidelines-children)

Resource: See Appendix A: Guidelines for Elevated BLL. These must be used if a child has results outside normal limits.

### 5. Tuberculin Risk Assessment and Test:

**Tuberculin Risk Assessment:** Required at the 1, 6, 12, and 24 month visits then annually beginning at age 3 years. An assessment is given using a risk assessment questionnaire. The questionnaire should assess at least four (4) major risk factors:

- Contact with TB disease
- Foreign birth
- Foreign travel to TB endemic countries; and
- Household contact with TB

The AAP Bright Futures Guidelines for Health Supervision of Infants, Children, and Adolescents (3\textsuperscript{rd} edition) recommends asking the following questions:

1) Was your child born in a country at high risk for tuberculosis?
2) Has your child traveled (had contact with resident populations) for longer than 1 week to a country a high risk for tuberculosis?
3) Has a family member or contact had tuberculosis or a positive tuberculin skin test?
**Documentation:** Validated risk assessment and responses. If positive on initial risk assessment questions, there should be a TB test recorded.

Resources: [https://brightfutures.aap.org/materials-and-tools/Pages/default.aspx](https://brightfutures.aap.org/materials-and-tools/Pages/default.aspx)

**Tuberculin Test**
TB testing is not required at any age. The TB test is only administered to a child when questions are positive on the TB risk assessment or as the practitioner designates.

**Documentation:** If administered, a recorded Tuberculin skin test. If the practitioner needs to defer testing for reasons that cannot be validated with professionally written guidelines, consult with state TB experts. If a child cannot be given the screening test on this day, a follow-up visit is necessary. Document risk appropriate attempts to contact and re-schedule the appointment if the parent fails to keep the follow up appointment.

If the TB skin test result for a high-risk child less than six (6) months is negative, please retest the child at six (6) months of age.

For more information visit the [Georgia Department of Public Health Tuberculosis (TB) Prevention and Control Program](https://www.dph.georgia.gov/Services/Health/EpidemicDisorders/Epidemiology/), [TB Public Health Clinic Forms](https://www.dph.georgia.gov/Services/Health/EpidemicDisorders/Epidemiology/TBForms) (reporting & notification forms, legal forms, case management/clinic forms, TB assessments), including the [Pediatric Tuberculosis (TB) Risk Assessment](https://www.dph.georgia.gov/Services/Health/EpidemicDisorders/Epidemiology/TBForms/PediatricTuberculosisRiskAssessment), are available.

**6. Dyslipidemia**

**Risk Assessment and selective screening when indicated:** At the 2, 4, 6, 8 year and adolescence (12 through 16 year) visits.

**Screening:** Once between 9 and 11 years and once between 17 and 20 years: Universal screening is needed if not done previously in late adolescence (see periodicity schedule).

**Documentation:** Results of risk assessment and screening. Abnormal findings during assessment or screening require further evaluation, follow-up or parental counseling.

7. **Sexually Transmitted Infections (STIs):**

   **Risk Assessment:** At the 11 through 20 year visits.

   **Screening:** Adolescents should be screened for sexually transmitted infections (STIs) per recommendations in the current edition of the AAP *Red Book: Report of the Committee on Infectious Diseases.*

   **Documentation:** Results of risk assessment and screening. Abnormal findings during assessment or screening require further evaluation, treatment, follow-up, referral or parental counseling.

8. **Human Immunodeficiency Virus (HIV):**

   **Risk Assessment:** At the 11 through 14 year and 19 through 20 year visits.

   **Screening:** Adolescents should be screened for HIV once between the ages of 15 and 18 years, according to the USPSTF recommendations ([https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/human-immunodeficiency-virus-hiv-infection-screening1](https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/human-immunodeficiency-virus-hiv-infection-screening1)), making every effort to preserve confidentiality of the adolescent. Those at increased risk of HIV infection, including those who are sexually active, participate in injection drug use, or are being tested for other STIs, should be tested for HIV and reassessed annually.

   **Documentation:** Results of risk assessment and screening. Abnormal findings during assessment or screening require further evaluation, treatment, follow-up, referral or parental counseling.

   The following in-office procedure codes are available for reimbursement for the routine HIV screening:

   - 86701 – Analysis for antibody to HIV-1 virus
   - 86702 – Analysis for antibody to HIV-2 virus
   - 86703 – Analysis for antibody to HIV-1 and HIV-2 virus (Oraquick test)
   - 87389 – Detection test for HIV-1 and HIV-2
   - 87390 – Detection test for HIV-1
   - 87391 – Detection test for HIV-2

   Refer to the Part II Policies and Procedures For Independent Lab Services Program Manual.

9. **Cervical Dysplasia (Pap Test)**

   Adolescents should not be routinely screened for cervical dysplasia prior to age 21 years.

   Indications for pelvic exams prior to age 21 are noted in the “Gynecologic Examination for Adolescents in the Pediatric Office Setting” ([http://pediatrics.aappublications.org/content/126/3/583.full](http://pediatrics.aappublications.org/content/126/3/583.full))
H. Oral Health

Every child should begin to receive oral health risk assessments by 6 months of age.

The AAP recommends both the establishment of a dental home and the first dental exam no later than 12 months of age.

Assessing for a dental home should occur at the 12-month and 18-month through 6-year visits.

Encourage the parent to select a dental home.

For the 12, 18, 24, and 30 month visits, assess whether the child has a dental home. If no dental home is identified, perform a risk assessment and refer to a dental home. Recommend brushing with fluoride toothpaste in the proper dosage for age. See Maintaining and Improving the Oral Health of Young Children” (http://pediatrics.aappublications.org/content/134/6/1224). For those at high risk, consider application of fluoride varnish for caries prevention.

At 3 and 6 years: Determine if the patient has a dental home. If not, a referral must be made. If a dental home has not been established, perform a risk assessment. For those at high risk, consider application of fluoride varnish for caries prevention.

Documentation: Document a referral or inability to refer to a dental home if one has not been established. Document the risk assessment if less than 6 years and dental home not established. Document dental appointment for older children and care per AAPD periodicity schedule. Any abnormal findings must have an appropriate intervention for all children.

An oral health risk assessment tool has been developed by the AAP/Bright Futures. This tool can be accessed at https://www.aap.org/en-us/Documents/oralhealth_RiskAssessmentTool.pdf (www.aap.org/oralhealth)

1. Fluoride Varnish

Once teeth are present, the application of fluoride varnish is required and may be applied every 3-6 months in the primary care or dental office for children between the ages of 6 months and 5 years. Indications for fluoride use are noted in the 2014 AAP clinical report “Fluoride Use in Caries Prevention in the Primary Care Setting” (http://pediatrics.aappublications.org/cgi/doi/10.1542/peds.2014-1699)
**Documentation**: Evidence that fluoride varnish was applied once between the ages of 6 months and 5 years OR evidence that the provider addressed the fluoride varnish requirement and/or its importance with the parent.

2. **Fluoride Supplementation**


If primary water source is deficient in fluoride, consider oral fluoride supplementation. See “Fluoride Use in Caries Prevention in the Primary Care Setting” ([http://pediatrics.aappublications.org/content/134/3/626](http://pediatrics.aappublications.org/content/134/3/626))

**Risk Assessment**: Required at the 6 through 12 month visits, 18 month through 30 month visits, and then annually beginning at 3 years through 16 years.

**Documentation**: Evidence that the provider addressed the fluoride supplementation requirement and/or its importance with the parent.

I. **Anticipatory Guidance Procedure**:

**For all ages**: Anticipatory guidance and health education must be offered. It is a federally required component of the EPSDT preventive health visit. Age appropriate topics/information must be presented during each visit. Providers may use oral and written information. Providers may refer to the specific guidance by age as listed in the Bright Futures Guidelines.

Note: Providers must document discussion or provision of guidance for all children on Injury and Violence Prevention. Bright Futures Guidelines recommend and DCH requires sleep positioning counseling and documentation of such at every visit for members aged birth to six (6) months. DCH encourages sleep positioning counseling through the nine (9) month visit.

**Documentation**: Topics or name of handout given.

J. **Referral/Treatment noted between the PCP and Specialist or Follow-Up for Abnormal Values**

All suspicious or abnormal findings identified during an EPSDT visit must be treated or be further evaluated. The provider must either treat (if qualified) or refer all members with abnormal findings.

**Documentation**: Evidence of appropriate plan of care, treatment or referral for all components, results, and overriding concerns.
903. Required Equipment and Required Location Where Services Are To Be Provided

In addition to an examination table and routine supplies, providers must have the following equipment in their office or clinic in order to complete the EPSDT preventive health exam:

1. Scale for weighing infants and other children;
2. Measuring board or appropriate device for measuring length or height in the recumbent position for infants and children up to the age of two (2) years;
3. Measuring board or accurate device for measuring height in the vertical position for children who are over two (2) years old;
4. Blood pressure apparatus with infant, child and adult cuffs;
5. Screening audiometer;
6. Eye charts appropriate for age of the child;
7. Ophthalmoscope and otoscope;
8. Developmental/Behavioral Health screening tools and supplies for the following:
   - Developmental Screening - The required developmental screenings at ages 9 months, 18 months, and 30 months must be accomplished using one or more of the recommended standardized developmental screening tools specified in Section 902.2.
   - Autism Screening
   - Depression Screening
   - Maternal Depression Screening
   - Tobacco, Alcohol, or Drug Use Assessment
9. Vaccines and immunization administration supplies; and
10. Lab supplies for appropriate lab tests/screenings.

The provider may also have a Centrifuge or other device for measuring hematocrit or hemoglobin.

904. Periodic, Catch-up and Interperiodic Visits

The Georgia Department of Community Health, Division of Medicaid adopted the updated 2017 Bright Futures Periodicity Schedule and the schedule’s components as the guidelines for each EPSDT preventive health visit. Please use these guidelines, the following tables and the EPSDT HIPAA referral codes (See Section 911) when billing for the EPSDT visit.

Table A: Use this table when billing for the EPSDT periodic visits of children who are on time for their visits according to the updated 2017 Bright Futures Periodicity schedule. One visit from each sequence may be billed.

Table B: Use this table when billing for the EPSDT periodic visits of children who have missed one or more of their EPSDT periodic visits according to the updated 2017 Bright Futures Periodicity schedule and need to get caught up with the Periodicity schedule.

Table C: Use this table when billing for the EPSDT interperiodic visits of children who are up to date on their periodic visits but have a medical necessity for another visit: i.e. referred to the EPSDT provider because of a suspected problem by a health, developmental, or educational professional who comes into contact with the child outside of the formal health care system or a need identified by the provider or parent.

Note: Children in state custody (foster care) may require more frequent EPSDT services. Effective March 3, 2014, all children in state custody were transitioned to Medicaid managed care.
Table A

On Time EPSDT Periodic Visit Procedure Codes

Use the preventive visit codes (99381-99385, 99391-99395) for Medicaid-eligible and PeachCare for Kids® (PCK)-eligible children. All preventive visits must be coded with the EP modifier (Refer to Table A) and appropriate diagnosis code (Refer to Table A-2). The 25 modifier must be included when a vaccine is administered during the preventive visit. A preventive visit that is not performed as specified in the periodicity schedule should be coded as a catch-up visit (Refer to Table B.) Catch-up visits are only available for children younger than three (3) years of age.

If an abnormality/ies is encountered or a preexisting problem is addressed during the EPSDT Periodic visit, and if the problem/abnormality is significant enough to require additional work to perform the key components of a problem-oriented E/M (evaluation and management) service, then the appropriate Office/Outpatient code 99211 or 99212 should also be reported. If the member is a new patient, defined as one who has not received any EPSDT services (face-to-face services reported with a CPT code) from a practitioner or any practitioner within the same group practice of the exact same specialty or subspecialty within the past 3 years, code the EPSDT preventive visit using the 9938x codes. If the member is an established patient, defined as one who has received an EPSDT service from a practitioner or any practitioner within the same group practice of the same specialty or subspecialty within the past 3 years, code the EPSDT preventive visit using the 9939x codes. Use the 99211 or 99212 code for the office visit component. (There is a reimbursement rate differential for PCK’s members as identified in Table C.)

Modifier EP and 25 should be added to the Office/Outpatient code to indicate that a significant, separately identifiable Evaluation and Management service was provided by the same EPSDT provider on the same day as the EPSDT Periodic visit. The appropriate EPSDT Periodic visit code is additionally reported. If an abnormality/ies is encountered use the appropriate HIPAA diagnosis code which relates to the medical service(s) provided.

Other helpful information

The blood lead level screening is due at the 12 and 24 month preventive visits and the preventive visit will not be reimbursed without documentation that the blood lead level screening occurred. Providers must bill CPT code 36415 or 36416 with ICD-10 diagnosis code Z13.88 to signify blood lead level screening.

Reimbursement for immunization administration will be provided when vaccines are administered and properly coded on the claim by the provider.

The appropriate EPSDT Referral Code should be documented on the EPSDT claim when an EPSDT preventive visit has occurred. (See Section 911 – EPSDT HIPAA Referral Codes and Appendix K – EPSDT HIPAA Referral Code Examples.)
<table>
<thead>
<tr>
<th>Sequence Numbers</th>
<th>HIPAA Procedure Code</th>
<th>HIPAA Modifier</th>
<th>Fee For Service Reimbursement</th>
<th>Periodic Exam to take place at stated age. Otherwise, code as Catch-Up Visit</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td>Newborn Visit (performed in the hospital)</td>
</tr>
<tr>
<td>2</td>
<td>99381 or 99391</td>
<td>EP</td>
<td>$67.38</td>
<td>3-5 days by 1 month</td>
</tr>
<tr>
<td>3</td>
<td>99382 or 99392</td>
<td>EP</td>
<td>$67.38</td>
<td>12 months 15 months</td>
</tr>
<tr>
<td>4</td>
<td>99383 or 99393</td>
<td>EP</td>
<td>$67.38</td>
<td>5 years 6 years</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td>7 years</td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td>8 years 9 years</td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td>10 years 11 years</td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td>12 years 13 years</td>
</tr>
<tr>
<td>9</td>
<td></td>
<td></td>
<td></td>
<td>14 years 15 years</td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td>16 years 17 years</td>
</tr>
<tr>
<td>11</td>
<td></td>
<td></td>
<td></td>
<td>18 years 19 years</td>
</tr>
<tr>
<td>12</td>
<td></td>
<td></td>
<td></td>
<td>20 years</td>
</tr>
</tbody>
</table>
Effective July 1, 2015, physicians and physician extenders who are eligible for the HB 76 FY 2016 Primary Care Providers (PCP) rate increase will be reimbursed at the following rates, as indicated below in Table A-1, when the specified codes are billed for established Medicaid-eligible and PCK-eligible members.

Effective July 1, 2016, physicians and physician extenders who are eligible for the HB 751 FY 2017 Primary Care Providers (PCP) rate increase will be reimbursed at the following rates, as indicated below in Table A-1, when the specified codes are billed for established Medicaid-eligible and PCK-eligible members.

Effective July 1, 2017, physicians and physician extenders who are eligible for the HB 44 FY 2018 Primary Care Providers (PCP) rate increase will be reimbursed at the following rates, as indicated below in Table A-1, when the specified codes are billed for established Medicaid-eligible and PCK-eligible members.

### Table A-1

<table>
<thead>
<tr>
<th>Age</th>
<th>Preventive Visit Code</th>
<th>HIPAA Modifier</th>
<th>HB 76 FY2016 Increased Reimbursement Rate</th>
<th>HB 751 FY2017 Increased Reimbursement Rate</th>
<th>HB 44 FY2018 Increased Reimbursement Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birth – 11 months</td>
<td>99381</td>
<td>EP</td>
<td>$86.47</td>
<td>$96.08</td>
<td></td>
</tr>
<tr>
<td></td>
<td>99391</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 months – 4 years</td>
<td>99382</td>
<td>EP</td>
<td>$92.46</td>
<td>$102.74</td>
<td>$111.27</td>
</tr>
<tr>
<td></td>
<td>99392</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 years – 11 years</td>
<td>99383</td>
<td>EP</td>
<td>$92.17</td>
<td>$102.41</td>
<td>$116.19</td>
</tr>
<tr>
<td></td>
<td>99393</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 years – 17 years</td>
<td>99384</td>
<td>EP</td>
<td>$101.03</td>
<td>$112.25</td>
<td>$131.62</td>
</tr>
<tr>
<td></td>
<td>99394</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18 years – 20 years</td>
<td>99385</td>
<td>EP</td>
<td>$103.24</td>
<td>$114.71</td>
<td>$127.75</td>
</tr>
<tr>
<td></td>
<td>99395</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table A-2 displays the correct ICD-10 diagnosis codes to be used when billing preventive health visits.

<table>
<thead>
<tr>
<th>ICD-10 Code</th>
<th>At this Age</th>
</tr>
</thead>
<tbody>
<tr>
<td>Z00.110</td>
<td>0 – 7 days</td>
</tr>
<tr>
<td>Z00.111</td>
<td>8 – 28 days</td>
</tr>
<tr>
<td>Z00.121 or Z00.129</td>
<td>29 days through 14 years</td>
</tr>
<tr>
<td>Z00.121 or Z00.129</td>
<td>15 years through 17 years</td>
</tr>
<tr>
<td>Z00.00 or Z00.01</td>
<td>18 years through 20 years</td>
</tr>
<tr>
<td>Z02 – Z02.89</td>
<td>0 through 20 years</td>
</tr>
</tbody>
</table>
TABLE B

Catch-Up EPSDT Visit Procedure Codes

Use Table B-1 for Medicaid-eligible and PeachCare for Kids®-eligible children who have missed their EPSDT periodic visit(s). Catch-up preventive visits are only available for children younger than three (3) years of age. All catch-up preventive visits must be coded with the EP and HA modifiers (see Table B-1) and appropriate diagnosis code (see Table B-1). The 25 modifier must be included when a vaccine is administered during the catch-up preventive visit.

The Health Check provider must complete all missed components during this catch-up visit but may only bill for one catch-up visit (Example - Child presents to the Health Check provider at eight (8) months of age and has missed the four and six month periodic visits. All components of the four and six month periodic visits must be included during the present catch-up visit and documentation must be provided for all periodic visit components included during this catch-up visit.) The appropriate EPSDT Catch-Up visit procedure code (see Table B-1 above) along with the EP and HA modifiers and appropriate diagnosis code (see Table B-1) must be included on the claim.

If abnormalities are encountered or a preexisting problem is addressed during the EPSDT Catch-Up visit, and if the problem/abnormality is significant enough to require additional work to perform the key components of a problem-oriented E/M service, then the appropriate Office/Outpatient code 99211 or 99212 should also be reported. The provider should use the appropriate HIPAA diagnosis code that relates to the medical service(s) provided and include modifiers EP and 25.

If the member is a new patient, one who has not received any EPSDT services (defined as face-to-face services reported with a CPT code) from a practitioner or any practitioner within the same group practice of the exact same specialty or subspecialty within the past 3 years, code the EPSDT preventive visit using the 9938x codes. If the member is an established patient, defined as one who has received an EPSDT service from a practitioner or any practitioner within the same group practice of the same specialty or subspecialty within the past 3 years, code the EPSDT preventive visit using the 9939x codes. Use the 99211 or 99212 codes for the office visit component. (There is a reimbursement rate differential for PCK’s members as identified in Table C.)

Other helpful information

The blood lead level screening is due at the 12 and 24 month preventive visits and the preventive visit will not be reimbursed without documentation that the blood lead level screening occurred. Providers must bill CPT code 36415 or 36416 with ICD-10 diagnosis code Z13.88 to signify blood lead level screening.

Reimbursement for immunization administration will be provided when vaccines are administered and properly coded on the claim by the provider.

The appropriate EPSDT Referral Code should be documented on the EPSDT claim when an EPSDT periodic visit has occurred. (See Section 911 – EPSDT HIPAA Referral Codes and Appendix K – EPSDT HIPAA Referral Code Examples.)
Tables B-1 and B-2 display the correct modifiers to be used when billing catch-up preventive health visits.

Effective July 1, 2016, physicians and physician extenders who are eligible for the HB 751 FY 2017 Primary Care Providers (PCP) rate increase will be reimbursed at the following rates, as indicated below in Table B-2, when the specified codes are billed for established Medicaid-eligible and PCK-eligible members.

Effective July 1, 2017, physicians and physician extenders who are eligible for the HB 44 FY 2018 Primary Care Providers (PCP) rate increase will be reimbursed at the following rates, as indicated below in Table B-2, when the specified codes are billed for established Medicaid-eligible and PCK-eligible members.

**Table B-1**

<table>
<thead>
<tr>
<th>HIPAA Proc Code</th>
<th>Age of Child</th>
<th>HIPAA Modifier</th>
<th>2nd modifier</th>
<th>Fee For Service Reimbursement</th>
</tr>
</thead>
<tbody>
<tr>
<td>99381 or 99391</td>
<td>0 days through 11 months</td>
<td>EP</td>
<td>HA</td>
<td>$67.38</td>
</tr>
<tr>
<td>99382 or 99392</td>
<td>12 months up to 3 years</td>
<td>EP</td>
<td>HA</td>
<td>$67.38</td>
</tr>
</tbody>
</table>

**Table B-2**

<table>
<thead>
<tr>
<th>HIPAA Proc Code</th>
<th>Age of Child</th>
<th>HIPAA Modifier</th>
<th>2nd modifier</th>
<th>HB 76 FY2016 Increased Reimbursement Rate</th>
<th>HB 751 FY2017 Increased Reimbursement Rate</th>
<th>HB 44 FY2018 Increased Reimbursement Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>99381</td>
<td>0 days through 11 months</td>
<td>EP</td>
<td>HA</td>
<td>$106.68</td>
<td>$86.47</td>
<td>$92.46</td>
</tr>
<tr>
<td>99391</td>
<td>0 days through 11 months</td>
<td>EP</td>
<td>HA</td>
<td>$106.68</td>
<td>$86.47</td>
<td>$92.46</td>
</tr>
<tr>
<td>99382</td>
<td>12 months up to 3 years</td>
<td>EP</td>
<td>HA</td>
<td>$111.27</td>
<td>$102.74</td>
<td>$111.27</td>
</tr>
<tr>
<td>99392</td>
<td>12 months up to 3 years</td>
<td>EP</td>
<td>HA</td>
<td>$102.74</td>
<td>$102.74</td>
<td>$102.74</td>
</tr>
</tbody>
</table>
Table B-3 displays the correct ICD-10 diagnosis codes to be used when billing catch-up preventive health visits.

**Table B-3**

<table>
<thead>
<tr>
<th>ICD-10 Diagnosis Code</th>
<th>At this Age</th>
</tr>
</thead>
<tbody>
<tr>
<td>Z00.110</td>
<td>0 – 7 days</td>
</tr>
<tr>
<td>Z00.111</td>
<td>8 – 28 days</td>
</tr>
<tr>
<td>Z00.121 or Z00.129</td>
<td>29 days to 3 years</td>
</tr>
<tr>
<td>Z02 – Z02.89</td>
<td>0 to 3 years</td>
</tr>
</tbody>
</table>
**TABLE C**

**Interperiodic EPSDT Visit Procedure Codes**

Per the Federal EPSDT policy guidelines, interperiodic screening, vision, hearing, and dental services which are medically necessary to determine the existence of suspected physical or mental illnesses or conditions are to be provided.

Use Table C-1 for Medicaid-eligible and PeachCare for Kids®-eligible children who are up to date on their periodic exams but have been referred because of a suspected problem to a qualified health provider by a health, developmental, or educational professional who comes into contact with the child outside of the formal health care system or a need identified by the provider or parent. The complete set of EPSDT preventive health visit components does not have to be performed. EPSDT providers must document the correct level of care when using office visit codes. The rate differential for PCK’s members are shown in Table C-1.

Code the EPSDT interperiodic visit (99201-99203, 99211-99214) with the EP modifier. When vaccines are administered during the interperiodic visit, code the EPSDT interperiodic visit (99201-99203, 99212-99214) with the EP and 25 modifiers. The National Correct Coding Initiative (NCCI) does not allow reimbursement of the 99211 code when it is billed together with any of the vaccine administration codes (90460, 90471-90474).

**Table C-1**

<table>
<thead>
<tr>
<th>HIPAA Procedure Code</th>
<th>HIPAA Modifier</th>
<th>HIPAA Diagnosis Code</th>
<th>Medicaid Fee For Service (FFS) Reimbursement</th>
<th>PeachCare for Kids® (PCK) Fee for Service (FFS) Reimbursement</th>
</tr>
</thead>
<tbody>
<tr>
<td>99201 (new patient)</td>
<td>EP</td>
<td>*</td>
<td>$35.13</td>
<td>$41.20</td>
</tr>
<tr>
<td>99202 (new patient)</td>
<td>EP</td>
<td>*</td>
<td>$54.57</td>
<td>$71.16</td>
</tr>
<tr>
<td>99203 (new patient)</td>
<td>EP</td>
<td>*</td>
<td>$76.33</td>
<td>$103.01</td>
</tr>
<tr>
<td>99211 (established patient)</td>
<td>EP</td>
<td>*</td>
<td>$17.46</td>
<td>$17.46</td>
</tr>
<tr>
<td>99212 (established patient)</td>
<td>EP</td>
<td>*</td>
<td>$29.67</td>
<td>$41.54</td>
</tr>
<tr>
<td>99213 (established patient)</td>
<td>EP</td>
<td>*</td>
<td>$40.70</td>
<td>$69.11</td>
</tr>
<tr>
<td>99214 (established patient)</td>
<td>EP</td>
<td>*</td>
<td>$62.71</td>
<td>$102.49</td>
</tr>
</tbody>
</table>

*Use the appropriate HIPAA diagnosis code that relates to the medical service(s) provided.
Effective July 1, 2015, physicians and physician extenders who are eligible for the HB 76 FY 2016 Primary Care Providers (PCP) Rate Increase will be reimbursed $63.14, as indicated below in Table C-2 when procedure code 99213 is billed. This rate increase does not apply to PeachCare for Kids® members.

Effective July 1, 2016, physicians and physician extenders who are eligible for the HB 751 FY 2017 Primary Care Providers (PCP) rate increase will be reimbursed at the following rates, as indicated below in Table C-2, when the specified codes are billed for established Medicaid-eligible and PeachCare for Kids®-eligible members.

Effective July 1, 2017, physicians and physician extenders who are eligible for the HB 44 FY 2018 Primary Care Providers (PCP) rate increase will be reimbursed at the following rates, as indicated below in Table C-2, when the specified codes are billed for established Medicaid-eligible and PCK-eligible members.

### Table C-2

<table>
<thead>
<tr>
<th>HIPAA Procedure Code</th>
<th>HIPAA Modifier</th>
<th>HIPAA Diagnosis Code</th>
<th>HB 76 FY2016 Increased Reimbursement Rate</th>
<th>HB 751 FY2017 Increased Reimbursement Rate</th>
<th>HB 44 FY2018 Increased Reimbursement Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>99201 (new patient)</td>
<td>EP *</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>99202 (new patient)</td>
<td>EP *</td>
<td></td>
<td>$41.30</td>
<td></td>
<td></td>
</tr>
<tr>
<td>99203 (new patient)</td>
<td>EP *</td>
<td></td>
<td>$71.33</td>
<td></td>
<td></td>
</tr>
<tr>
<td>99211 (established patient)</td>
<td>EP *</td>
<td></td>
<td></td>
<td></td>
<td>$18.971 (FFS)</td>
</tr>
<tr>
<td>99212 (established patient)</td>
<td>EP *</td>
<td></td>
<td></td>
<td></td>
<td>$19.792 (PCK)</td>
</tr>
<tr>
<td>99213 (established patient)</td>
<td>EP *</td>
<td></td>
<td>$63.141 (FFS)</td>
<td>$70.15</td>
<td></td>
</tr>
<tr>
<td>99214 (established patient)</td>
<td>EP *</td>
<td></td>
<td></td>
<td></td>
<td>$103.72</td>
</tr>
</tbody>
</table>

*Use the appropriate HIPAA diagnosis code that relates to the medical service(s) provided.

1 This rate increase does not apply to PeachCare for Kids® members.

2 This rate increase does not apply to Medicaid FFS members.
Table C

Interperiodic Vision and Hearing Screening

An enrolled provider may use the codes as indicated below in Table C-3 when billing for vision and/or hearing screening only. For example, a recheck of a failed hearing screening or a child who needs Form 3300 (Certificate of Vision, Hearing, Dental and Nutrition Screening) completed. Separate reimbursement is not allowed when these screenings are performed during the periodic preventive visit. Please see Table C-3 below.

Table C-3

<table>
<thead>
<tr>
<th>HIPAA Procedure Code</th>
<th>HIPAA Modifier</th>
<th>Interperiodic Screening</th>
<th>ICD-10 Diagnosis Code</th>
<th>PCK and FFS Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>99173</td>
<td>EP</td>
<td>Interperiodic Vision</td>
<td>Z01.00 or Z01.01 Or appropriate abnormal results code</td>
<td>$5.62</td>
</tr>
<tr>
<td>V5008, 92551–92553, 92555-92556</td>
<td>EP</td>
<td>Interperiodic Hearing</td>
<td>Z01.10 or Z01.110 Or Z01.118 Or appropriate abnormal results code</td>
<td>$5.62</td>
</tr>
</tbody>
</table>

Note: The Georgia Department of Public Health’s Form 3300 has been revised to document a nutrition screening. More information and a copy of the form can be found at: http://www.gachd.org/DPH_Form_3300.pdf

The determination of whether an interperiodic screen is medically necessary may be made by a health, developmental, or educational professional who comes into contact with the child outside of the formal health care system [e.g., State early intervention or special education programs, Head Start and day care programs, the Special Supplemental Food Program for Women, Infants and Children (WIC), and other nutritional assistance programs]. Providers may not bill interperiodic and periodic visits on the same day.
905. Immunizations

905.1 Recommended Immunization Schedule:

The Recommended Childhood Immunization Schedule should be used as the guideline for administering immunizations.

905.2 Delayed Immunizations:

Practitioners who begin the immunization process on children who are late or at times other than the recommended optimal immunization schedule may use recommendations from the Advisory Committee on Immunization Practices (ACIP) - see schedule for Children and Adolescents Who Start Late.

905.3 Vaccines for Children (VFC) Program:

It is recommended that all Health Check providers enroll in the Vaccines For Children program to provide immunizations to Medicaid eligible children whose ages are birth through eighteen (18) years of age. If the Health Check provider giving the EPSDT preventive health exam does not wish to participate in VFC, it is expected that they administer vaccines at the time of service and understand that only the administration fee will be reimbursed. The Vaccines For Children (VFC) program is a federally funded and state operated vaccine supply program that began October 1, 1994. The program supplies, at no cost to all public health and private health care providers, federally purchased vaccines to be administered to children in certain groups. Children eligible to receive VFC-provided vaccines include the following:

A. children enrolled in Medicaid;
B. children who do not have health insurance;
C. children who are American Indian or Alaskan native; and
D. children who have health insurance but for whom vaccines are not a covered benefit.

Note: PeachCare for Kids® members may receive state purchased vaccines.

Questions regarding enrollment and vaccine orders should be directed to the appropriate VFC program (1-800-848-3868).

Since vaccines are provided at no cost to the Health Check provider for children eighteen (18) years and younger, only administration costs are allowed to be submitted for reimbursement for vaccines administered to this age group.
905.4 Tdap and Meningococcal Requirements

Beginning in the 2014-2015 academic school year (effective July 1, 2014), the Georgia Department of Public Health (DPH) Rule (511-2-2) requires all students born on or after January 1, 2002 entering or transferring into seventh (7th) grade and any “new entrant” entering into 8th-12th grades in Georgia must provide proof that the student has received one dose of Tdap (tetanus, diphtheria, pertussis) vaccine and one dose of meningococcal conjugate (MCV4) vaccine. DPH guidelines state that the student must have received the meningococcal vaccine on or after their 10th birthday for entry into the 7th grade. A student that received the meningococcal vaccine before their 10th birthday will need to be revaccinated on or after his/her 10th birthday. There is a minimum time interval of 8 weeks between the previous dose of the MCV4 vaccine and the newly required dose.

This law affects all public and private schools including, but not limited to, charter schools, community schools, juvenile court schools and other alternative school settings (excluding homeschool). “New Entrant” means any child entering any school in Georgia for the first time or entering after having been absent from a Georgia school for more than twelve months or one school year.
Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger, United States, 2019
(For those who fall behind or start late, see the catch-up schedule)

### Table 1
Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger
United States, 2019

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Birth</th>
<th>1 mo</th>
<th>2 mos</th>
<th>4 mos</th>
<th>6 mos</th>
<th>9 mos</th>
<th>12 mos</th>
<th>15 mos</th>
<th>18 mos</th>
<th>19-23 mos</th>
<th>2-3 yrs</th>
<th>4-6 yrs</th>
<th>7-10 yrs</th>
<th>11-12 yrs</th>
<th>13-15 yrs</th>
<th>16 yrs</th>
<th>17-18 yrs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis B (HepB)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td></td>
<td></td>
<td>3rd dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rotavirus (RV) / RV1 (2-dose series) / RSV (3-dose series)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td></td>
<td></td>
<td>See Notes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diphtheria, tetanus, &amp; acellular pertussis (DTaP&lt;7 yrs)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td></td>
<td></td>
<td>3rd dose</td>
<td></td>
<td>4th dose</td>
<td></td>
<td>5th dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemophilus influenzae type b (Hib)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td></td>
<td></td>
<td>See Notes</td>
<td></td>
<td>3rd or 4th dose</td>
<td>See Notes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal conjugate (PCV13)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td></td>
<td></td>
<td>3rd dose</td>
<td></td>
<td>4th dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactivated poliovirus (IPV&lt;18 yrs)</td>
<td>1st dose</td>
<td>2nd dose</td>
<td></td>
<td></td>
<td>3rd dose</td>
<td></td>
<td>4th dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza (IV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Annual vaccination 1 or 2 doses</td>
<td>Annual vaccination 1 or 2 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza (LAIV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Annual vaccination 1 dose only</td>
<td>Annual vaccination 1 dose only</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, mumps, rubella (MMR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>See Notes</td>
<td></td>
<td>1st dose</td>
<td></td>
<td>2nd dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella (VAR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>See Notes</td>
<td></td>
<td>1st dose</td>
<td></td>
<td>2nd dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A (HepA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>See Notes</td>
<td></td>
<td>2-dose series</td>
<td>See Notes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal (MenACWY-D ≥9 mos; MenACWY-CIM ≥2 mos)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>See Notes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetanus, diphtheria, &amp; acellular pertussis (TdAp&lt;7 yrs)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>See Notes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human papillomavirus (HPV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>See Notes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1st dose</td>
<td></td>
<td>2nd dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal polysaccharide (PPSV23)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>See Notes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NOTE:** The above recommendations must be read along with the footnotes of this schedule
Catch-up Immunization Schedule for persons aged 4 months – 18 years who start late or who are more than 1 month behind

### Table 2

**Catch-up immunization schedule for persons aged 4 months—18 years who start late or who are more than 1 month behind, United States, 2019**

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Minimum Age for Dose 1</th>
<th>Minimum Age for Dose 2</th>
<th>Minimum Interval Between Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis B</td>
<td>出生</td>
<td>6周</td>
<td>8周 and at least 16 weeks after first dose. Minimum age for first dose is 24 weeks.</td>
</tr>
<tr>
<td>Yellow fever</td>
<td>6周</td>
<td>8周</td>
<td>8周 and at least 16 weeks after first dose. Minimum age for first dose is 24 weeks.</td>
</tr>
<tr>
<td>Diphtheria, tetanus, and破伤风 pertussis</td>
<td>6周</td>
<td>8周</td>
<td>8周 and at least 16 weeks after first dose. Minimum age for first dose is 24 weeks.</td>
</tr>
<tr>
<td>Measles, mumps, rubella</td>
<td>6周</td>
<td>8周</td>
<td>8周 and at least 16 weeks after first dose. Minimum age for first dose is 24 weeks.</td>
</tr>
<tr>
<td>Inactivated poliovirus</td>
<td>6周</td>
<td>8周</td>
<td>8周 and at least 16 weeks after first dose. Minimum age for first dose is 24 weeks.</td>
</tr>
<tr>
<td>Varicella</td>
<td>6周</td>
<td>8周</td>
<td>8周 and at least 16 weeks after first dose. Minimum age for first dose is 24 weeks.</td>
</tr>
<tr>
<td>Haemophilus influenza type b</td>
<td>6周</td>
<td>8周</td>
<td>8周 and at least 16 weeks after first dose. Minimum age for first dose is 24 weeks.</td>
</tr>
<tr>
<td>Pneumococcal conjugate</td>
<td>6周</td>
<td>8周</td>
<td>8周 and at least 16 weeks after first dose. Minimum age for first dose is 24 weeks.</td>
</tr>
<tr>
<td>Inactivated poliovirus</td>
<td>6周</td>
<td>8周</td>
<td>8周 and at least 16 weeks after first dose. Minimum age for first dose is 24 weeks.</td>
</tr>
</tbody>
</table>

**Children and adolescents age 7 through 18 years**

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Minimum Age for Dose 1</th>
<th>Minimum Age for Dose 2</th>
<th>Minimum Interval Between Doses</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tetanus, diphtheria, tetanus,破伤风 pertussis</td>
<td>不适用</td>
<td>8周</td>
<td>8周 and at least 16 weeks after first dose. Minimum age for first dose is 24 weeks.</td>
</tr>
<tr>
<td>Haemophilus influenza type b</td>
<td>6周</td>
<td>8周</td>
<td>8周 and at least 16 weeks after first dose. Minimum age for first dose is 24 weeks.</td>
</tr>
<tr>
<td>Measles, mumps, rubella</td>
<td>6周</td>
<td>8周</td>
<td>8周 and at least 16 weeks after first dose. Minimum age for first dose is 24 weeks.</td>
</tr>
<tr>
<td>Varicella</td>
<td>6周</td>
<td>8周</td>
<td>8周 and at least 16 weeks after first dose. Minimum age for first dose is 24 weeks.</td>
</tr>
</tbody>
</table>

**NOTE:** The above recommendations must be read along with the footnotes of this schedule. Refer to footnotes at [https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf](https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf)
### Recommended Child and Adolescent Immunization Schedule by Medical Indication, United States, 2019

#### Table 3

<table>
<thead>
<tr>
<th>VACCINE</th>
<th>Pregnancy</th>
<th>Immuno-compromised status (excluding HIV infection)</th>
<th>HIV infection CD4+ count</th>
<th>Kidney failure, end-stage renal disease, on hemodialysis</th>
<th>Heart disease, chronic lung disease</th>
<th>CSF leaks/ cochlear implants</th>
<th>Asplenia and persistent complement deficiencies</th>
<th>Chronic liver disease</th>
<th>Diabetes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hepatitis B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rotavirus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diphtheria tetanus &amp;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemophilus influenza type b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal conjugate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inactivated poliovirus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza (IV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Influenza (LAIV)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Measles, mumps, rubella</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Varicella</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatitis A</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningooccal ACWY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetanus, diphtheria &amp;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haemophilus influenza type b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meningococcal B</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pneumococcal polysaccharide</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:**

1. For additional information regarding HIV laboratory parameters and use of live vaccines, see the General Best Practice Guidelines for Immunization "Altered ImmunoCOMPETENCE at www.cdc.gov/vaccines/hcp/acip-recs/general-recc/immunoComp.html" and Table 4.1 Item (c) at www.cdc.gov/vaccines/hcp/acip-recs/general-recc/contraindications.html.

2. Severe Combined Immunodeficiency

3. LAIV contraindicated for children 2-4 years of age with asthma or wheezing during the preceding 12 months.
The above recommendations are located at https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf
### Recommended Adult Immunization Schedule by Medical Condition and Other Indications

**United States, 2019**

<table>
<thead>
<tr>
<th>Vaccine</th>
<th>Pregnancy</th>
<th>Immuno-compromised (excluding HIV infection)</th>
<th>HIV Infection CD4 count</th>
<th>Anemia, complement deficiencies</th>
<th>End-stage renal disease, on hemodialysis</th>
<th>Heart or lung disease, alcoholism</th>
<th>Chronic liver disease</th>
<th>Diabetes</th>
<th>Health care personnel</th>
<th>Men who have sex with men</th>
</tr>
</thead>
<tbody>
<tr>
<td>Td or Td</td>
<td>1 dose Td each pregnancy</td>
<td>CONTRAINDIATED</td>
<td>1 dose annually</td>
<td>PRECAUTION</td>
<td>1 dose annually</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MMR</td>
<td>CONTRAINDIATED</td>
<td>1 or 2 doses depending on indication</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VAR</td>
<td>CONTRAINDIATED</td>
<td>2 doses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RZV (preferred)</td>
<td>DELAY</td>
<td>2 doses at age ≥50 yrs</td>
<td></td>
<td>1 dose at age ≥60 yrs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ZVL</td>
<td>CONTRAINDIATED</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV Female</td>
<td>DELAY</td>
<td>3 doses through age 26 yrs</td>
<td>2 or 3 doses through age 26 yrs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HPV Male</td>
<td>3 doses through age 26 yrs</td>
<td>2 or 3 doses through age 21 yrs</td>
<td></td>
<td>2 or 3 doses through age 26 yrs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCV13</td>
<td>1 dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PPSV23</td>
<td>1, 2, or 3 doses depending on age and indication</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HepA</td>
<td>2 or 3 doses depending on vaccine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HepB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MenACWY</td>
<td>1 or 2 doses depending on indication, then booster every 5 yrs if risk remains</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MenB</td>
<td>PRECAUTION</td>
<td>2 or 3 doses depending on vaccine and indication</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hib</td>
<td>3 doses HSCT recipients only</td>
<td>1 dose</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### Notes:
1. For LAIV does not apply to alcoholism. 2. See notes for influenza (H3N2 and H1N1), mumps, and rubella and varicella vaccinations. 3. Hematopoietic stem cell transplant.

---

The above recommendations are located at [https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf](https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf)
906. Diagnostic, Treatment and Referral Services

All suspicious or abnormal findings identified during an EPSDT preventive health visit must be treated or be further evaluated.

When an EPSDT service is needed but not performed during the EPSDT preventive health visit, the child provider should be appropriately referred for diagnosis.

For non-CMO (care management organization) Medicaid and PeachCare for Kids® Fee-For Service (FFS) members, the screening provider must either treat (if qualified) or refer all members with abnormal findings. Members needing referrals must be appropriately referred to Medicaid or PeachCare for Kids® enrolled providers. For information on billing levels allowed for treatment during the EPSDT periodic and interperiodic visits, see section 1003. Billing Tips.

If the provider is not the member’s EPSDT PCP, the provider must notify the member’s PCP of the preventive health/interperiodic visit to discuss any clinical findings which require prompt medical attention. Referral and prior authorization may be required for children who are assigned a PCP.

The level of treatment required should determine whether additional services are billed or provided during the EPSDT scheduled visit.

907. Lead Risk Assessment and Screening

907.1 Purpose:

The purpose of screening for lead absorption is to identify children who have either symptomatic or asymptomatic lead poisoning and to intervene as quickly as possible to reduce their blood lead levels.

907.2 Lead Screening:

A. Since 1989, Federal law has required that children enrolled in Medicaid must have their blood lead level measured at 12 and 24 months of age.

B. A blood lead test, capillary or venous, must be used when screening Medicaid-eligible children. A capillary Blood Lead Test that is elevated (≥ 10ug/dL reported by a certified lab or ≥ 6ug/dL with the Lead Care II analyzer) must be confirmed with a repeat Blood Lead Test (confirmatory venous specimen is preferred) at a certified laboratory.

C. ALL venous sample lead screening tests conducted using any Magellan Diagnostic lead testing system should be laboratory analyzed by a properly accredited laboratory.
907.3 Lead Health Education and Anticipatory Guidance

Health education is a required component of screening services (EPSDT benefit in accordance with section 1905(r) of the Act) and includes anticipatory guidance.

Anticipatory Guidance regarding Lead Exposure

Anticipatory guidance should be provided to families when children are:

A. 3-6 months of age and again at 12 months.
B. Between the ages of 24 and 72 months at well-child visits and when a lead risk assessment questionnaire is administered.

The following topics should be covered with anticipatory guidance:

A. Effects of lead poisoning on children
B. Sources of lead poisoning
C. Pathways of exposure (including placental exposure)
D. How to prevent a child’s exposure to lead hazards
E. Appropriate schedule for testing children for lead poisoning

907.4 Lead Case Management

All children whose initial screening test shows an elevated blood lead level should follow the Georgia Healthy Homes and Lead Poisoning Prevention Program’s (GHHLPPP) Case Management Guidelines. Georgia Department of Public Health (DPH) Lead Hazard Risk Assessors, under the guidance of the GHHLPPP, will perform an environmental lead risk assessment for all children with a confirmed blood lead level of >10 ug/dL, as well as provide education about low cost methods to reduce identified lead hazards. As a primary care provider, you will be notified by a DPH Lead Hazard Risk Assessor of the results of the environmental lead risk assessment and remediation recommendations.

Refer to the GHHLPPP Case Management Guidelines located in Appendix A, Guidelines in Screening and Reporting Elevated Blood Lead Levels.
908. Oral Health and Dental Services

Per the Federal EPSDT policy guidelines, dental services must be provided to eligible members under twenty-one years of age. Dental services required under the EPSDT benefit include:

- Dental care needed for relief of pain, infection, restoration of teeth, and maintenance of dental health (provided at as early an age as necessary); and
- Emergency, preventive, and therapeutic services for dental disease that, if left untreated, may become acute dental problems or cause irreversible damage to the teeth or supporting structures.

In addition, medically necessary oral health and dental services, including those identified during an oral screening or a dental exam, are covered under the EPSDT benefit.

Refer to the Dental Services Program Policy and Procedures Manual.

In accordance with the American Academy of Pediatric Dentistry (AAPD) Periodicity of Examination, Preventive Dental Services, Anticipatory Guidance/Counseling, and Oral Treatment for Infants, Children, and Adolescents, dental providers should refer to the “Recommendations for Pediatric Oral Health Assessment, Preventive Services, and Anticipatory Guidance/Counseling” Schedule. The AAPD intends these recommendations to help practitioners make clinical decisions concerning preventive oral health interventions, including anticipatory guidance and preventive counseling, for infants, children, and adolescents. The schedule may be assessed at http://www.aapd.org/assets/1/7/perodicity-aapdschedule.pdf
**Recommendations for Pediatric Oral Health Assessment, Preventive Services, and Anticipatory Guidance/Counseling**

Since each child is unique, these recommendations are designed for the care of children who have no contributing medical conditions and are developing normally. These recommendations will need to be modified for children with special health care needs or if disease or trauma manifests variations from normal. The American Academy of Pediatric Dentistry (AAPD) emphasizes the importance of very early professional intervention and the continuity of care based on the individualized needs of the child. Refer to the text of this guideline for supporting information and references.

![Recommendations Table](image)

---

*American Academy of Pediatric Dentistry (AAPD) 2009 “Recommendations for Pediatric Oral Health Assessment, Preventive Services, and Anticipatory Guidance/Counseling”*
FOOTNOTES
1. First examination at the eruption of the first tooth and no later than 12 months. Repeat every 6 months or as indicated by child’s risk status/susceptibility to disease. Includes assessment of pathology and injuries.
2. By clinical examination.
3. Must be repeated regularly and frequently to maximize effectiveness.
4. Timing, selection, and frequency determined by child’s history, clinical findings, and susceptibility to oral disease.
5. Consider when systemic fluoride exposure is suboptimal. Up to at least 16 years.
6. Appropriate discussion and counseling should be an integral part of each visit for care.
7. Initially, responsibility of parent; as child matures, jointly with parent; then, when indicated, only child.
8. At every appointment; initially discuss appropriate feeding practices, then the role of refined carbohydrates and frequency of snacking in caries development and childhood obesity.
9. Initially play objects, pacifiers, car seats; when learning to walk; then with sports and routine playing, including the importance of mouth guards.
10. At first, discuss the need for additional sucking: digits vs pacifiers; then the need to wean from the habit before malocclusion or skeletal dysplasia occurs. For school-aged children and adolescent patients, counsel regarding any existing habits such as fingernail biting, clenching, or bruxism.
11. For caries-susceptible primary molars, permanent molars, premolars, and anterior teeth with deep pits and fissures; placed as soon as possible after eruption.

909. Other Related Medicaid Programs (This is not an inclusive list)
See the policies and procedures manual of the related programs for complete information. Provider Manuals relevant to EPSDT providers include, but may not be limited to:
- Advanced Nurse Practitioner Services
- Children’s Intervention Services (CIS)
- Children’s Intervention School Services (CISS)
- Dental Services
- Diagnostic Screening and Preventive Services (DSPS)
- Durable Medical Equipment (DME) Services
- Federally Qualified Health Center (FQHC) Services
- Georgia Pediatric Program (GAPP)
- Hospice Services
- Hospital Services
- Medicaid Medicaid/PeachCare for Kids® Provider Billing Manuals
- Nurse Midwifery Services
- Orthotic and Prosthetic Services
- Pharmacy Services
- Physician Assistant Services
- Physician Services
- Rural Health Clinic (RHC) Services
- Vision Care Services

Provider Manuals are available for downloading. Contact DXC Technology (DXC) at 1-800-766-4456 or visit the website at www.mmis.georgia.gov for more information.
910. **Summary of Non-covered Services**

Non-Covered Services include:

- Screenings performed outside the provider’s office or clinic.
- Services provided in a manner inconsistent with the provisions of this manual.

911. **EPSDT Profile (Appointment Tracking System)**

The purpose of the EPSDT Appointment Tracking System is to track enrolled Fee-For-Service children eligible for services and to assist providers in conducting and documenting outreach and follow-up activities to EPSDT families and children.

The EPSDT Appointment Tracking System fully supports the State’s goals of providing appropriate and continuing screening and treatment services to Georgia’s children and of preventing more costly health problems by encouraging regular health care.

This system provides immediate access to medical and dental information on EPSDT members through online inquiry and provides a reminder call system at no cost to the EPSDT provider. These capabilities enhance the control and operation of the EPSDT program and allow information gathering to support research and program development.

In collaboration with the monthly EPSDT roster (Periodic Screenings Due Report), the EPSDT Profile (Appointment Tracking System) provides:

1. Member’s demographic information in addition to the last dates for Hearing (Interperiodic Hearing), Vision (Interperiodic Vision), EPSDT Medical and Dental screenings.

2. Detailed information on the member’s entire EPSDT history. This allows the provider to view the member’s entire EPSDT history and document outreach attempts as a result of letters/rosters distributed. Based on the notice type distributed by DXC, all the provider has to do is document the member’s response and a response date. For example, if the provider arranges a future appointment with the member, he/she will select scheduled appointment under the drop down box for response type and enter the date of the appointment under response date.

3. The Response Type options on the drop down box are:
   a. Set Appointment (EPSDT preventive health screening visit)
   b. Set Appointment (Dental)
   c. Set Appointment (Blood Lead).
   d. Screen Completed

4. The last section of the EPSDT Profile is the critical health information. EPSDT medical and dental providers are encouraged to enter information determined to be useful to another Health Care professional in the delivery of care to the member (For example, allergic to Penicillin).

5. If you need further instructions, feel free to click on the help link.
912. **EPSDT HIPAA Referral Codes**

The Centers for Medicare and Medicaid Services (CMS) defines an EPSDT referral as a member scheduled for another appointment with the EPSDT Provider or a referral to another provider for further needed diagnostic and treatment services as a result of at least one health problem identified during the EPSDT preventive health visit. Effective with HIPAA implementation, CMS and DCH require documentation of EPSDT Referral Codes when submitting EPSDT Screening Code Claims (See Appendix K for examples). When completing the Health Insurance Claim Form [CMS-1500], the EPSDT Referral Codes must be entered in the shaded area of box 24H. (See Appendix L)

**Example 1**: If the EPSDT screening is normal, the referral code is NU (No follow up visit needed)

**Example 2**: If the EPSDT screening indicates the need for further diagnostic and treatment services and a follow-up visit is necessary, use the applicable referral code(s):

- AV  Available, Not Used: Patient refused referral
- S2  Under Treatment: Patient is currently under treatment for health problem and has a return appointment.
- ST  New Services Requested: Referral to another provider for diagnostic or corrective treatment/scheduled.

913. **Access to Mental Health Services**

Behavioral Health Link operates the Georgia Crisis and Access Line (GCAL) through a contract with the Department of of Behavioral Health and Developmental Disabilities (DBHDD). To access mental health, addictive disease, and crisis services 24 hours a day, 7 days per week call 1-800-715-4225 (GCAL) or go to [www.mygcal.com](http://www.mygcal.com)

914. **Services for Foster Care Children**

As of March 3, 2014, children, youth, and young adults in state custody, children receiving adoption assistance and a select group of children under the Juvenile Justice system, were transitioned to Medicaid managed care under the Georgia Families 360° Program. Amerigroup Community Care is the single Care Management Organization (CMO) managing this population (see Appendix I). Children in state custody under the Kenny A. Consent Decree are required to have an EPSDT preventive health visit and a dental visit within 10 days of official transition to state custody. Unless otherwise noted, EPSDT services for all other children enrolled in the Georgia Families 360° Program should follow the Bright Futures Periodicity Schedule.
PART II - CHAPTER 1000

Basis for Reimbursement

1001. Fee for Service Reimbursement Methodology

The Division will pay the lower of the lowest price regularly and routinely offered to any segment of the general public for the same service or items on the same date(s) of service, the lowest price charged to other third party payers, or effective with dates of service July 1, 2003, the statewide maximum allowable reimbursement which is 84.645% of Medicare’s Resource Based Relative Value Scale (RBRVS) for 2000 for Region IV (Atlanta). All procedure codes recognized and adopted after the 2000 RBRVS are subject to the statewide maximum allowable reimbursement – 84.645% of the Region IV Medicare RBRVS in effect at the time the procedure code was adopted.

1002. Vaccines for Children

Since the Vaccines For Children (VFC) program supplies vaccines to providers at no cost to the provider for children birth through eighteen (18) years who have Medicaid, the Division will reimburse an administration fee only for immunizations given to Medicaid enrolled children of this age group. These fees cover the cost of administering the immunizations as well as any paper work involved (including an immunization or health certificate). Refer to Appendix C-2 for the reimbursement rates for the administration of vaccines provided by the VFC program for the Medicaid-eligible children birth through eighteen (18) years. Appendix C-2 also includes the reimbursement rate for the administration of state-purchased vaccines for the PeachCare for Kids® Fee for Service population, for children birth through age eighteen (18) years.

For members nineteen (19) years of age through twenty (20) years of age, VFC stock is not available. Providers must use their own stock of vaccines for these Medicaid eligible members. Health Check providers may include a vaccine administration code on their EPSDT claims when vaccines are administered to members nineteen (19) years of age through twenty (20) years of age. The Division will reimburse for the vaccine product and for vaccine administration. Billing tips for vaccine administration and the effective date for this change are located in Appendix C-1 of this manual and providers are strongly encouraged to follow those tips.
1003. Billing Tips

The following are tips to assist with billing for EPSDT screening services and interperiodic visits.

1. The EPSDT preventive health visit is reimbursed as a package of services. All of the age appropriate EPSDT preventive health visit components (as identified in the updated 2017 Bright Futures periodicity schedule) must be completed for each screening visit and billed under one procedure code except where indicated. All preventive or well-child services, except normal newborn care in the hospital, must be billed under the EPSDT Program following the policies and procedures as outlined in this manual.

2. EPSDT preventive health visits must be referred by or performed by the child’s primary care practitioner in order for those services to be reimbursed. Only one (1) periodic preventive or well-child visit will be reimbursed per member at each age appropriate interval, as specified in the periodicity schedule (excluding foster care members).

3. Providers must perform the age appropriate hearing and vision screening in order to be reimbursed for the complete EPSDT preventive health exam. Providers may not refer the child to another provider for hearing and vision screening which is required at the time of the EPSDT preventive health visit.

4. When a visit is found to be medically necessary between periodic visit sequences, the EPSDT provider may be reimbursed by billing the appropriate interperiodic visit procedure code. An interperiodic visit cannot be billed on the same date of service as a complete EPSDT preventive health visit.

5. The Georgia Medicaid program reimburses for many of the Diagnostic and Treatment services under other Medicaid programs.

6. Developmental Screenings

A developmental screening should be performed at the following periodic visits: 9, 18, and 30 months. Providers must bill code 96110 with the EP modifier and the appropriate preventive ICD-10 diagnosis code in order to receive reimbursement for this screening.

Only one (1) developmental screening will be reimbursed at each of these intervals. If the child is not seen at the 9, 18, or 30 month visit, a developmental screening should be performed during the catch-up visit for the missed periodic visit. This catch-up developmental screening should be billed, using the EP and HA modifiers with code 96110 and the appropriate preventive ICD-10 code. The provider can only bill one (1) catch-up developmental screening during any one (1) catch-up interval.
7. **Autism Screenings**

Autism screenings should be performed at the 18 and 24 month periodic visits (or catch-up visits). Providers must bill code 96110 with the EP,UA or EP,UA,HA modifiers and the appropriate ICD-10 diagnosis code in order to receive reimbursement for this screening.

Autism screenings when performed outside of the Bright Futures requirements can also be reported. Providers must bill code 96110 with the EP,UA modifiers and Z13.41 or the applicable ICD-10 diagnosis code to receive reimbursement for the screening.

8. **Brief Emotional/Behavioral Assessments**

   **Periodic Screening Visits**

   An annual depression screening should be performed for members ages 12 years through 20 years during the EPSDT periodic screening visit. When completed during the periodic visit, the depression screening can be reported as a brief emotional/behavioral assessment. Providers should bill code 96127 with the EP modifier, POS 99 and the appropriate ICD-10 diagnosis code in order to receive reimbursement.

   **Non-Periodic Screening Visits (Sick Visits)**

   Brief emotional/behavioral assessments, when performed during non-periodic screening visits, can also be reported for the following:

   - depression screenings (outside of the BF requirements); AND
   - emotional/behavioral assessments conducted for other conditions, such as ADHD, suicidal risk, anxiety, eating disorders, etc.

   Brief emotional/behavioral assessments performed during non-periodic visits should be billed with the E/M office visit code (992xx) and reported with procedure code 96127, the appropriate ICD-10 diagnosis code, along with the EP modifier and POS 99.

   Procedure code 96127:

   - is reimbursed at the current default rate
   - should be listed only once per claim for multiple units
     - units submitted should not exceed acceptable medically unlikely edit (MUE) maximum established by CMS
9. **Patient-Focused Health Risk Assessments**

Patient focused health risk assessments performed during the EPSDT periodic screening visit in accordance with the Bright Futures requirements may be reported (i.e., tobacco, alcohol, or drug use assessment; anemia risk assessment; lead risk assessment).

Providers should bill procedure code 96160 with the EP modifier, POS 99 and the appropriate ICD-10 diagnosis code in order to receive reimbursement. Code the health risk assessment (96160) with the EP, 59 modifiers when reporting the health risk assessment(s) and vaccine administration codes for the same visit.

Health risk assessments when performed outside of the Bright Futures requirements can also be reported. Health risk assessments performed during non-periodic visits should be reported with procedure code 96160, the appropriate ICD-10 diagnosis code, along with the EP modifier and POS 99. Code the health risk assessment (96160) with the EP, 59 modifiers when reporting the health risk assessment(s) and vaccine administration codes for the same visit.

Procedure Code 96160:

- is reimbursed at the current default rate.
- should be listed only once per claim for multiple units.
- units submitted should not exceed acceptable medically unlikely edit (MUE) maximum established by CMS.

10. **Caregiver-Focused Health Risk Assessments**

Caregiver focused health risk assessments performed during the EPSDT periodic screening visit in accordance with the Bright Futures requirements may be reported, (i.e., maternal depression screening).

A maternal depression screening should be performed during the following EPSDT periodic screening visits:

- By 1 month
- 2 month
- 4 month
- 6 month

Providers should bill procedure code 96161 with the EP modifier, POS 99 and the appropriate ICD-10 diagnosis code in order to receive reimbursement. Code the caregiver focused health risk assessment (96161) with the EP, 59 modifiers when reporting the health risk assessment(s) and vaccine administration codes for the same visit.

Caregiver focused health risk assessments when performed outside of the Bright Futures requirements can also be reported. Health risk assessments performed during non-periodic visits should be reported with procedure code 96161, the appropriate ICD-10 diagnosis code, along with the EP modifier and POS 99. Code the health risk assessment (96161) with the EP, 59 modifiers when reporting the health risk assessment(s) and vaccine administration codes (90460, 90471-74) for the same visit.
Procedure Code 96161:
- is reimbursed at the current default rate.
- should be listed only once per claim for multiple units.
- units submitted should not exceed acceptable medically unlikely edit (MUE) maximum established by CMS.

11. **Hematocrit and Hemoglobin Level**

The laboratory tests due at the twelve (12) month visit for hematocrit and hemoglobin levels may be performed as in office tests at the time of the EPSDT preventive health visit by the PCP; or the blood sample may be obtained by the PCP and submitted to a Medicaid contracted lab; or the member may be sent to a Medicaid contracted lab for the blood draw and laboratory analysis. The PCP must document in the medical record which option was selected. These tests cannot be sent to a non-participating laboratory for analysis.

12. **Federally required Blood Lead Level (BLL) screening**

If FFS EPSDT providers use private laboratories for BLL screening or perform BLL screening using an in office Lead Analyzer, the EPSDT provider cannot file a claim for reimbursement of the BLL test.

The Georgia Public Health Laboratory provides analysis of blood lead specimen and charges a laboratory fee. Fee for Service providers may submit claims to DCH for this fee if the blood sample is obtained by them during the visit and sent to the GPHL for analysis. To ensure accurate reimbursement, FFS providers must submit the CPT code 83655 with modifier EP and 90 or 91 on the CMS 1500 claim form along with the CPT codes 36415 or 36416 – modifier EP and ICD-10 diagnosis code Z13.88. Additional details regarding this process are contained in Appendix C-4.

13. **Vaccine Administration**

In order to receive the administration fee from the Division for administering federally or state purchased vaccines for children 0 – 18 years of age, the child must be a Medicaid or PeachCare for Kids® member. Since the federally or state purchased vaccines are provided at no cost to the provider, the Division will only reimburse an administration fee based upon the Division’s maximum allowable rate. (See Chapter 1000, Section 1002). The vaccine’s National Drug Code (NDC) is not required to be included on the EPSDT claim for reimbursement for the administration of federally or state purchased vaccines for children 0-18 years of age.

Beginning April 1, 2013, providers should bill any and all of the following appropriate vaccine administration codes, when administering VFC vaccines, as they apply: 90460, 90471, 90472, 90473, 90474. Additional details regarding the use of the vaccine administration codes are contained in Appendix C-1.
EPSDT providers may bill the EPSDT Program for vaccines administered to members nineteen (19) years of age through twenty (20) years of age. Include the vaccine CPT code, diagnosis code, and NDC, along with the appropriate vaccine administration code(s) [90471, 90472, 90473, 90474] on the EPSDT claim. The Division will reimburse for the vaccine product (providers must use their own stock of vaccines) and for vaccine administration. Additional details regarding the use of the vaccine administration codes and the effective date for this change are contained in Appendix C-1.

14. **Office Visit Codes**

Providers must use place of service (POS) code 99 when billing office visits for EPSDT preventive health screening services. All diagnostic x-ray, laboratory testing (except hematocrit, hemoglobin) and/or treatment services provided to the EPSDT member at the time of the preventive health visit, can be billed on the same CMS 1500 claim form as the EPSDT preventive health visit if the EPSDT provider uses a CMS 1500 form to bill Diagnostic and Treatment Services (i.e., Physician Services, Nurse Practitioner Services, etc.).

Effective May 1, 2015, paper claims are no longer accepted by DXC Technology. As part of the Georgia Paperless Initiative, providers are required to submit CMS 1500 claims electronically over the GAMMIS web portal. For more information regarding the Paperless Initiative, please access the web portal and review all related Banner Messages.

If an EPSDT provider uses a UB 04 to bill Diagnostic and Treatment services (i.e., Hospitals, Rural Health Clinics, etc.), they may also bill the EPSDT preventive health visit services on the UB 04.

15. **School-Based Influenza Vaccine Clinics**

Public Health providers must use place of service (POS) code 03 when billing the vaccine administration fee for Influenza vaccines administered during school-based Influenza vaccine clinics held within their county of jurisdiction. Only the Influenza vaccine administration will be reimbursed during these school-based Influenza vaccine clinics.

16. **School-Based Telemedicine Services**

LEAs enrolled as Health Check providers to serve as telemedicine originating sites only will be allowed to bill the telemedicine originating site facility fee (procedure code Q3014). The LEA provider should report procedure code Q3014 along with the EP and GT modifiers, POS 03, and the appropriate ICD-10 diagnosis code(s). The diagnosis code(s) should be the same diagnosis code(s) listed on the distant site (rendering) provider’s claim.

The rendering provider serving as the telemedicine distant site should report the E/M office visit code (992xx) along with the GT modifier (including any other applicable modifiers), the appropriate POS, and the ICD-10 diagnosis code(s).
In order for the originating site (LEA) provider to receive reimbursement for procedure code Q3014, a corresponding paid history claim from the distant site provider must be found in GAMMIS. The distant site provider’s claim billed for the same member, same date of service, with an E/M office visit code (992xx), the same ICD-10 diagnosis code(s) and the GT modifier, will confirm that a telemedicine service was rendered. If no record of the E/M claim is found that aligns with the LEA provider’s originating site claim, the originating site claim will suspend up to 30 days after submission in search of the E/M claim. If no record of an E/M claim is found within 30 days after submission of the LEA provider’s originating site claim, reimbursement to the LEA provider will be denied. It is the responsibility of the LEA provider to contact the provider who rendered the distant site service to determine if the E/M visit was billed.

The telemedicine originating facility fee is reimbursed at the current DEFAULT rate.

17. **Consultation Services**

Effective July 1, 2014, providers enrolled in the EPSDT Program, may bill for reimbursement of the following office/outpatient consultation codes: 99241, 99242, 99243, 99244, 99245. The EP modifier must be added to the applicable code along any other applicable modifiers. A consultation service can be rendered once every three years.

18. **Tobacco Cessation Counseling Services**

Effective January 1, 2014, the Division began coverage of tobacco cessation counseling services to all Medicaid members. Providers enrolled in the EPSDT Program may bill 99406 and 99407 for the reimbursement of tobacco cessation counseling. The EP modifier must be added to the applicable code.

The tobacco cessation counseling must be rendered in a face-to-face setting with the member. Only two 12-week tobacco cessation treatment periods will be allowed per member per year. The provider must document the services in the member’s medical record every 30 days during the 12-week treatment period.

19. **Incontinence Supplies**

Incontinence supplies are covered for children ages 4 through 21 years who have an underlying medical condition that prevents control of the bowels or bladder. There must be documentation of the patient’s diagnosis which supports the medical necessity of all items requested. Incontinence supplies must be prescribed by the physician who is responsible for treating the condition. Incontinence supplies are not covered for convenience. Providers may bill the following procedure codes: T4521-T4535, T4541, T4544 for the incontinence supplies. Prior approval (PA) is required. Refer to the Durable Medical Equipment (DME) Manual for further guidance.
20. Fluoride Varnish

Once teeth are present, the application of fluoride varnish is required and may be applied every 3-6 months in the primary care or dental office for children between the ages of 6 months and 5 years.

21. Other Procedure Codes

When billing for EPSDT screening services and interperiodic visits, only the procedure codes for those services found in this manual may be reimbursed under the EPSDT Program. Reimbursement for other services billable to Medicaid is covered under the program areas overseeing the delivery of those services.

22. National Correct Coding Initiative (NCCI) Medically Unlikely Edits (MUEs) Limits

Providers are reminded to bill in compliance with the NCCI MUE limit for procedure codes and to check the MUE file, at minimum, on a quarterly basis for updates. Procedure codes submitted with frequencies greater than the allowed MUE will be denied according to the NCCI MUE regulations set by CMS.

23. NCCI Procedure-To-Procedure (PTP) Edits

Providers are reminded to bill in compliance with the NCCI PTP edits. The NCCI PTP edits define pairs of Healthcare Common Procedure Coding System (HCPCS)/Current Procedural Terminology (CPT) codes that should not be reported together. The purpose of the PTP edits is to prevent improper payments when incorrect code combinations are reported. Procedure codes that should not be reported together will be denied according to the NCCI PTP edits defined by CMS.
### 24. **Other Reimbursement Rates**

<table>
<thead>
<tr>
<th>Procedure Code &amp; Description</th>
<th>Modifier(s)</th>
<th>Current Default Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>96110 – Developmental Screening</td>
<td>EP or EP HA</td>
<td>$11.77</td>
</tr>
<tr>
<td>96110 – Autism Screening</td>
<td>EP UA or EP UA HA</td>
<td>$11.77</td>
</tr>
<tr>
<td>96127 – Brief Emotional/ Behavioral Assessment (depression screening)</td>
<td>EP</td>
<td>$4.55</td>
</tr>
<tr>
<td>96160 – Patient-Focused Health Risk Assessment (i.e., tobacco, alcohol, drug use risk assessment)</td>
<td>EP</td>
<td>$3.95</td>
</tr>
<tr>
<td>96161 – Caregiver-Focused Health Risk Assessment (i.e., maternal depression screening)</td>
<td>EP</td>
<td>$3.95</td>
</tr>
<tr>
<td>Q3014 – Telehealth Originating Site Facility Fee</td>
<td>EP</td>
<td>$20.52</td>
</tr>
<tr>
<td>99241 – Patient Office Consultation, typically 15 minutes</td>
<td>EP</td>
<td>$48.05</td>
</tr>
<tr>
<td>99242 – Patient Office Consultation, typically 30 minutes</td>
<td>EP</td>
<td>$78.78</td>
</tr>
<tr>
<td>99243 – Patient Office Consultation, typically 40 minutes</td>
<td>EP</td>
<td>$100.50</td>
</tr>
<tr>
<td>99244 – Patient Office Consultation, typically 60 minutes</td>
<td>EP</td>
<td>$139.12</td>
</tr>
<tr>
<td>99245 – Patient Office Consultation, typically 80 minutes</td>
<td>EP</td>
<td>$180.61</td>
</tr>
<tr>
<td>99406 – Smoking and Tobacco Use Intermediate Counseling, Greater than 3 minutes up to 10 minutes</td>
<td>EP</td>
<td>$10.51</td>
</tr>
<tr>
<td>99407 – Smoking and Tobacco Use Intensive Counseling, Greater than 10 minutes</td>
<td>EP</td>
<td>$20.71</td>
</tr>
</tbody>
</table>

*Reviewed 9/20/2019*
Effective July 1, 2016, physicians and physician extenders who are eligible for the HB 751 FY 2017 Primary Care Providers (PCP) rate increase will be reimbursed $180.26 when procedure code 99244 is billed for established Medicaid-eligible and PeachCare for Kids®-eligible members.

Effective July 1, 2017, physicians and physician extenders who are eligible for the HB 44 FY 2018 Primary Care Providers (PCP) rate increase will be reimbursed at the following rates, as indicated in the table below when the specified codes are billed for established Medicaid-eligible and PCK-eligible members.

<table>
<thead>
<tr>
<th>Procedure Code</th>
<th>Description</th>
<th>Modifier(s)</th>
<th>HB 751 FY2017 Increased Reimbursement Rate</th>
<th>HB 44 FY2018 Increased Reimbursement Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>99241</td>
<td>Patient Office Consultation, typically 15 minutes</td>
<td>EP</td>
<td>n/a</td>
<td>$48.05</td>
</tr>
<tr>
<td>99242</td>
<td>Patient Office Consultation, typically 30 minutes</td>
<td>EP</td>
<td>n/a</td>
<td>$88.77</td>
</tr>
<tr>
<td>99243</td>
<td>Patient Office Consultation, typically 40 minutes</td>
<td>EP</td>
<td>n/a</td>
<td>$121.39</td>
</tr>
<tr>
<td>99244</td>
<td>Patient Office Consultation, typically 60 minutes</td>
<td>EP</td>
<td>$180.26</td>
<td>n/a</td>
</tr>
<tr>
<td>99245</td>
<td>Patient Office Consultation, typically 80 minutes</td>
<td>EP</td>
<td>n/a</td>
<td>$220.80</td>
</tr>
<tr>
<td>99406</td>
<td>– Smoking and Tobacco Use Intermediate Counseling, greater than 3 min up to 10 min</td>
<td>EP</td>
<td>n/a</td>
<td>$13.59</td>
</tr>
<tr>
<td>99407</td>
<td>– Smoking and Tobacco Use Intensive Counseling, greater than 10 minutes</td>
<td>EP</td>
<td>n/a</td>
<td>$26.91</td>
</tr>
</tbody>
</table>

Questions regarding Medicaid billing should be directed to Georgia Health Partnership (GHP) at 1-800-766-4456 or ‘contact us’ at www.mmis.georgia.gov
The mission of the Georgia Healthy Homes and Lead Poisoning Prevention Program (GHHLPPP) is to eliminate childhood lead poisoning in Georgia.

Screening Guidelines: Children

Screening for lead poisoning helps identify children who need interventions to reduce their blood lead levels. Many children who may have been exposed to lead or who are at risk for lead poisoning go without being screened. This makes their chances of being harmed by lead greater. Parents and providers should know when a child should be tested for lead poisoning.

Guidelines in Screening and Reporting Elevated Blood Lead Levels:

**Lead Screening Requirements & Medical Management Recommendations**

(For Children ages 6 to 72 months)

**RISK FACTORS ASSESSMENT QUESTIONNAIRE**

---ask these questions at the 6, 9, 12, 18, 24 months and 3, 4, 5, 6 years of age preventive visits---

1. Is your child living in or regularly visiting, or has your child lived in or regularly visited, a house or child care center built before 1978?

2. Does your child have a sibling or playmate that has or has had lead poisoning?

3. Does your child come in contact with an adult who works in an industry or has a hobby that uses lead (battery factory, steel smelter, stained glass, fishing or hunting)?

4. Does your child live near an active lead smelter, battery recycle plant, or other industry likely to release lead?

5. Does your child chew on or eat non-food items like paint chips or dirt?

6. Has your child spent more than 1 week in South or Central America, Africa, or Asia since their last blood test?

7. Does anyone in your family use ethnic folk remedies; use imported cosmetics or eat candies made outside the United States; or use pottery imported from South or Central America, Africa or Asia?

If the answer is YES or UNKNOWN to any of the questions, a blood lead test is necessary!

Test the blood of ALL Medicaid children for lead poisoning at 12 and 24 months of age AND children 3 to 6 years of age if never tested regardless of their risk factors.
# Lead Screening Requirements and Medical Management Recommendations for Children

Test ALL Medicaid children at 12 and 24 months of age AND children 3 to 6 years of age if never tested regardless of their risk factors

It is a Federal Requirement
Recommended Medical and Case Management Actions

<table>
<thead>
<tr>
<th>Blood Lead Level (BLL)</th>
<th>Confirmatory Blood Lead Test</th>
<th>Hospitalization</th>
<th>Chelation Therapy</th>
<th>Blood Lead Level Re-Test</th>
<th>Referrals</th>
<th>History &amp; Physical</th>
<th>Lead Poisoning Education</th>
<th>Reducing Exposure &amp; Absorption</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 - 9 μg/dl</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Within 1 year</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>10 - 14 μg/dl</td>
<td>Within 1 day to 3 months – venous or capillary</td>
<td>No</td>
<td>No</td>
<td>See Retest Chart below</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>15 - 19 μg/dl</td>
<td>Within 1 day to 3 months – venous or capillary</td>
<td>No</td>
<td>No</td>
<td>See Retest Chart below</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>20 - 44 μg/dl</td>
<td>Within 1 day to 3 months – venous or capillary</td>
<td>No</td>
<td>No</td>
<td>See Retest Chart below</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>45 - 69 μg/dL</td>
<td>Within 1 day to 1 month – venous or capillary</td>
<td>No if home is lead-safe</td>
<td>Yes</td>
<td>See Retest Chart below</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>&gt;70 μg/dL or Higher</td>
<td>Within 24-48 hours, venous only</td>
<td>YES MEDICAL EMERGENCY</td>
<td>Yes</td>
<td>See Retest Chart below</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

There is no safe level of lead in the body — damage caused by lead poisoning is permanent and irreversible!

1 If the child’s blood lead level persists between 10-14 μg/dl (2 blood lead tests 3 months apart) proceed according to the level of care for 15-19 μg/dL.
Explanation of Recommended Medical and Case Management Actions

(A) **Chelation Therapy**: if chelation therapy is indicated, the child should be immediately removed from the hazardous environment until the child’s environment is made lead-safe; however, if the home is already lead-safe, the child may remain in the home unless hospitalization is indicated.

(B) **Referrals**: contact local health department and/or GHHLPPP to assist in case management and environmental investigations.

(C) **History and Physical**: take medical, environmental, and nutritional history, test for anemia and iron deficiency, assess neurological, psychosocial, and language development, screen all siblings under age 6, and evaluate risk of other family members, especially pregnant women.

(D) **Lead Poisoning Education**: discuss sources of lead, effects of lead, lead-based paint hazards associated with living in a pre-1978 and/or renovating a pre-1978 home. Discuss how lead affects prenatal care and well child care at ages 3, 6, and 12 months and explain what blood lead levels mean and their significance. Lastly, contact GHHLPPP for information.

(E) **Reducing Exposure and Absorption**: discuss damp cleaning to remove lead dust on surfaces, eliminating access to deteriorating lead paint surfaces, and ensuring regular meals which are low in fat and rich in calcium and iron; contact GHHLPPP for materials.

**ELEVATED BLOOD LEAD RE-TEST CHART**

Use this chart to determine when to retest children who are **confirmed as lead-poisoned**. Venous testing is **strongly preferred**, but capillary testing is acceptable.

<table>
<thead>
<tr>
<th>If the child’s last confirmed BLL was...</th>
<th>and... if the child’s blood lead level HAS NOT DROPPED at least 3 μg/dl over a span of at least 3 months...</th>
<th>if the child’s blood lead level HAS DROPPED at least 3 μg/dl over a span of at least 3 months...</th>
</tr>
</thead>
<tbody>
<tr>
<td>10-14 μg/dL</td>
<td>3 months</td>
<td>6 months</td>
</tr>
<tr>
<td>15-19 μg/dL</td>
<td>3 months</td>
<td>3 months</td>
</tr>
<tr>
<td>20-24 μg/dL</td>
<td>1 month</td>
<td>2 months</td>
</tr>
<tr>
<td>25-44 μg/dL</td>
<td>1 month</td>
<td>1 month</td>
</tr>
<tr>
<td>45-69 μg/dL</td>
<td>1 month after chelation</td>
<td>1 month after chelation</td>
</tr>
<tr>
<td>≥70 μg/dL</td>
<td>1 month after chelation</td>
<td>1 month after chelation</td>
</tr>
</tbody>
</table>

Retesting should occur until the blood lead level is less than 10 μg/dL for six months, all lead hazards have been removed, housing is made lead-safe, and no new exposure exists.

---

Rev. 10/12  
Rev. 04/14  
Rev. 07/15  
Rev. 10/19

---

Department of Public Health, 2 Peachtree Street NW, 13th Floor, Atlanta, Ga, 30303, Phone (404) 657-6534 | For more info: Toll Free 1-888-247-9054 | Fax (404) 463-4039  
Lead Screening Guidelines for Children
Screening for lead poisoning helps identify children who need interventions to reduce their blood lead levels. Many children who may have been exposed to lead or who are at risk for lead poisoning go without being screened. This makes their chances of being harmed by lead greater. Parents and providers should know when a child should be tested for lead poisoning.

Medicaid and PeachCare for Kids
All children enrolled in Medicaid and PeachCare for Kids® should be tested for lead poisoning and offered certain services based on the following schedule:

<table>
<thead>
<tr>
<th>Age</th>
<th>Lead Blood Test</th>
<th>Lead Risk Assessment Questionnaire</th>
<th>Anticipatory Guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 months</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>9 months</td>
<td>X (risk assessment if not enrolled in Medicaid)</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>12 months</td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>24 months</td>
<td>X (risk assessment if not enrolled in Medicaid)</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>36-72 months</td>
<td>X - If there's no record of previous test at 12 and 24 months</td>
<td>X - Complete annually unless blood lead test performed</td>
<td>X</td>
</tr>
</tbody>
</table>


Lead Risk Assessment Questionnaire
The GHHLPPP Childhood Lead Risk Questionnaire can be found at: [https://dph.georgia.gov/lead-screening-guidelines-children](https://dph.georgia.gov/lead-screening-guidelines-children) in **English**, **Spanish** and **Vietnamese**.

When using the questionnaire, blood lead tests should be done right away if the child is at high risk (one or more "yes" or "I don't know" answers on the lead risk assessment questionnaire) for lead exposure. Completing this questionnaire does not count as a lead screening.

Blood Lead Test
A blood test is the preferred method for lead screening. There are two tests used to obtain blood lead specimens: capillary blood test or venous blood test. Finger stick capillary blood tests (the Lead Care II Analyzer uses capillary blood) can be done as the initial screening. However, a lab analyzed sample is necessary for confirmation. Safety measures should be taken to reduce the risk of contamination of the capillary blood sample. These measures include:

- Rinsing powder from the examination gloves
- Thoroughly washing patient's hands with soap and water, then drying them before taking a sample.
A venous blood test can be done as the initial screening as well. This method should always be used to confirm elevated blood lead test results when a capillary test was used as the initial screening. Alternatively, a second lab analyzed capillary test can be used to confirm an initial capillary test when the test is conducted according to the schedule in Table 1 - Lead Screening Requirements and Medical Management Recommendations for Children ages 6 to 72 months.

All venous sample lead screening tests conducted using any Magellan Diagnostic lead testing system should be laboratory analyzed by a properly accredited laboratory.

If a child’s capillary Blood Lead Test comes back elevated (≥10µg/dL reported by a certified lab or ≥6µg/dL using the Lead Care II analyzer), then a confirmatory test must be performed. The confirmatory diagnostic test should be lab analyzed and done according to the schedule in Table 1 - Lead Screening Requirements and Medical Management Recommendations for Children ages 6 to 72 months.

If the schedule in Table 1 is not followed and 6 months has gone by since the initial screening test, the next test is considered a new screening test. Decisions on follow-up testing should be made based on the results of the new screening test, not on the basis of the original screening test.

Lab Submission

The Waycross Regional Laboratory provides an analysis of blood lead specimens to Georgia children less than 72 months of age. The provider’s office should contact the laboratory to use this service. GHHLPPP does not recommend or endorse the use of another lab.

Waycross Public Health Laboratory
1751 Gus Karle Parkway
Waycross, Georgia 31503
912-338-7050

Reporting Guidelines

Laboratories attempt to test each lead specimen on the day it arrives. The reports are mailed back to providers on the same day. All laboratory data is sent monthly in electronic format to GHHLPPP.

Providers should report the results of all screening and follow-up blood lead level (BLL) tests to GHHLPPP. Because data from laboratories often do not include demographic information, complete reports from providers’ office are very important. If reports are not complete, GHHLPPP may contact providers’ offices for missing information.

Results must be reported by:

- [State Electronic Notification Disease Surveillance System (SendSS)](https://www.depbio.org/sslcompass/login)
  - SendSS is a web-based reporting system designed to collect information about notifiable diseases in Georgia. [Click here](https://www.depbio.org/sslcompass/login/) for reporting instructions. [Click here](https://www.depbio.org/sslcompass/login/) for Blood Lead Test Reporting Log spreadsheet template.
Providers who utilize the Lead Care II Analyzer to perform blood lead tests should report the Lead Care II Analyzer generated results to the GHHLPPP. On a weekly basis, providers should upload their test results to the State Electronic Notification Disease Surveillance System (SendSS). SendSS recommends providers keep track of their Lead Care II Analyzer test results by documenting those results in a Blood Lead Test Reporting Log provided by GHHLPPP (link above). If reports are not complete, GHHLPPP may contact providers’ offices for missing information. Complete a new Blood Lead Reporting each week. Upload the Blood Lead Test Reporting Log and submit weekly to the GHHLPPP via SendSS. For uploading instructions, refer to the SendSS Registration and Login Manual for Uploading Lead Report Files.

Blood Lead Test Reporting Log: Click here
Registration and Login Manual
for Uploading Lead Report Files
Version 4.0

Table of Contents

Registration Procedure
Signing In
File Upload Process

Registration and Login Manual for Uploading Lead Report Files may be accessed at:

Registration procedure

The home page can be accessed with the following URL and is best viewed using Microsoft Internet Explorer Version 6.x.x. https://sendss.state.ga.us

In order to gain access to SENDSS, you will first need to fill in a registration form and create a login. This can be done by pressing “Click Here” as shown above [1].

• Remember to use a userid that is easily remembered
• Fill out Password Information
1. Select the type of organization you will be entering cases for.
2. Select the name of your organization. If you cannot find your organization select “Enter a New Organization” from the select box and the section will change and appear as below.
3. City, County, State, and District are not editable once an organization is entered into SendSS. If all the information for this section does not appear when you select an organization, you will be asked to provide it the first time you log in to SendSS.

1. This section appears if a new user needs to enter an organization for which SendSS does not have a current user. Please fill in all information and press “Add”. Then continue filling out the registration form.
October 2019

EPSDT Services – Health Check Program

1. Select the type of access you will require from SendSS from section 1. At a minimum, please check “Lead User”
2. Please answer the questions in section 2.
3. Enter any comments in this section
4. Press “Save” to complete your registration.

Signing In

SendSS
State Electronic Notifiable Disease Surveillance System

Welcome to SendSS v4!

If you are new to SendSS and have not yet registered for a user account, please Click Here to fill out the short registration form. Once you have received your account confirmation by email, you will be able to begin using SendSS.

Thank you for taking the time to register. An email will be sent to you once you have been approved.

User Id: [enter user id]
Password: [enter password]

If you forget your password, you can request a new one. You can also find frequently asked questions here.

Login
**Key to features**

1. Help – A link to documentation and manual for SendSS version 4.0.
2. Contact Us – Send an internal message.
3. Warnings and Messages – Text will appear in red to alert users of failed logins or other relevant messages such as successful registration.
4. User Id – Enter the user id you chose when registering.
5. Password – Enter the password you chose when registering. This password must be reset every 3 months. After 3 months SendSS will allow 3 grace logins before locking your account. You will be prompted to change your password at this time.
6. Forgot Password – Click here to request your password.
7. Frequently Asked Questions –
8. VeriSign -- The certificate authority utilized by SENDSS is Verisign. Clicking on the graphic will display the validity of the SSL certificate.
9. SendSS Demo System -- Clicking on this image will take you to the Demonstration site. A separate registration is required to access this site.
10. Health Statistics Query -- This link will take you to the Notifiable Disease Query
11. Georgia Peach – Click this image to access the Georgia State Epidemiology Web site.

**SendSS - Disclaimer**

**SendSS Privacy Statement**

This system will allow persons authorized by DHR to access protected health information about individuals for reporting and treatment purposes. This information is entitled to significant privacy protections under federal and state law. The Health Insurance Portability and Accountability Act of 1996 (HIPAA) permits a covered entity to use and disclose protected health information without written authorization if the use or disclosure is for treatment, payment, or healthcare operations. However, HIPAA requires covered entities to have in place appropriate administrative, technical, and physical safeguards to protect the privacy of protected health information. The disclosure of this information to unauthorized persons or for unauthorized purposes is prohibited without the written consent of the person who is the subject of the information, unless specifically permitted by federal or state law. Unauthorized disclosures of this information may result in significant criminal or civil penalties, as well as punishment up to and including the termination of employment. Failure to properly logout of SENDSS can result in an unauthorized disclosure. Any unauthorized disclosures will be investigated promptly and thoroughly prosecuted.

Agreeing with the Privacy Statement confirms your status as an authorized SENDSS user who is accessing the database only for reporting and treatment purposes. Agreeing with the Privacy Statement also confirms that as an authorized SENDSS user you will reasonably safeguard protected health information from any use or disclosure that is in violation of the Privacy Statement or state and federal law.


Before you can enter the system, you must accept the Privacy Statement [1]. Selecting “I disagree with this statement” will terminate your login and return you to the login page.
File Upload Process

To upload a lead report file, begin by moving your mouse over the “Admin Tab” and clicking on the “File Transfer” menu item:

You will see a screen that asks you to select a file for uploading. To do this, click the browse button:

Locate the folder where you have saved the lead report files and then click the file name. After clicking on the file, click the open button:
You should see the file name that you selected appear in the box next to the browse button:
Click the “Upload File” button. Once the file is uploaded the screen will refresh and the file will appear in the list of recently uploaded files, as below:

You are finished!
# Georgia Childhood Lead Poisoning Prevention Program
## Case Management Guidelines

<table>
<thead>
<tr>
<th>Blood Lead Level</th>
<th>Recommendations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>&lt; 5 µg/dL</strong></td>
<td>• No safe threshold above “0” has been identified. Medical provider should provide anticipatory guidance for any blood lead level (BLL) above “0”.</td>
</tr>
</tbody>
</table>
| **5 – 9µg/dL**   | • Perform additional blood lead tests within 1 year according to the Georgia Childhood Lead Screening Guidelines.*  
• GHHLPPP will provide educational material to parents  
• GHHLPPP will contact parents for consultation on confirmed cases |
| **10 – 19µg/dL** | Per GHHLPPP recommendations, the **medical provider** will:  
• Conduct diagnostic (confirmatory) test (venous preferred) within 3 months. If child is < 12 months old or it is believed the BLL may be increasing rapidly, the test should be done earlier.  
• Test other children in the home <72 months of age who have not been tested in the last 6 months.  
• Conduct nutritional assessment  
• Continue testing at 3 month intervals until all the following conditions are met:  
  o BLL has remained <10µg/dL for at least 6 months (two tests at least 3 months apart)  
  o Lead hazards have been controlled.  
  o There are no new sources of lead exposure  
GHHLPPP or the Case Management Provider will send, by mail, or deliver the following information to the caregiver:  
• Child should receive a diagnostic (confirmatory) test (venous preferred) within 3 months.  
• Recommendation to have other children in the home <72 months of age who have not been tested in the last 6 months, tested.  
GHHLPPP will refer the case to one of the Regional Healthy Homes Coordinators (RHHC)  
**Regional Healthy Homes Coordinator** or Case Management Provider will give in-person (or in some cases by phone or mail) to caregiver:  
• Information on lead poisoning cause and effect, environmental lead hazard reduction, and nutrition.  
• Information on WIC services available.  
• Information on Children 1st Program information (newborns to 5 years old)  
• Information on Children’s Medical Services (CMS) if child =>5 years old  
**Regional Healthy Homes Coordinator** will also:  
• Conduct or arrange an environmental risk assessment by a certified risk assessor. Risk assessment should occur within 2 weeks of receiving referral from GHHLPPP. |
## Georgia Childhood Lead Poisoning Prevention Program
### Case Management Guidelines

<table>
<thead>
<tr>
<th>Blood Lead Level</th>
<th>Recommendations</th>
</tr>
</thead>
</table>
| **20 – 44µg/dL** | Per GHHLPPP recommendations, the medical provider will:  
  - Conduct diagnostic (confirmatory) test (venous preferred) within 1 week-1 month  
  - Test other children in the home <72 months of age who have not been tested in the last 6 months.  
  - Conduct comprehensive medical evaluation including nutritional assessment  
  - Continue testing at 3 month intervals until all the following conditions are met:  
    - BLL has remained <10µg/dL for at least 6 months (two tests at least 3 months apart)  
    - Lead hazards have been controlled.  
    - There are no new sources of lead exposure  
  
  GHHLPPP or the Case Management Provider will send, by mail, the following information to the caregiver:  
  - Child should receive a diagnostic (confirmatory) test (venous preferred) within 1 week to 1 month,  
  - Recommendation to have other children in the home <72 months of age who have not been tested in the last 6 months, tested.  
  
  GHHLPPP will refer the case to one of the Regional Healthy Homes Coordinators (RHHC)  

  **Regional Healthy Homes Coordinator** or the Case Management Provider will give in-person (or in some cases by phone or mail) to caregiver:  
  - Information on lead poisoning cause and effect, environmental lead hazard reduction, and nutrition.  
  - Information on WIC services available.  
  - Information on Children’s Medical Services (CMS) if child =>5 years old  

  **Regional Healthy Homes Coordinator** will also:  
  - Conduct or arrange an environmental risk assessment by a certified risk assessor. Risk assessment should occur within 1-2 weeks of receiving referral from GHHLPPP.  
  - Send by mail (or in some cases call) a summary of risk assessment and recommendations to the caregiver, property owner and medical provider.  
  - Provide a copy of the risk assessment in approved format to GHHLPPP. |
| **45 – 69µg/dL** | **URGENT** Per GHHLPPP recommendations, the medical provider will:  
  - Conduct diagnostic (confirmatory) test (venous preferred) within 24-48 hours.  
  - Test other children in the home <72 months of age who have not been tested in the last 6 months.  
  - Conduct comprehensive medical evaluation, including nutrition assessment and consider pharmacologic treatment. Contact the Georgia Poison Center for consultation. |
<table>
<thead>
<tr>
<th>Blood Lead Level</th>
<th>Recommendations</th>
</tr>
</thead>
</table>
| 45 – 69µg/dL     | • Continue testing at 1-2 month intervals until all the following conditions are met:  
|                  |   o BLL has remained <45µg/dL for at least 4 months (two tests at least 2 months apart) then start follow up blood lead testing at 3 month intervals until BLL has remained <10µg/dL for at least 6 months (two tests at least 3 months apart)  
|                  |   o All identified lead hazards have been controlled  
|                  |   Note: A child receiving chelation therapy MAY NOT return to the home until all lead hazards have been controlled.  
|                  |   o There are no new sources of lead exposure.  
|                  | GHHLPPP or the Case Management Provider will give, by phone, the following recommendation to the caregiver:  
|                  |   • Child should receive a diagnostic (confirmatory) test (venous preferred) within 24-48 hours,  
|                  |   • Recommendation to have other children in the home <72 months of age who have not been tested in the last 6 months, tested.  
|                  | GHHLPPP will refer the case to one of the Regional Healthy Homes Coordinators (RHHC)  
| Regional Healthy Homes Coordinator | or the Case Management Provider will give in-person (or in some cases by phone) to caregiver:  
|                  |   • Information on lead poisoning cause and effect, environmental lead hazard reduction, and nutrition.  
|                  |   • Information on WIC services available.  
|                  |   • Information on Children 1st Program information (newborns to 5 years old)  
|                  |   • Information on Children’s Medical Services (CMS) if child =>5 years old  
| Regional Healthy Homes Coordinator | will also:  
|                  |   • Conduct or arrange an environmental risk assessment by a certified risk assessor.  
|                  |   Risk assessment should occur within 48 hours of receiving referral from GHHLPPP.  
|                  |   • Call-in a summary of risk assessment and recommendations to the caregiver, property owner and medical provider.  
|                  |   • Provide a copy of the risk assessment in approved format to GHHLPPP.  |
| > 70µg/dL        | MEDICAL EMERGENCY. DO NOT DELAY MEDICAL TREATMENT.  
|                  | Per GHHLPPP recommendations, the medical provider will:  
|                  |   • Conduct diagnostic (confirmatory) test (venous preferred) as emergency lab test.  
|                  |   • Conduct immediate medical evaluation and pharmacologic treatment. Contact the Georgia Poison Center for consultation.  
|                  |   • Test other children in the home <72 months of age who have not been tested in the last 6 months. |
### Blood Lead Level | Recommendations
--- | ---
> 70µg/dL | • Continue testing at 1-2 month intervals until all the following conditions are met:  
  o BLL remains <45µg/dL for at least 4 months (two tests at least 2 months apart) then start follow up blood lead testing at 3 month intervals until BLL has remained <10µg/dL for at least 6 months (two tests at least 3 months apart)  
  o All identified lead hazards have been controlled  
  Note: A child receiving chelation therapy MAY NOT return to the home until all lead hazards have been controlled.  
  o There are no new sources of lead exposure.

GHHLPPP or the Case Management Provider will give, by phone, the following recommendation to the caregiver:

- Child should receive a diagnostic (confirmatory) test (venous preferred) immediately.
- Recommendation to have other children in the home <72 months of age who have not been tested in the last 6 months, tested.

GHHLPPP will refer the case to one of the Regional Healthy Homes Coordinators (RHHC)

**Regional Healthy Homes Coordinator** or the Case Management Provider will give in-person (or in some cases by phone) to caregiver:

- Information on lead poisoning cause and effect, environmental lead hazard reduction, and nutrition.
- Information on WIC services available.
- Information on Children 1st Program information (newborns to 5 years old)
- Information on Children’s Medical Services (CMS) if child =>5 years old

**Regional Healthy Homes Coordinator** will also:

- Conduct or arrange an environmental risk assessment by a certified risk assessor. Risk assessment should occur within 24 hours of receiving referral from GHHLPPP.
- Call-in a summary of risk assessment and recommendations to the caregiver, property owner and medical provider
- Provide a copy of the risk assessment in approved format to GCLPPP.
- If child must go to different housing unit post chelation, RHHC will inspect the new unit for lead hazards and inform medical provider that home is lead safe prior to child’s release from hospital.

*GA-AAP recommends a follow-up blood test within 3 months if the initial test is 5-9 µg/dL

**For questions on the GHHLPPP guidelines, please contact:**
Georgia Healthy Homes and Lead Poisoning Prevention Program  
2 Peachtree Street, NW | 13th Floor | Atlanta, GA 30303  
Phone: 404-657-6534 | Fax: 404-463-4039  
[https://dph.georgia.gov/lead](https://dph.georgia.gov/lead)
ENVIRONMENTAL LEAD RISK ASSESSMENTS

Certified Lead Risk Assessors who conduct the initial environmental lead risk assessment should bill Medicaid using code T1028 and the appropriate diagnosis code. For follow up clearance inspections following removal of the lead hazards, the certified lead risk assessor should bill Medicaid using code T1028 with the U-1 modifier. For additional information, please consult the Diagnostic Screening and Preventive Services (DSPS) Manual.

<table>
<thead>
<tr>
<th>Procedure Code</th>
<th>Initial lead investigation</th>
<th>Post hazard abatement</th>
</tr>
</thead>
<tbody>
<tr>
<td>T1028</td>
<td></td>
<td>T1028 - (Modifier U-1)</td>
</tr>
</tbody>
</table>

Georgia and other Lead Resources

Lead Information for Professionals and Parents
For information on lead poisoning and prevention, professionals and parents can call GHHLPPP (Georgia Healthy Homes and Lead Poisoning Prevention Program) at 404-657-6534 or the National Lead Information Center at 1-800-424-lead (5323).

Georgia Public Health Laboratory (GPHL)
The Georgia Public Health Laboratory, which has locations in Decatur and Waycross performs blood lead testing on children for the Georgia Healthy Homes and Lead Poisoning Prevention Program (GHHLPPP). Contact information:

GPHL
1749 Clairmont Road
Decatur, GA 30033
Phone 1-800-GEORGIA.

Emergency Information on Lead:
Call the Georgia Poison Center at 1-800-222-1222.
Sources of Lead

Common Sources of Lead

- Lead-based paint
- Lead dust, which is produced by aging lead-based paint
- Soil, which is contaminated by lead emissions from gasoline (prior to 1978), lead-based paint chips, storage of old batteries, etc.
- Water which flows through lead pipes or copper pipes soldered with lead (prior to 1986)
- Improperly glazed ceramic pottery and cooking utensils

Industries

- Battery manufacturers or reclamation
- Window replacement
- Bronze manufacture
- Firing range instructors
- Gas station attendants
- Glass manufacturers
- Lead pigment manufacture
- Lead smelters and refiners
- Plumbers, pipe fitters
- Policemen who work in automobile tunnels
- Printers
- Radiator manufacture or repair
- Shipbuilders
- Welders or Cutters – Steel burning or cutting (dismantling bridges, ships, etc.)
- Bridge or ship workers (including airports and boats)
- Construction workers, particularly those doing:
  - Department of Transportation (DOT) Sign Makers
  - Painting
  - Remodeling
  - Renovation
  - Road work (specifically painters)

Hobbies, Sports, Other

- Moonshine whiskey
- Car or boat repair
- Fishing
- Glazed pottery making
- Home remodeling
- Lead soldering
- Making lead shot or bullet
- Shooting at firing range
- Stained glass manufacture
- Additives to some “health foods” and imported candies
- Substance Use
- Toy soldiers (leaded)
- Folk Remedies – Most commonly found in Mexican, Asian Indian, and Middle Eastern groups. Names include: Alarcon, Alkohl, Azarcon, Bali Goli, Coral, Ghasard, Greta, Liga, Pay-loo-ah, Rueda. Cosmetics, used commonly by those from the Middle East and India.
**Guidelines in Screening and Reporting for TB Disease and Infection**

**Tuberculin Skin Testing**

Mantoux tuberculin skin testing is the standard method of identifying persons infected with M. tuberculosis. Multiple puncture tests should **NOT** be used to determine whether a person is infected.

The Mantoux test is performed by giving an intradermal injection of 0.1 ml of purified protein derivative (PPD) tuberculin containing 5 tuberculin units (TU) into either the volar or dorsal surface of the forearm. The injection should be made with a disposable tuberculin syringe, just beneath the surface of the skin, with the needle bevel facing upward. This should produce a discrete, pale elevation of the skin (a wheal) 6 mm to 10 mm in diameter.

The reaction to the Mantoux test should be read by a trained health care worker 48 to 72 hours after the injection. If a patient fails to show up for the scheduled reading, a positive reaction may still be measurable up to 1 week after testing.

However, if a patient who fails to return within 72 hours has a negative reaction, tuberculin testing should be repeated.

The area of induration (palpable swelling) around the site of injection is the reaction to tuberculin. The diameter of the indurated area should be measured across the forearm (perpendicular to the long axis). Erythema (redness) should not be measured. All reactions should be recorded in millimeters of induration, even those classified as negative. If no induration is found, “0 mm” should be recorded.

**Reporting requirements**

In Georgia, all tuberculosis must be reported immediately to the local county health department. Physicians, hospitals, laboratories and other health care providers are required to report any of the following:

- Any child less than 5 years discovered with Latent TB Infection
- Any confirmed case of TB
- Any suspected case of TB
- Any person being treated with two (2) or more anti-tuberculosis drugs
- Any positive culture for Mycobacterium tuberculosis
- Any positive smear for AFB (Acid Fast Bacilli)
How to report

- Report cases electronically through the State Electronic Notifiable Disease Surveillance System (SENDSS)
- Complete a Notifiable Disease Report Form and mail in an envelope marked CONFIDENTIAL, or
- Call your District Health Office
- If your District Health Office cannot be reached, call the Georgia Department of Public Health, TB Section at 404-657-2634.

Childhood TB Risk Assessment Questionnaires

The AAP Bright Futures Guidelines for Health Supervision of Infants, Children, and Adolescents (3rd edition) recommends asking the following questions:

1) Was your child born in a country at high risk for tuberculosis?
2) Has your child traveled (had contact with resident populations) for longer than 1 week to a country a high risk for tuberculosis?
3) Has a family member or contact had tuberculosis or a positive tuberculin skin test?

Resource: [https://brightfutures.aap.org/materials-and-tools/Pages/default.aspx](https://brightfutures.aap.org/materials-and-tools/Pages/default.aspx)

For more information about tuberculosis in Georgia: contact
Georgia Tuberculosis (TB) Section
2 Peachtree St. NW
12th Floor
Atlanta, GA 30303
(Phone) 404-657-2634
(Fax) 404-463-3460

The TB Program has the legal responsibility for all TB clients in Georgia regardless of who provides the direct services. TB services are available to all who fall within the service criteria without regard to the client's ability to pay.

### APPENDIX C-1

**Vaccine Administration Codes**

<table>
<thead>
<tr>
<th>HIPAA Procedure Code</th>
<th>HIPAA Modifier</th>
<th>Procedure Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>90460</td>
<td>EP</td>
<td>Pediatric Immunization Administration Code. Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional.</td>
</tr>
<tr>
<td>90471</td>
<td>EP</td>
<td>Non-Age Specific Immunization Administration Code. Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); one vaccine (single or combination vaccine/toxoid).</td>
</tr>
<tr>
<td>90472</td>
<td>EP</td>
<td>Non-Age Specific Immunization Administration Code. Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid).</td>
</tr>
<tr>
<td>90473</td>
<td>EP</td>
<td>Non-Age Specific Immunization Administration Code. Immunization administration (includes intranasal or oral administration); one vaccine (single or combination vaccine/toxoid).</td>
</tr>
<tr>
<td>90474</td>
<td>EP</td>
<td>Non-Age Specific Immunization Administration Code. Immunization administration (includes intranasal or oral administration); each additional vaccine (single or combination vaccine/toxoid).</td>
</tr>
</tbody>
</table>

### Vaccine Administration Code for Face-to-Face Counseling

**90460** - Vaccine administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional.

90460 is reported when both of the following requirements are met: (1) The patient must be 18 years of age or younger. (2) The physician or other qualified health care professional must perform face-to-face vaccine counseling associated with the administration. *(Any clinical staff can do the actual administration of the vaccine per the physician’s or the qualified health care professional’s orders.)*

If both of these requirements are not met, report a non-age specific vaccine administration code(s) (90471-90474) instead.

**90460 may be reported for more than one (1) unit of vaccine administered during a single office visit.**

Note: Local Public Health Departments May use vaccine administration code 90460 only if a physician or other qualified health care professional performs face-to-face vaccine counseling associated with administration of the vaccine.
A ‘qualified health care professional’ is an individual who by education, training, licensure/regulation, facility credentialing (when applicable), and payer policy is able to perform a professional service within their scope of practice and independently report a professional service. These professionals are distinct from ‘clinical staff.’ A clinical staff member is a person who works under the supervision of a physician or other qualified health care professional and who is allowed by law, regulation, facility, and payer policy to perform or assist in the performance of specified professional services, but who does not individually report any professional services. (CPT 2012)

**Non-Age Specific Vaccine Administration Codes**

These codes must be used when there is no face-to-face physician counseling associated with vaccine administration. The add-on codes (90472, 90474) may also be used in conjunction with the 90460 code.

Codes 90471 and 90473 are used to code for the first vaccine given during a single office visit. Codes 90472 and 90474 are considered add-on codes (*hence the + symbol next to them*) to 90471 and 90473, respectively. This means that the provider will use 90472 and 90474 in addition to 90471 or 90473 if more than one vaccine is administered during a visit. Providers may use 90460 for the first (i.e., counseled) vaccine and 90472 or 90474 for the second (i.e., non-counseled) vaccine. Note that there can only be one first administration during a given visit.

90471 - Vaccine administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); one vaccine (single or combination vaccine/toxoid)

Do not report 90471 in conjunction with 90473 or 90460

+90472 - Vaccine administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure.)

May use 90472 in conjunction with 90471 or 90473 or 90460

90473 - Vaccine administration (includes intranasal or oral administration); one vaccine (single or combination vaccine/toxoid)

Do not report 90473 in conjunction with 90471 or 90460

+90474 - Vaccine administration (includes intranasal or oral administration); each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure.)

May use 90474 in conjunction with 90471 or 90473 or 90460

**Vaccine Administration Codes for 19 – 20 year olds**

EPSDT providers may bill the EPSDT benefit for vaccines administered to members nineteen (19) years of age through twenty (20) years of age. Providers must include the vaccine’s CPT, NDC, and diagnosis code, along with the appropriate vaccine administration code(s) [90471, 90472, 90473, 90474] on the EPSDT claim. The Division will reimburse for the vaccine product (providers must use their own stock of vaccines) and for vaccine administration.
Billing Tips

• Code the vaccine administration with the appropriate vaccine administration code and the EP modifier.

• For the vaccine, code the vaccine product code, the associated diagnosis code and the EP modifier.

• The primary vaccine administration code (90460, 90471, or 90473) must precede the add-on vaccine administration code(s) (90472 or 90474), if applicable.

• The vaccine product code must immediately follow the corresponding vaccine administration code.

• Code the vaccine administration code(s), the vaccine product code(s), and the preventive or interperiodic visit on the same claim when vaccines are administered during a preventive or interperiodic visit. Each vaccine administration code should be listed only once per claim. If multiple vaccine product codes correspond to the same vaccine administration code, the vaccine administration code is listed once with the appropriate number of units indicated.

• 90460 may be reported for more than one (1) unit of vaccine administered during a single office visit.

• May report diagnosis code Z00.121 or Z00.129 or Z23.0 with each of the vaccine administration codes ONLY when vaccines are administered during EPSDT preventive health visits for members through age 17 years.

• May report diagnosis code Z00.00 or Z00.01 or Z23.0 with the applicable vaccine administration code ONLY when vaccines are administered during EPSDT preventive health visits for members age 15 years through 20 years.

• Use the appropriate vaccine diagnosis code with the vaccine administration code when the vaccine is administered outside of the EPSDT preventive health visit.

• Code the EPSDT preventive visit (9938x or 9939x) with the EP and the 25 modifiers when vaccines are administered during the preventive health visit.

• Code the EPSDT interperiodic visits (99201-99203 or 99212-99214) with the EP and the 25 modifiers when vaccines are administered during the interperiodic health visit.

• The National Correct Coding Initiative (NCCI) does not allow reimbursement of the 99211 code when it is billed together with any of the vaccine administration codes regardless of whether the 25 modifier is appended to the 99211 code.
Effective January 1, 2013, the vaccine administration reimbursement rates for administering immunizations under the EPSDT Program were adjusted. The Medicaid maximum allowable reimbursement for vaccine administration is $10.00 for Medicaid Fee for Service Providers and $18.50 for PeachCare for Kids® Fee for Service Providers, as indicated in Table C-1a.

### Table C-1a

<table>
<thead>
<tr>
<th>HIPAA Procedure Code</th>
<th>Medicaid Fee For Service (FFS) Reimbursement</th>
<th>PeachCare for Kids® (PCK) Fee For Service (FFS) Reimbursement</th>
</tr>
</thead>
<tbody>
<tr>
<td>90460</td>
<td>$10.00</td>
<td>$18.50</td>
</tr>
<tr>
<td>90471</td>
<td>$10.00</td>
<td>$18.50</td>
</tr>
<tr>
<td>90472</td>
<td>$10.00</td>
<td>$18.50</td>
</tr>
<tr>
<td>90473</td>
<td>$10.00</td>
<td>$18.50</td>
</tr>
<tr>
<td>90474</td>
<td>$10.00</td>
<td>$18.50</td>
</tr>
</tbody>
</table>

Effective July 1, 2016, physicians and physician extenders who are eligible for the HB 751 FY 2017 Primary Care Providers (PCP) rate increase will be reimbursed the following rates, as indicated below in Table C-1b, when the specified codes are billed for established Medicaid-eligible and PeachCare for Kids®-eligible members.

### Table C-1b

<table>
<thead>
<tr>
<th>HIPAA Procedure Code</th>
<th>Medicaid Fee For Service (FFS) Reimbursement</th>
<th>PeachCare for Kids® (PCK) Fee For Service (FFS) Reimbursement</th>
</tr>
</thead>
<tbody>
<tr>
<td>90460</td>
<td>$21.93</td>
<td>$21.93</td>
</tr>
<tr>
<td>90471</td>
<td>$23.54</td>
<td>$23.54</td>
</tr>
<tr>
<td>90472</td>
<td>$11.98</td>
<td>$18.50</td>
</tr>
</tbody>
</table>

Effective July 1, 2017, physicians and physician extenders who are eligible for the HB 44 FY 2018 Primary Care Providers (PCP) rate increase will be reimbursed at the following rates, as indicated below in Table C-1c, when the specified codes are billed for established Medicaid-eligible and PCK-eligible members.

### Table C-1c

<table>
<thead>
<tr>
<th>HIPAA Procedure Code</th>
<th>Medicaid Fee For Service (FFS) Reimbursement</th>
<th>PeachCare for Kids® (PCK) Fee For Service (FFS) Reimbursement</th>
</tr>
</thead>
<tbody>
<tr>
<td>90473</td>
<td>$23.54</td>
<td>$23.54</td>
</tr>
<tr>
<td>90474</td>
<td>$11.98</td>
<td>$18.50</td>
</tr>
</tbody>
</table>
**APPENDIX C-2**

**Vaccine Procedure and Diagnosis Codes**  
(Ages Birth through 18 years)

The following vaccine procedure and diagnosis codes must be included on the claim, following the vaccine administration code, when billing for vaccine administration.

<table>
<thead>
<tr>
<th>HIPAA Procedure Code</th>
<th>HIPAA Modifier</th>
<th>Procedure Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>90620</td>
<td>EP</td>
<td>Meningococcal recombinant protein and outer membrane vesicle vaccine, serogroup B (MenB-4C), 2 dose schedule, for intramuscular use (10-18 years) [Bexsero]</td>
</tr>
<tr>
<td>90621</td>
<td></td>
<td>Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use (10-18 years) [Trumenba]</td>
</tr>
<tr>
<td>90633</td>
<td>EP</td>
<td>Hepatitis A vaccine (HepA), pediatric/adolescent dosage-2 dose schedule, for intramuscular use</td>
</tr>
<tr>
<td>90636</td>
<td>EP</td>
<td>Combination Hepatitis A/Hepatitis B vaccine, adult dosage, 3 dose, for intramuscular use (18 years)</td>
</tr>
<tr>
<td>90647</td>
<td>EP</td>
<td>Haemophilus influenzae type B vaccine (Hib), PRP-OMP conjugate, 3 dose schedule, for intramuscular use</td>
</tr>
<tr>
<td>90648</td>
<td></td>
<td>Haemophilus influenzae type b vaccine (Hib), PRP-T conjugate, 4 dose schedule, for intramuscular use</td>
</tr>
<tr>
<td>90651</td>
<td>EP</td>
<td>Human Papillomavirus (HPV) vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58 nonavalent (9vHPV), 2 or 3-dose schedule, for intramuscular use (females and males 9 years and older) [Gardasil 9]</td>
</tr>
<tr>
<td>90674</td>
<td></td>
<td>Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit preservative and antibiotic free, 0.5mL dosage, for intramuscular use</td>
</tr>
<tr>
<td>90685</td>
<td>EP</td>
<td>Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use</td>
</tr>
<tr>
<td>90686</td>
<td></td>
<td>Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use</td>
</tr>
<tr>
<td>90687</td>
<td></td>
<td>Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.25 mL dosage, for intramuscular use</td>
</tr>
<tr>
<td>90688</td>
<td></td>
<td>Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use</td>
</tr>
<tr>
<td>90672</td>
<td></td>
<td>Influenza virus vaccine (FluMist), quadrivalent, live (LAIIV4), for intranasal use (2 years and older)</td>
</tr>
<tr>
<td>90756</td>
<td></td>
<td>Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5mL dosage, for intramuscular use</td>
</tr>
<tr>
<td>HIPAA Procedure Code</td>
<td>HIPAA Modifier</td>
<td>Procedure Code Description</td>
</tr>
<tr>
<td>----------------------</td>
<td>---------------</td>
<td>----------------------------</td>
</tr>
<tr>
<td>90670 EP</td>
<td></td>
<td>Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use</td>
</tr>
<tr>
<td>90680 EP</td>
<td></td>
<td>Rotavirus vaccine, pentavalent (RV5), 3 dose schedule, live, for oral use (RotaTeq)</td>
</tr>
<tr>
<td>90681 EP</td>
<td></td>
<td>Rotavirus vaccine, human, attenuated (RV1), 2 dose schedule, live, for oral use (Rotarix)</td>
</tr>
<tr>
<td>90696 EP</td>
<td></td>
<td>Diphtheria, tetanus toxoids, and acellular pertussis vaccine and inactivated poliovirus vaccine, (DTaP-IPV), for intramuscular use (ages 4-6 years)</td>
</tr>
<tr>
<td>90698 EP</td>
<td></td>
<td>Diphtheria, tetanus toxoids, acellular pertussis vaccine, Haemophilus influenza type B, and inactivated poliovirus vaccine (DTaP-IPV/Hib), for intramuscular use</td>
</tr>
<tr>
<td>90700 EP</td>
<td></td>
<td>Diphtheria, tetanus toxoids, and acellular pertussis vaccine (DTaP), for intramuscular use (ages younger than 7 years)</td>
</tr>
<tr>
<td>90707 EP</td>
<td></td>
<td>Measles, mumps, and rubella virus vaccine (MMR), live, for subcutaneous use</td>
</tr>
<tr>
<td>90710 EP</td>
<td></td>
<td>Measles, mumps, rubella, and varicella vaccine (MMRV), live, for subcutaneous use</td>
</tr>
<tr>
<td>90713 EP</td>
<td></td>
<td>Poliovirus vaccine (IPV), inactivated, for subcutaneous or intramuscular use</td>
</tr>
<tr>
<td>90714 EP</td>
<td></td>
<td>Tetanus and diphtheria toxoids (Td) adsorbed, preservative free, for intramuscular use (7 years to 18 years, 11 months)</td>
</tr>
<tr>
<td>90715 EP</td>
<td></td>
<td>Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), for intramuscular use (7 years to 18 years, 11 months)</td>
</tr>
<tr>
<td>90716 EP</td>
<td></td>
<td>Varicella virus vaccine (VAR), live, for subcutaneous use</td>
</tr>
<tr>
<td>90723 EP</td>
<td></td>
<td>Diphtheria, tetanus toxoids, acellular pertussis vaccine, Hepatitis B and inactivated poliovirus vaccine (DTaP-Hep B-IPV), for intramuscular use</td>
</tr>
<tr>
<td>90732 EP</td>
<td></td>
<td>Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, when administered to 2 years or older, for subcutaneous or intramuscular use</td>
</tr>
<tr>
<td>90734 EP</td>
<td></td>
<td>Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier, (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use</td>
</tr>
<tr>
<td>90744 EP</td>
<td></td>
<td>Hepatitis B vaccine (HepB), pediatric/adolescent dosage, 3 dose schedule, for intramuscular use</td>
</tr>
<tr>
<td>90747 EP</td>
<td></td>
<td>Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage, 4 dose schedule, for intramuscular use</td>
</tr>
</tbody>
</table>
The Division will reimburse for the vaccine product (providers must use their own stock of vaccines) and for vaccine administration for vaccines administered to Medicaid-eligible members nineteen (19) years of age through twenty (20) years of age. Providers who administer any one of the vaccines listed below will receive reimbursement for administering each vaccine PLUS reimbursement for the vaccine product. The reimbursement rates for the vaccine products may be found in the Physicians’ Injectable Drug List Manual. Providers must include the vaccine’s procedure and diagnosis codes on the claim.

### Vaccine Procedure and Diagnosis Codes (Ages 19 through 20 years)

<table>
<thead>
<tr>
<th>HIPAA Procedure Code</th>
<th>HIPAA Modifier</th>
<th>Procedure Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>90620</td>
<td>EP</td>
<td>Meningococcal recombinant protein and outer member vesicle vaccine, serogroup B (MenB-4C), 2 dose schedule, for intramuscular use (Bexsero)</td>
</tr>
<tr>
<td>90621</td>
<td>EP</td>
<td>Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use (Trumenba)</td>
</tr>
<tr>
<td>90632</td>
<td>EP</td>
<td>Hepatitis A vaccine (HepA), adult dosage, for intramuscular use</td>
</tr>
<tr>
<td>90636</td>
<td>EP</td>
<td>Combination Hepatitis A/Hepatitis B vaccine, adult dosage, 3 dose, for intramuscular use</td>
</tr>
<tr>
<td>90746</td>
<td>EP</td>
<td>Hepatitis B vaccine (HepB), adult dosage 3 dose schedule, for intramuscular use</td>
</tr>
<tr>
<td>90747</td>
<td>EP</td>
<td>Hepatitis B vaccine (HepB), dialysis or immunosuppressed patient dosage 4 dose, for intramuscular use</td>
</tr>
<tr>
<td>90651</td>
<td>EP</td>
<td>Human Papillomavirus HP vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonaivalent (9vHPV), 2 or 3-dose schedule, for intramuscular use (females &amp; males) [Gardasil 9]</td>
</tr>
<tr>
<td>90656</td>
<td>EP</td>
<td>Influenza virus vaccine, trivalent (IIV3), split virus, preservative free, 0.5 mL dosage, for intramuscular use</td>
</tr>
<tr>
<td>90674</td>
<td></td>
<td>Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, preservative and antibiotic free, 0.5mL dosage, for intramuscular use</td>
</tr>
<tr>
<td>90682</td>
<td></td>
<td>Influenza virus vaccine, quadrivalent (RIV4), derived from recombinant DNA, hemagglutinin (HA) protein only, preservative and antibiotic free, for intramuscular use</td>
</tr>
<tr>
<td>90686</td>
<td></td>
<td>Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use</td>
</tr>
<tr>
<td>90688</td>
<td></td>
<td>Influenza virus vaccine, quadrivalent (IIV4), split virus, 0.5 mL dosage, for intramuscular use</td>
</tr>
<tr>
<td>90672</td>
<td></td>
<td>Influenza virus vaccine (FluMist), quadrivalent, live (LAIV4), for intranasal use (2 years and older)</td>
</tr>
<tr>
<td>90756</td>
<td></td>
<td>Influenza virus vaccine, quadrivalent (ccIIV4), derived from cell cultures, subunit, antibiotic free, 0.5mL dosage, for intramuscular use</td>
</tr>
</tbody>
</table>
### Vaccine Procedure and Diagnosis Codes
(Ages 19 through 20 years)

<table>
<thead>
<tr>
<th>HIPAA Procedure Code</th>
<th>HIPAA Modifier</th>
<th>Procedure Code Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>90707</td>
<td>EP</td>
<td>Measles, mumps, and rubella virus vaccine (MMR), live, for subcutaneous use</td>
</tr>
<tr>
<td>90713</td>
<td>EP</td>
<td>Poliovirus vaccine (IPV), inactivated, for adults at high risk, for subcutaneous or intramuscular use</td>
</tr>
<tr>
<td>90714</td>
<td>EP</td>
<td>Tetanus and diphtheria toxoids (Td) absorbed, preservative free, for intramuscular use</td>
</tr>
<tr>
<td>90715</td>
<td>EP</td>
<td>Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), for intramuscular use</td>
</tr>
<tr>
<td>90716</td>
<td>EP</td>
<td>Varicella virus vaccine (VAR), live, for subcutaneous use</td>
</tr>
<tr>
<td>90670, 90732</td>
<td>EP</td>
<td>Pneumococcal conjugate vaccine, 13 valent (PCV13), for intramuscular use</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pneumococcal polysaccharide vaccine, 23-valent (PPSV23), adult or immunosuppressed patient dosage, for subcutaneous or intramuscular use</td>
</tr>
<tr>
<td>90734</td>
<td>EP</td>
<td>Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier, (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use</td>
</tr>
</tbody>
</table>
The maximum reimbursement rate for the TB skin test provided by private providers is $8.13 and $3.00 for public health providers.

Use the following procedure and diagnosis codes to document the Tuberculin Skin Test.

<table>
<thead>
<tr>
<th>HIPAA Procedure Code</th>
<th>ICD-10 Diagnosis Code</th>
<th>HIPAA Modifier</th>
<th>Procedure Code Description</th>
<th>Fee For Service Reimbursement</th>
</tr>
</thead>
<tbody>
<tr>
<td>86580</td>
<td>Z11.1</td>
<td>EP</td>
<td>TB Skin Test</td>
<td>$3.00 (public) $8.13 (private)</td>
</tr>
</tbody>
</table>
**APPENDIX C-4**

*Blood Lead Level Testing Procedure Codes*

**Blood Lead Level (BLL):**

Blood Lead Screenings should be performed at the 12 and 24 month periodic visits (or catch-up visits). There are two tests used to obtain blood lead level (BLL) specimens: capillary blood test or venous blood test. Finger stick capillary blood tests can be done as the initial screening; however, a lab analyzed sample is necessary for confirmation. The specimen may be sent to a private laboratory for analysis, the analysis may be performed using an in-office blood lead level analyzer (the Lead Care II Analyzer uses capillary blood), or sent to the Georgia Public Health Laboratory (GPHL).

Providers should bill code 83655 with the EP modifier, diagnosis code Z13.88 (or other applicable diagnosis code that indicates the child is receiving a screening blood lead test), on the same claim with the appropriate blood test code 36415 (blood lead venous) or 36416 (blood lead capillary).

<table>
<thead>
<tr>
<th>HIPAA Procedure Code</th>
<th>HIPAA Modifier</th>
<th>Procedure Code Description</th>
<th>ICD-10 Diagnosis Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>83655</td>
<td>EP</td>
<td>Blood Lead Level Test</td>
<td>Z13.88*</td>
</tr>
<tr>
<td>36415</td>
<td>EP</td>
<td>Blood Lead Level Venous</td>
<td>Z13.88</td>
</tr>
<tr>
<td>36416</td>
<td>EP</td>
<td>Blood Lead Level Capillary</td>
<td>Z13.88</td>
</tr>
</tbody>
</table>

*Z13.88 (or other applicable diagnosis code that indicates the child is receiving a screening blood lead test)*

Providers who send BLL specimen to the Georgia Public Health Laboratory (GPHL) will be billed $10.00 lab handling fee assessed by the GPHL. Therefore, Fee For Service (FFS) providers should bill code 83655 with modifiers EP, 90 or EP, 91 and diagnosis code Z13.88 on the same claim with the appropriate codes (36415 or 36416) as seen below. This billing will result in a FFS reimbursement of $10.00 for the lab handling fee assessed by the GPHL. This reimbursement is only available when documentation supports that the BLL specimen was sent to the GPHL.

<table>
<thead>
<tr>
<th>HIPAA Procedure Code</th>
<th>HIPAA Modifier</th>
<th>ICD-10 Diagnosis Code</th>
<th>Fee For Service Reimbursement</th>
</tr>
</thead>
<tbody>
<tr>
<td>83655</td>
<td>EP, 90 or EP, 91</td>
<td>Z13.88*</td>
<td>$10.00 (only available when documentation supports that the BLL specimen was sent to the GPHL)</td>
</tr>
<tr>
<td>36415</td>
<td>EP</td>
<td>Z13.88</td>
<td></td>
</tr>
<tr>
<td>36416</td>
<td>EP</td>
<td>Z13.88</td>
<td></td>
</tr>
</tbody>
</table>

*Z13.88 (or other applicable diagnosis code that indicates the child is receiving a screening blood lead test)*
<table>
<thead>
<tr>
<th>Diagnosis Code/ Modifier</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Z13.88</td>
<td>Encounter for screening for disorder due to exposure to contaminants.</td>
</tr>
<tr>
<td>Modifier 90</td>
<td>Reference (Outside) Laboratory: When laboratory procedures are performed by a party other than the treating or reporting practitioner, the procedure may be identified by adding modifier 90 to the usual procedure number.</td>
</tr>
<tr>
<td>Modifier 91</td>
<td>Repeat Clinical Diagnostic Laboratory Test: In the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results.</td>
</tr>
</tbody>
</table>
APPENDIX D

Children's Intervention Services

The Children’s Intervention Services (CIS) program offers coverage for restorative and/or rehabilitative services to eligible members in non-institutional settings. Services must be determined medically necessary and be recommended and documented as appropriate interventions by a physician or other licensed practitioner of the healing arts, within their scope of practice under state law, for the maximum reduction of physical disability or developmental delay and restoration of the member to the best possible functional level.

The CIS program is comprised of seven intervention services that must be provided by licensed practitioners of the healing arts. The seven services are:

- Audiology
- Nursing
- Nutrition provided by licensed dieticians
- Occupational Therapy
- Physical Therapy
- Counseling provided by licensed clinical Social Workers
- Speech-language Pathology

Qualified providers must be currently licensed as audiologists, registered nurses, dietitians, occupational therapists, physical therapists, clinical social workers, or speech-language pathologists.
APPENDIX E

Medicaid Non-Emergency Transportation

People enrolled in the Medicaid program need to get to and from health care services, but many do not have any means of transportation. The Non-Emergency Transportation Program (NET) provides a way for Medicaid recipients to get that transportation so they can receive necessary medical services covered by Medicaid.

How do I get non-emergency transportation services?
If you are a Medicaid recipient and have no other way to get to medical care or services covered by Medicaid, you can contact a transportation broker to take you. In most cases, you must call three days in advance to schedule transportation. Urgent care situations and a few other exceptions can be arranged more quickly. Each broker has a toll-free telephone number to schedule transportation services, and is available weekdays (Monday-Friday) from 7 a.m. to 6 p.m. All counties in Georgia are grouped into five regions for NET services. A NET Broker covers each region. If you need NET services, you must contact the NET Broker serving the county you live in to ask for non-emergency transportation. See the chart below to determine which broker serves your county, and call the broker's telephone number for that region.

What if I have problems with a NET broker?
The Division of Medical Assistance (DMA) monitors the quality of the services brokers provide, handling consumer complaints and requiring periodic reports from the brokers. The state Department of Audits also performs on-site evaluations of the services provided by each broker. If you have a question, comment or complaint about a broker, call the Member CIC at 866-211-0950.

<table>
<thead>
<tr>
<th>Region</th>
<th>Broker/Phone Number</th>
<th>Counties Served</th>
</tr>
</thead>
<tbody>
<tr>
<td>North</td>
<td>Southeastrans</td>
<td>Banks, Barrow, Bartow, Catoosa, Chattooga, Cherokee, Cobb, Dade, Dawson, Douglas, Fannin, Floyd, Forsyth, Franklin, Gilmer, Gordon, Habersham, Hall, Haralson, Jackson, Lumpkin, Morgan, Murray, Paulding, Pickens, Polk, Rabun, Stephens, Towns, Union, Walker, Walton, White, and Whitfield</td>
</tr>
<tr>
<td></td>
<td>Toll free 1-866-388-9844</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Local 678-510-4555</td>
<td></td>
</tr>
<tr>
<td>Atlanta</td>
<td>Southeastrans 404-209-4000</td>
<td>Fulton, DeKalb, and Gwinnett</td>
</tr>
<tr>
<td>Central</td>
<td>LogistiCare</td>
<td>Baldwin, Bibb, Bleckley, Butts, Carroll, Clayton, Coweta, Dodge, Fayette, Heard, Henry, Jasper, Jones, Lamar, Laurens, Meriwether, Monroe, Newton, Pike, Putnam, Rockdale, Spalding, Telfair, Troup, Twiggs, and Wilkinson</td>
</tr>
<tr>
<td></td>
<td>Toll free 1-888-224-7981</td>
<td></td>
</tr>
</tbody>
</table>

Rev. 4/12
Rev. 7/12
<table>
<thead>
<tr>
<th>Region</th>
<th>Broker/Phone Number</th>
<th>Counties Served</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>East</strong></td>
<td>LogistiCare</td>
<td>Appling, Bacon, Brantley, Bryan, Bulloch, Burke, Camden, Candler, Charlton, Chatham, Clarke, Columbia, Effingham, Elbert, Emanuel, Evans, Glascock, Glynn, Greene, Hancock, Hart, Jeff Davis, Jefferson, Jenkins, Johnson, Liberty, Lincoln, Long, Madison, McDuffie, McIntosh, Montgomery, Oconee, Oglethorpe, Pierce, Richmond, Screven, Taliaferro, Tattnall, Toombs, Truettlen, Ware, Warren, Washington, Wayne, Wheeler, and Wilkes</td>
</tr>
<tr>
<td></td>
<td>Toll free</td>
<td>1-888-224-7988</td>
</tr>
<tr>
<td><strong>Southwest</strong></td>
<td>LogistiCare</td>
<td>Atkinson, Baker, Ben Hill, Berrien, Brooks, Calhoun, Chattahoochee, Clay, Clinic, Coffee, Colquitt, Cook, Crawford, Crisp, Decatur, Dooly, Dougherty, Early, Echols, Grady, Harris, Houston, Irwin, Lanier, Lee, Lowndes, Macon, Marion, Miller, Mitchell, Muscogee, Peach, Pulaski, Quitman, Randolph, Schley, Seminole, Stewart, Sumter, Talbot, Taylor, Terrell, Thomas, Tift, Turner, Upson, Webster, Wilcox, and Worth</td>
</tr>
<tr>
<td></td>
<td>Toll free</td>
<td>1-888-224-7985</td>
</tr>
</tbody>
</table>
APPENDIX F

Childhood Obesity –
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents

Body Mass Index (BMI)

What is BMI?

Body Mass Index (BMI) is used as a screening tool to identify possible weight problems for children and adolescents. The Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics (AAP) recommend the use of BMI to screen for overweight and obesity in children and adolescents aged 2 through 19 years.

BMI is a number calculated from a child’s weight and height. BMI does not measure body fat directly, but it is a reliable indicator of body fatness for most children and adolescents.

For children and adolescents, BMI is age- and sex-specific and is often referred to as BMI-for-age. A child’s weight status is determined using an age- and sex-specific percentile for BMI rather than the BMI categories used for adults because children’s body composition varies as they age and varies between boys and girls.

What is a BMI percentile?

After the BMI is calculated for children and adolescents, the BMI number is plotted on the BMI-for-age growth charts (for either girls or boys) to obtain a percentile ranking. Percentiles are the most commonly used indicator to assess the size and growth patterns of individual children in the United States. The percentile indicates the relative position of the child’s BMI number among children of the same sex and age. The CDC’s growth charts show the weight status categories used with children and adolescents.

<table>
<thead>
<tr>
<th>WEIGHT STATUS CATEGORY</th>
<th>PERCENTILE RANGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Underweight</td>
<td>Less than the 5th percentile</td>
</tr>
<tr>
<td>Healthy Weight</td>
<td>5th percentile to less than the 85th percentile</td>
</tr>
<tr>
<td>Overweight</td>
<td>85th to less than the 95th percentile</td>
</tr>
<tr>
<td>Obese</td>
<td>Equal to or greater than the 95th percentile</td>
</tr>
</tbody>
</table>

These percentiles are based on the CDC’s growth charts which are available at http://www.cdc.gov/growthcharts/
**How to calculate BMI using a handheld calculator?**

The BMI can be calculated using either English or metric units.

With the metric system, the formula for BMI is weight in kilograms divided by height in meters squared. Since height is commonly measured in centimeters, an alternate calculation formula, dividing the weight in kilograms by the height in centimeters squared, and then multiplying the result by 10,000, can be used.

Formula: \( \text{weight (kg)} / [\text{height (m)}]^2 \)

When using English measurements, ounces (oz.) and fractions must be changed to decimal values. Then, calculate BMI by dividing weight in pounds (lbs.) by height in inches (in) squared and multiplying by a conversion factor of 703. Plot the calculated BMI to obtain the BMI percentile.

Formula: \( \text{weight (lb.)} / [\text{height (in)}]^2 \times 703 \)

**How to interpret BMI?**

Calculating the BMI-for-age for children of different ages and sexes may yield the same numeric result, but the result may fall at a different percentile for each child for one or both of the following reasons:

- The normal BMI-related changes that take place as children age and as growth occurs (ex. The amount of body fat changes with age).

- The normal BMI-related differences between sexes (ex. The amount of body fat differs between girls and boys).
Documentation for HEDIS Compliance – Weight Assessment

Documentation in the medical record for BMI must include the following:

- Height
- Weight
- BMI percentile

Documentation must include height, weight and BMI percentile during the measurement year. The height, weight and BMI percentile must be from the same data source. Either of the following meets criteria for BMI percentile: BMI percentile documented as a value (e.g., 85<sup>th</sup> percentile) OR BMI percentile plotted on an age-growth chart. Only evidence of the BMI percentile or BMI percentile plotted on an age-growth chart meets HEDIS criteria.

ICD-10 Codes to Identify BMI

<table>
<thead>
<tr>
<th>BMI Code</th>
<th>BMI Percentile</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Z68.51</td>
<td>&lt; 5&lt;sup&gt;th&lt;/sup&gt; percentile for age</td>
<td>Underweight</td>
</tr>
<tr>
<td>Z68.52</td>
<td>5&lt;sup&gt;th&lt;/sup&gt; to &lt; 85&lt;sup&gt;th&lt;/sup&gt; percentile for age</td>
<td>Normal/ Healthy Weight Range</td>
</tr>
<tr>
<td>Z68.53</td>
<td>85&lt;sup&gt;th&lt;/sup&gt; to &lt; 95&lt;sup&gt;th&lt;/sup&gt; percentile for age</td>
<td>Overweight</td>
</tr>
<tr>
<td>Z68.54</td>
<td>≥ 95&lt;sup&gt;th&lt;/sup&gt; percentile for age</td>
<td>Obese</td>
</tr>
</tbody>
</table>

FFS EPSDT providers are encouraged to report BMI diagnosis codes with the EPSDT preventive health codes. Do not point the preventive health visit code to the BMI diagnosis code because this will cause the FFS claim to deny payment.
Counseling for Nutrition

Guidelines
The Dietary Guidelines for Americans (http://health.gov/dietaryguidelines/2015/guidelines/) comprise core principles to help people, ages 2 years and older, develop healthy lifestyles based on individual needs, likes, and dislikes related to both eating and physical activity. The Dietary Guidelines recommend that children and adolescents consume a healthy eating pattern that accounts for all foods and beverages within an appropriate calorie level. A healthy eating pattern includes a variety of vegetables from all of the subgroups, fruits, grains, fat-free or low-fat dairy, a variety of protein foods and oils. A healthy eating pattern limits saturated fats and trans fats, added sugars, and sodium.

Documentation for HEDIS compliance – Counseling for Nutrition
Documentation (in the medical record) of counseling for nutrition must include a statement indicating the date and at least one of the following:

- Discussion of current nutrition behaviors (e.g., eating habits, dieting behaviors).
- Checklist indicating nutrition was addressed.
- Counseling or referral for nutrition education.
- Member received educational materials on nutrition during a face-to-face visit.
- Anticipatory guidance for nutrition.
- Weight or obesity counseling.

ICD-10 Code to Identify Counseling for Nutrition
- Z71.3 – nutritional counseling

FFS EPSDT providers are encouraged to report the nutrition diagnosis code with the EPSDT preventive health codes. Do not point the preventive health visit code to the nutrition and physical activity counseling diagnosis code because this will cause the FFS claim to deny payment.

Counseling for Physical Activity

Guidelines
The Physical Activity Guidelines for Americans (http://health.gov/paguidelines/guidelines/children.aspx) describe the types and amounts of physical activity that offer substantial health benefits for children and adolescents (ages 6 to 17) and adults. The Physical Activity Guidelines for Americans complement the Dietary Guidelines for Americans, and together the documents provide guidance on the importance of being physically active and eating healthy foods to promote health and reduce the risk of chronic diseases. The Physical Activity Guidelines recommend that children and adolescents have 60 minutes (1 hour) or more of physical activity each day. Physical activity includes aerobic/endurance activities (to increase cardiorespiratory fitness), muscle-strengthening (resistance training which builds strong muscles), and bone-strengthening (weight-bearing or weight-loading activities which promote bone growth and strength).
**Documentation for HEDIS Compliance – Counseling for Physical Activity**

Documentation (in the medical record) of counseling for physical activity must include a statement indicating the date and at least one of the following:

- Discussion of current physical activity behaviors (e.g., exercise routine, participation in sports activities, exam for sports participation).
- Checklist indicating physical activity was addressed.
- Counseling or referral for physical activity.
- Member received educational materials on physical activity during a face-to-face visit.
- Anticipatory guidance specific to the child’s physical activity.
- Weight or obesity counseling.

The following notations or examples of documentation are not compliant with HEDIS requirements:

- **BMI**
  - No BMI percentile documented in medical record or plotted on age-growth chart.
  - Notation of BMI value only.
  - Notation of height and weight only.

- **Nutrition**
  - No counseling/education on nutrition and diet.
  - Counseling/education before or after the HEDIS measurement year.
  - Notation of “health education” or “anticipatory guidance” without specific mention of nutrition.
  - A physical exam finding or observation alone (e.g., well-nourished) is not compliant because it does not indicate counseling for nutrition.
  - Notation of “health education” or “anticipatory guidance” without specific mention of nutrition.

- **Physical Activity**
  - No counseling/education on physical activity.
  - Notation of “cleared for gym class” along without documentation of a discussion.
  - Counseling/education before or after the HEDIS measurement year.
  - Notation of “health education” or “anticipatory guidance” without specific mention of physical activity.
  - Notation of anticipatory guidance related solely to safety (e.g., wears helmet or water safety) without specific mention of physical activity recommendations.
  - Notation solely related to screen time (computer or television) without specific mention of physical activity.

**Services may be rendered during a visit other than a well-child visit.** These services count if the specified documentation is present, regardless of the primary intent of the visit. **Services specific to the assessment or treatment of an acute or chronic condition do not count toward the “Counseling for Nutrition” and “Counseling for Physical Activity” measures.**
APPENDIX G

EPSDT Program Required Equipment Form

☐ Scale for Weighing Infants present
☐ Scale for Weighing Children and Adolescents present
☐ Measuring Board or Device for measuring Length or Height in the recumbent position for Infants and Children up to the age of two (2) present
☐ Measuring Board or Device for measuring Height in the vertical position for children who are over two (2) years old present
☐ Blood Pressure apparatus with infant, child, and adult cuffs present
☐ Screening audiometer present
☐ Centrifuge or other device for measuring hematocrit or hemoglobin may be present
☐ Eye charts appropriate for age of the child present
☐ Developmental/Behavioral, Alcohol/Substance Abuse and Depression screening tools and supplies present (The required developmental screenings at ages 9 months, 18 months, and 30 months must be accomplished using one or more of the recommended standardized developmental screening tools specified in Section 902.2)
☐ Vaccines and immunization administration supplies present
☐ Lab supplies for appropriate lab tests/screenings present
☐ Ophthalmoscope and Otoscope present

The information supplied in this document is true, accurate and complete and is hereby released to the Georgia Department of Community Health, Division of Medicaid, for purpose of enrolling in the EPSDT Program. I understand that falsification, omission or misrepresentation of any information in this enrollment document will result in a denial of enrollment, the closure of current enrollment, and the denial of future enrollment request, and may be punishable by criminal, civil or other administrative actions. I understand that my completion of this form certifies that I have the necessary equipment as listed in Part II-Policies and Procedures Manual for the EPSDT Program.

_____________________________  _______________________
Provider Name                  Date

_____________________________
Provider Title

_____________________________
Provider/Confirmation Number
APPENDIX H
Georgia Families

Georgia Families® (GF) is a statewide program designed to deliver health care services to members of Medicaid, PeachCare for Kids®, and Planning for Healthy Babies® (P4HB) recipients. The program is a partnership between the Department of Community Health (DCH) and private care management organizations (CMOs). By providing a choice of health plans, Georgia Families allows members to select a health care plan that fits their needs.

It is important to note that GF is a full-risk program; this means that the four CMOs licensed in Georgia to participate in GF are responsible and accept full financial risk for providing and authorizing covered services. This also means a greater focus on case and disease management with an emphasis on preventative care to improve individual health outcomes.

The four licensed CMOs:

<table>
<thead>
<tr>
<th>CMO Name</th>
<th>Phone Number</th>
<th>Website Link</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amerigroup Community Care</td>
<td>1-800-454-3730</td>
<td><a href="http://www.amerigroup.com">www.amerigroup.com</a></td>
</tr>
<tr>
<td>CareSource</td>
<td>1-855-202-1058</td>
<td><a href="http://www.caresource.com">www.caresource.com</a></td>
</tr>
<tr>
<td>Peach State Health Plan</td>
<td>866-874-0633</td>
<td><a href="http://www.pshpgeorgia.com">www.pshpgeorgia.com</a></td>
</tr>
<tr>
<td>WellCare of Georgia</td>
<td>866-231-1821</td>
<td><a href="http://www.wellcare.com">www.wellcare.com</a></td>
</tr>
</tbody>
</table>

Children, parent/caretaker with children, pregnant women and women with breast or cervical cancer on Medicaid, as well as children enrolled in PeachCare for Kids® are eligible to participate in Georgia Families. Additionally, Planning for Healthy Babies® (P4HB) recipients receive services through Georgia Families® (GF). Children in foster care or receiving adoption assistance and certain youths committed to juvenile justice are enrolled in Georgia Families 360°.


<table>
<thead>
<tr>
<th>Eligibility Categories for Georgia Families:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Included Populations</strong></td>
<td><strong>Excluded Populations</strong></td>
</tr>
<tr>
<td>Parent/Caretaker with Children</td>
<td>Aged, Blind and Disabled</td>
</tr>
<tr>
<td>Transitional Medicaid</td>
<td>Nursing home</td>
</tr>
<tr>
<td>Pregnant Women (Right from the Start</td>
<td>Long-term care (Waivers, SOURCE)</td>
</tr>
<tr>
<td>Medicaid – RSM)</td>
<td>Federally Recognized Indian Tribe</td>
</tr>
<tr>
<td>Children (Right from the Start Medicaid –</td>
<td>Georgia Pediatric Program (GAPP)</td>
</tr>
<tr>
<td>RSM)</td>
<td>Children’s Medical Services program</td>
</tr>
<tr>
<td>Women Eligible Due to Breast and Cervical</td>
<td>Hospice</td>
</tr>
<tr>
<td>Cancer</td>
<td></td>
</tr>
<tr>
<td>PeachCare for Kids®</td>
<td>Medicare Eligible</td>
</tr>
<tr>
<td>Parent/Caretaker with Children</td>
<td>Medicaid</td>
</tr>
<tr>
<td>Children under 19</td>
<td>Supplemental Security Income (SSI)</td>
</tr>
<tr>
<td>Women’s Health Medicaid (WHM)</td>
<td>Medically Needy</td>
</tr>
<tr>
<td>Refugees</td>
<td>Recipients enrolled under group health plans</td>
</tr>
<tr>
<td>Planning for Healthy Babies®</td>
<td>Individuals enrolled in a Community Based Alternatives for Youths (CBAY)</td>
</tr>
<tr>
<td>Resource Mothers Outreach</td>
<td></td>
</tr>
</tbody>
</table>

Medicaid and PeachCare for Kids® members will continue to be eligible for the same services they receive through traditional Medicaid and state Value Added Benefits. Members will not have to pay more than they paid for Medicaid co-payments or PeachCare for Kids® premiums. With a focus on health and wellness, the CMOs will provide members with health education and prevention programs giving them the tools needed to live healthier lives. Providers participating in Georgia Families will have the added assistance of the CMOs to educate members about accessing care, referrals to specialists, member benefits, and health and wellness education. **All four CMOs are State-wide.**

The Department of Community Health has contracted with four CMOs to provide these services:
- Amerigroup Community Care
- CareSource
- Peach State Health Plan
- WellCare of Georgia

Members can contact Georgia Families for assistance to determine which program best fits their family’s needs. If members do not select a plan, Georgia Families will select a health plan for them.

Members can visit the Georgia Families Web site at www.georgia-families.com or call 1-800-GA-ENROLL (1-888-423-6765) to speak to a representative who can give them information about the CMOs and the health care providers.
The following categories of eligibility are included and excluded under Georgia Families:

<table>
<thead>
<tr>
<th>COE</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>104</td>
<td>LIM – Adult</td>
</tr>
<tr>
<td>105</td>
<td>LIM – Child</td>
</tr>
<tr>
<td>118</td>
<td>LIM – 1st Yr Trans Med Ast Adult</td>
</tr>
<tr>
<td>119</td>
<td>LIM – 1st Yr Trans Med Ast Child</td>
</tr>
<tr>
<td>122</td>
<td>CS Adult 4 Month Extended</td>
</tr>
<tr>
<td>123</td>
<td>CS Child 4 Month Extended</td>
</tr>
<tr>
<td>135</td>
<td>Newborn Child</td>
</tr>
<tr>
<td>170</td>
<td>RSM Pregnant Women</td>
</tr>
<tr>
<td>171</td>
<td>RSM Child</td>
</tr>
<tr>
<td>180</td>
<td>P4HB Inter Pregnancy Care</td>
</tr>
<tr>
<td>181</td>
<td>P4HB Family Planning Only</td>
</tr>
<tr>
<td>182</td>
<td>P4HB ROMC - LIM</td>
</tr>
<tr>
<td>183</td>
<td>P4HB ROMC - ABD</td>
</tr>
<tr>
<td>194</td>
<td>RSM Expansion Pregnant Women</td>
</tr>
<tr>
<td>195</td>
<td>RSM Expansion Child &lt; 1 Yr</td>
</tr>
<tr>
<td>196</td>
<td>RSM Expn Child w/DOB &lt; = 10/1/83</td>
</tr>
<tr>
<td>197</td>
<td>RSM Preg Women Income &lt; 185 FPL</td>
</tr>
<tr>
<td>245</td>
<td>Women’s Health Medicaid</td>
</tr>
<tr>
<td>471</td>
<td>RSM Child</td>
</tr>
<tr>
<td>506</td>
<td>Refugee (DMP) – Adult</td>
</tr>
<tr>
<td>507</td>
<td>Refugee (DMP) – Child</td>
</tr>
<tr>
<td>508</td>
<td>Post Ref Extended Med – Adult</td>
</tr>
<tr>
<td>509</td>
<td>Post Ref Extended Med – Child</td>
</tr>
<tr>
<td>510</td>
<td>Refugee MAO – Adult</td>
</tr>
<tr>
<td>511</td>
<td>Refugee MAO – Child</td>
</tr>
<tr>
<td>571</td>
<td>Refugee RSM - Child</td>
</tr>
<tr>
<td>595</td>
<td>Refugee RSM Exp. Child &lt; 1</td>
</tr>
<tr>
<td>596</td>
<td>Refugee RSM Exp Child DOB &lt; = 10/01/83</td>
</tr>
<tr>
<td>790</td>
<td>Peachcare &lt; 150% FPL</td>
</tr>
<tr>
<td>791</td>
<td>Peachcare 150 – 200% FPL</td>
</tr>
<tr>
<td>792</td>
<td>Peachcare 201 – 235% FPL</td>
</tr>
<tr>
<td>793</td>
<td>Peachcare &gt; 235% FPL</td>
</tr>
<tr>
<td>835</td>
<td>Newborn</td>
</tr>
<tr>
<td>836</td>
<td>Newborn (DFACS)</td>
</tr>
<tr>
<td>871</td>
<td>RSM (DHACS)</td>
</tr>
<tr>
<td>876</td>
<td>RSM Pregnant Women (DHACS)</td>
</tr>
<tr>
<td>894</td>
<td>RSM Exp Pregnant Women (DHACS)</td>
</tr>
<tr>
<td>895</td>
<td>RSM Exp Child &lt; 1 (DHACS)</td>
</tr>
<tr>
<td>897</td>
<td>RSM Pregnant Women Income &gt; 185% FPL (DHACS)</td>
</tr>
<tr>
<td>898</td>
<td>RSM Child &lt; 1 Mother has Aid = 897 (DHACS)</td>
</tr>
</tbody>
</table>
### Included Categories of Eligibility (COE):

<table>
<thead>
<tr>
<th>COE</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>918</td>
<td>LIM Adult</td>
</tr>
<tr>
<td>919</td>
<td>LIM Child</td>
</tr>
<tr>
<td>920</td>
<td>Refugee Adult</td>
</tr>
<tr>
<td>921</td>
<td>Refugee Child</td>
</tr>
</tbody>
</table>

### Excluded Categories of Eligibility (COE):

<table>
<thead>
<tr>
<th>COE</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>124</td>
<td>Standard Filing Unit – Adult</td>
</tr>
<tr>
<td>125</td>
<td>Standard Filing Unit – Child</td>
</tr>
<tr>
<td>131</td>
<td>Child Welfare Foster Care</td>
</tr>
<tr>
<td>132</td>
<td>State Funded Adoption Assistance</td>
</tr>
<tr>
<td>147</td>
<td>Family Medically Needy Spend down</td>
</tr>
<tr>
<td>148</td>
<td>Pregnant Women Medical Needy Spend down</td>
</tr>
<tr>
<td>172</td>
<td>RSM 150% Expansion</td>
</tr>
<tr>
<td>180</td>
<td>Interconceptional Waiver</td>
</tr>
<tr>
<td>210</td>
<td>Nursing Home – Aged</td>
</tr>
<tr>
<td>211</td>
<td>Nursing Home – Blind</td>
</tr>
<tr>
<td>212</td>
<td>Nursing Home – Disabled</td>
</tr>
<tr>
<td>215</td>
<td>30 Day Hospital – Aged</td>
</tr>
<tr>
<td>216</td>
<td>30 Day Hospital – Blind</td>
</tr>
<tr>
<td>217</td>
<td>30 Day Hospital – Disabled</td>
</tr>
<tr>
<td>218</td>
<td>Protected Med/1972 Cola - Aged</td>
</tr>
<tr>
<td>219</td>
<td>Protected Med/1972 Cola – Blind</td>
</tr>
<tr>
<td>220</td>
<td>Protected Med/1972 Cola - Disabled</td>
</tr>
<tr>
<td>221</td>
<td>Disabled Widower 1984 Cola - Aged</td>
</tr>
</tbody>
</table>
**Excluded Categories of Eligibility (COE):**

<table>
<thead>
<tr>
<th>COE</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>222</td>
<td>Disabled Widower 1984 Cola – Blind</td>
</tr>
<tr>
<td>223</td>
<td>Disabled Widower 1984 Cola – Disabled</td>
</tr>
<tr>
<td>224</td>
<td>Pickle - Aged</td>
</tr>
<tr>
<td>225</td>
<td>Pickle – Blind</td>
</tr>
<tr>
<td>226</td>
<td>Pickle – Disabled</td>
</tr>
<tr>
<td>227</td>
<td>Disabled Adult Child - Aged</td>
</tr>
<tr>
<td>227</td>
<td>Disabled Adult Child - Aged</td>
</tr>
<tr>
<td>229</td>
<td>Disabled Adult Child – Disabled</td>
</tr>
<tr>
<td>230</td>
<td>Disabled Widower Age 50-59 – Aged</td>
</tr>
<tr>
<td>231</td>
<td>Disabled Widower Age 50-59 – Blind</td>
</tr>
<tr>
<td>232</td>
<td>Disabled Widower Age 50-59 – Disabled</td>
</tr>
<tr>
<td>233</td>
<td>Widower Age 60-64 – Aged</td>
</tr>
<tr>
<td>234</td>
<td>Widower Age 60-64 – Blind</td>
</tr>
<tr>
<td>235</td>
<td>Widower Age 60-64 – Disabled</td>
</tr>
<tr>
<td>236</td>
<td>3 Mo. Prior Medicaid – Aged</td>
</tr>
<tr>
<td>237</td>
<td>3 Mo. Prior Medicaid – Blind</td>
</tr>
<tr>
<td>238</td>
<td>3 Mo. Prior Medicaid – Disabled</td>
</tr>
<tr>
<td>239</td>
<td>Abd Med. Needy Defacto – Aged</td>
</tr>
<tr>
<td>240</td>
<td>Abd Med. Needy Defacto – Blind</td>
</tr>
<tr>
<td>241</td>
<td>Abd Med. Needy Defacto – Disabled</td>
</tr>
<tr>
<td>242</td>
<td>Abd Med Spend down – Aged</td>
</tr>
<tr>
<td>243</td>
<td>Abd Med Spend down – Blind</td>
</tr>
<tr>
<td>244</td>
<td>Abd Med Spend down – Disabled</td>
</tr>
</tbody>
</table>
### Excluded Categories of Eligibility (COE):

<table>
<thead>
<tr>
<th>COE</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>246</td>
<td>Ticket to Work</td>
</tr>
<tr>
<td>247</td>
<td>Disabled Child – 1996</td>
</tr>
<tr>
<td>250</td>
<td>Deeming Waiver</td>
</tr>
<tr>
<td>251</td>
<td>Independent Waiver</td>
</tr>
<tr>
<td>252</td>
<td>Mental Retardation Waiver</td>
</tr>
<tr>
<td>253</td>
<td>Laurens Co. Waiver</td>
</tr>
<tr>
<td>254</td>
<td>HIV Waiver</td>
</tr>
<tr>
<td>255</td>
<td>Cystic Fibrosis Waiver</td>
</tr>
<tr>
<td>259</td>
<td>Community Care Waiver</td>
</tr>
<tr>
<td>280</td>
<td>Hospice – Aged</td>
</tr>
<tr>
<td>281</td>
<td>Hospice – Blind</td>
</tr>
<tr>
<td>282</td>
<td>Hospice – Disabled</td>
</tr>
<tr>
<td>283</td>
<td>LTC Med. Needy Defacto – Aged</td>
</tr>
<tr>
<td>284</td>
<td>LTC Med. Needy Defacto – Blind</td>
</tr>
<tr>
<td>285</td>
<td>LTC Med. Needy Defacto – Disabled</td>
</tr>
<tr>
<td>286</td>
<td>LTC Med. Needy Spend down – Aged</td>
</tr>
<tr>
<td>287</td>
<td>LTC Med. Needy Spend down – Blind</td>
</tr>
<tr>
<td>288</td>
<td>LTC Med. Needy Spend down – Disabled</td>
</tr>
<tr>
<td>289</td>
<td>Institutional Hospice – Aged</td>
</tr>
<tr>
<td>290</td>
<td>Institutional Hospice – Blind</td>
</tr>
<tr>
<td>291</td>
<td>Institutional Hospice – Disabled</td>
</tr>
<tr>
<td>301</td>
<td>SSI – Aged</td>
</tr>
<tr>
<td>302</td>
<td>SSI – Blind</td>
</tr>
</tbody>
</table>
## Excluded Categories of Eligibility (COE):

<table>
<thead>
<tr>
<th>COE</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>303</td>
<td>SSI – Disabled</td>
</tr>
<tr>
<td>304</td>
<td>SSI Appeal – Aged</td>
</tr>
<tr>
<td>305</td>
<td>SSI Appeal – Blind</td>
</tr>
<tr>
<td>306</td>
<td>SSI Appeal – Disabled</td>
</tr>
<tr>
<td>307</td>
<td>SSI Work Continuance – Aged</td>
</tr>
<tr>
<td>309</td>
<td>SSI Work Continuance – Disabled</td>
</tr>
<tr>
<td>308</td>
<td>SSI Work Continuance – Blind</td>
</tr>
<tr>
<td>315</td>
<td>SSI Zebley Child</td>
</tr>
<tr>
<td>321</td>
<td>SSI E02 Month – Aged</td>
</tr>
<tr>
<td>322</td>
<td>SSI E02 Month – Blind</td>
</tr>
<tr>
<td>323</td>
<td>SSI E02 Month – Disabled</td>
</tr>
<tr>
<td>387</td>
<td>SSI Trans. Medicaid – Aged</td>
</tr>
<tr>
<td>388</td>
<td>SSI Trans. Medicaid – Blind</td>
</tr>
<tr>
<td>389</td>
<td>SSI Trans. Medicaid – Disabled</td>
</tr>
<tr>
<td>410</td>
<td>Nursing Home – Aged</td>
</tr>
<tr>
<td>411</td>
<td>Nursing Home – Blind</td>
</tr>
<tr>
<td>412</td>
<td>Nursing Home – Disabled</td>
</tr>
<tr>
<td>424</td>
<td>Pickle – Aged</td>
</tr>
<tr>
<td>425</td>
<td>Pickle – Blind</td>
</tr>
<tr>
<td>426</td>
<td>Pickle – Disabled</td>
</tr>
<tr>
<td>427</td>
<td>Disabled Adult Child – Aged</td>
</tr>
<tr>
<td>428</td>
<td>Disabled Adult Child – Blind</td>
</tr>
<tr>
<td>429</td>
<td>Disabled Adult Child – Disabled</td>
</tr>
</tbody>
</table>
### Excluded Categories of Eligibility (COE):

<table>
<thead>
<tr>
<th>COE</th>
<th>DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>445</td>
<td>N07 Child</td>
</tr>
<tr>
<td>446</td>
<td>Widower – Aged</td>
</tr>
<tr>
<td>447</td>
<td>Widower – Blind</td>
</tr>
<tr>
<td>448</td>
<td>Widower – Disabled</td>
</tr>
<tr>
<td>460</td>
<td>Qualified Medicare Beneficiary</td>
</tr>
<tr>
<td>466</td>
<td>Spec. Low Inc. Medicare Beneficiary</td>
</tr>
<tr>
<td>575</td>
<td>Refugee Med. Needy Spend down</td>
</tr>
<tr>
<td>660</td>
<td>Qualified Medicare Beneficiary</td>
</tr>
<tr>
<td>661</td>
<td>Spec. Low Income Medicare Beneficiary</td>
</tr>
<tr>
<td>662</td>
<td>Q11 Beneficiary</td>
</tr>
<tr>
<td>663</td>
<td>Q12 Beneficiary</td>
</tr>
<tr>
<td>664</td>
<td>Qua. Working Disabled Individual</td>
</tr>
<tr>
<td>815</td>
<td>Aged Inmate</td>
</tr>
<tr>
<td>817</td>
<td>Disabled Inmate</td>
</tr>
<tr>
<td>870</td>
<td>Emergency Alien – Adult</td>
</tr>
<tr>
<td>873</td>
<td>Emergency Alien – Child</td>
</tr>
<tr>
<td>874</td>
<td>Pregnant Adult Inmate</td>
</tr>
<tr>
<td>915</td>
<td>Aged MAO</td>
</tr>
<tr>
<td>916</td>
<td>Blind MAO</td>
</tr>
<tr>
<td>917</td>
<td>Disabled MAO</td>
</tr>
<tr>
<td>983</td>
<td>Aged Medically Needy</td>
</tr>
<tr>
<td>984</td>
<td>Blind Medically Needy</td>
</tr>
<tr>
<td>985</td>
<td>Disabled Medically Needy</td>
</tr>
</tbody>
</table>
HEALTH CARE PROVIDERS

For information regarding the participating health plans (enrollment, rates, and procedures), please call the numbers listed below.

Prior to providing services, you should contact the member’s health plan to verify eligibility, PCP assignment and covered benefits. You should also contact the health plan to check prior authorizations and submit claims.

<table>
<thead>
<tr>
<th>Amerigroup Community Care</th>
<th>CareSource</th>
<th>Peach State Health Plan</th>
<th>WellCare of Georgia</th>
</tr>
</thead>
</table>

Registering immunizations with GRITS:
If you are a Vaccine for Children (VFC) provider, please continue to use the GRITS (Georgia Immunization Registry) system for all children, including those in Medicaid and PeachCare for Kids®, fee-for-service, and managed care.

Important tips for the provider to know/do when a member comes in:
Understanding the process for verifying eligibility is now more important than ever. You will need to determine if the patient is eligible for Medicaid/PeachCare for Kids® benefits and if they are enrolled in a Georgia Families health plan. Each plan sets its own medical management and referral processes. Members will have a new identification card and primary care provider assignment.

You may also contact DXC at 1-800-766-4456 (statewide) or www.mmis.georgia.gov for information on a member’s health plan.

Use of the Medicaid Management Information System (MMIS) web portal:
The call center and web portal will be able to provide you information about a member’s Medicaid eligibility and health plan enrollment. DXC will not be able to assist you with benefits, claims processing or prior approvals for members assigned to a Georgia Families health plan. You will need to contact the member’s plan directly for this information.
Participating in a Georgia Families’ health plan:

Each health plan will assign provider numbers, which will be different from the provider’s Medicaid provider number and the numbers assigned by other health plans.

Billing the health plans for services provided:

For members who are in Georgia Families, you should file claims with the member’s health plan.

If a claim is submitted to DXC in error:

DXC will deny the claim with a specific denial code. Prior to receiving this denial, you may go ahead and submit the claim to the member’s health plan.

Credentialing

Effective August 1, 2015, Georgia’s Department of Community Health (DCH) implemented a NCQA certified Centralized Credentialing Verification Process utilizing a Credentialing Verification Organization (CVO). This functionality has been added to the Georgia Medicaid Management Information System (GAMMIS) website (www.MMIS.georgia.gov) and has streamlined the time frame that it takes for a provider to be fully credentialed.

Credentialing and recredentialing services is provided for Medicaid providers enrolled in Georgia Families and/or the Georgia Families 360° program.

This streamlined process results in administrative simplification thereby preventing inconsistencies, as well as the need for a provider to be credentialed or recredentialed multiple times.

The CVO’s one-source application process:
- Saves time
- Increases efficiency
- Eliminates duplication of data needed for multiple CMOs
- Shortens the time period for providers to receive credentialing and recredentialing decisions

The CVO will perform primary source verification, check federal and state databases, obtain information from Medicare’s Provider Enrollment Chain Ownership System (PECOS), check required medical malpractice insurance, confirm Drug Enforcement Agency (DEA) numbers, etc. A Credentialing Committee will render a decision regarding the provider’s credentialing status. Applications that contain all required credentialing and recredentialing materials at the time of submission will receive a decision within 45 calendar days. Incomplete applications that do not contain all required credentialing documents will be returned to the provider with a request to supplement all missing materials. Incomplete applications may result in a delayed credentialing or recredentialing decision. The credentialing decision is provided to the CMOs.
HP provider reps will provide training and assistance as needed. Providers may contact HP for assistance with credentialing and recredentialing by dialing 1-800-766-4456.

**Assignment of separate provider numbers by all of the health plans:**

Each health plan will assign provider numbers, which will be different from the provider’s Medicaid provider number and the numbers assigned by other health plans.

**Billing the health plans for services provided:**

For members who are in Georgia Families, you should file claims with the member’s health plan.

**If a claim is submitted to DXC in error:**

DXC will deny the claim with a specific denial code. Prior to receiving this denial, you may go ahead and submit the claim to the member’s health plan.

**Receiving payment:**

Claims should be submitted to the member’s health plan. Each health plan has its own claims processing and you should consult the health plan about their payment procedures.
Health plans payment of clean claims:

Each health plan (and subcontractors) has its own claims processing and payment cycles. The claims processing and payment timeframes are as follows:

<table>
<thead>
<tr>
<th>Amerigroup Community Care</th>
<th>CareSource</th>
<th>Peach State Health Plan</th>
<th>WellCare of Georgia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amerigoup runs claims cycles twice each week (on Monday and Thursday) for clean claims that have been adjudicated.</td>
<td>CareSource runs claims cycles twice each week on Saturdays and Tuesdays for clean claims that have been adjudicated.</td>
<td>Peach State has two weekly claims payment cycles per week that produces payments for clean claims to providers on Monday and Wednesday.</td>
<td>WellCare runs claims payment cycles up to six (6) times each week for clean claims. For further information, please refer to the WellCare website, the WellCare provider manual, or contact Customer Service at 866-231-1821</td>
</tr>
<tr>
<td>Monday Claims run: Checks mailed on Tuesday. Providers enrolled in ERA/EFT receive the ACH on Thursday.</td>
<td>Pharmacy: Payment cycles for pharmacies is weekly on Wednesdays.</td>
<td>Pharmacy: Payment cycles for pharmacies is weekly on Wednesdays.</td>
<td>Pharmacy: Payment cycles for pharmacies is weekly on Wednesdays.</td>
</tr>
<tr>
<td>Thursday Claims run: Checks mailed on Wednesday. Providers enrolled in ERA/EFT receive the ACH on Tuesday.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dental:</strong> Checks are mailed weekly on Thursday for clean claims.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Vision:</strong> Checks are mailed weekly on Wednesday for clean claims (beginning June 7th)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pharmacy:</strong> Checks are mailed to pharmacies weekly on Friday (except when a holiday falls</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amerigroup Community Care</td>
<td>CareSource</td>
<td>Peach State Health Plan</td>
<td>WellCare of Georgia</td>
</tr>
<tr>
<td>--------------------------</td>
<td>------------</td>
<td>-------------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>on Friday, then mailed the next business day)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**How often can a patient change his/her PCP?**

<table>
<thead>
<tr>
<th>Amerigroup Community Care</th>
<th>CareSource</th>
<th>Peach State Health Plan</th>
<th>WellCare of Georgia</th>
</tr>
</thead>
</table>
| Anytime | Members can change their PCP one (1) time per month. However, members can change their PCP at any time under extenuating circumstances such as:  
  • Member requests to be assigned to a family member’s PCP  
  • PCP does not provide the covered services a member seeks due to moral or religious objections  
  • PCP moves, retires, etc. | Within the first 90 days of a member’s enrollment, he/she can change PCP monthly. If the member has been with the plan for 90 days or longer, the member can change PCPs once every six months. There are a few exclusions that apply and would warrant an immediate PCP change. | Members can change PCPs for any reason within the first 90 days of their enrollment. After the first 90 days, members may change PCPs once every six months. |
Once the patient requests a PCP change, how long it takes for the new PCP to be assigned:

<table>
<thead>
<tr>
<th>Amerigroup Community Care</th>
<th>CareSource</th>
<th>Peach State Health Plan</th>
<th>WellCare of Georgia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Next business day</td>
<td>PCP selections are updated in CareSource’s systems daily.</td>
<td>PCP changes made before the 24th day of the month and are effective for the current month. PCP changes made after the 24th day of the month are effective for the first of the following month.</td>
<td>PCP changes made between the 1st and 10th of the month will go into effect right away. Changes made after the 10th of the month will take effect at the beginning of the next month</td>
</tr>
</tbody>
</table>

**PHARMACY**

Georgia Families does provide pharmacy benefits to members. Check with the member’s health plan about who to call to find out more about enrolling to provide pharmacy benefits, including information about their plans reimbursement rates, specific benefits that are available, including prior approval requirements.

To request information about contracting with the health plans, you can call the CMOs provider enrollment services.

<table>
<thead>
<tr>
<th>Amerigroup Community Care</th>
<th>CareSource</th>
<th>Peach State Health Plan</th>
<th>WellCare of Georgia</th>
</tr>
</thead>
<tbody>
<tr>
<td>800-454-3730</td>
<td>844-441-8024</td>
<td>866-874-0633</td>
<td>866-300-1141</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>or <a href="https://www.wellcare.com/en/Georgia/Become-a-Provider">https://www.wellcare.com/en/Georgia/Become-a-Provider</a></td>
</tr>
</tbody>
</table>

All providers must be enrolled as a Medicaid provider to be eligible to contract with a health plan to provide services to Georgia Families members.
The CMO Pharmacy Benefit Managers (PBM) and the Bin Numbers, Processor Control Numbers and Group Numbers are:

<table>
<thead>
<tr>
<th>Health Plan</th>
<th>PBM</th>
<th>BIN #</th>
<th>PCN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Americigroup Community Care</td>
<td>ESI</td>
<td>003858</td>
<td>MA</td>
</tr>
<tr>
<td>CareSource</td>
<td>CVS Caremark</td>
<td>004336</td>
<td>MCAIDADV</td>
</tr>
<tr>
<td>Peach State Health Plan</td>
<td>Envolve Pharmacy Solutions (PBM) Caremark (Claims Processor)</td>
<td>004336</td>
<td>MCAIDADV</td>
</tr>
<tr>
<td>WellCare of Georgia</td>
<td>Caremark</td>
<td>004336</td>
<td>MCAIDADV</td>
</tr>
</tbody>
</table>

If a patient does not have an identification card:

Providers can check the enrollment status of Medicaid and PeachCare for Kids® members through DXC by calling 1-800-766-4456 or going to the web portal at www.mmis.georgia.gov. DXC will let you know if the member is eligible for services and the health plan they are enrolled in. You can contact the member’s health plan to get the member’s identification number.

Use of the member’s Medicaid or PeachCare for Kids® identification number to file a pharmacy claim:

<table>
<thead>
<tr>
<th>Amerigroup Community Care</th>
<th>CareSource</th>
<th>Peach State Health Plan</th>
<th>WellCare of Georgia</th>
</tr>
</thead>
<tbody>
<tr>
<td>No, you will need the member’s health plan ID number</td>
<td>Yes, you may also use the health plan ID number.</td>
<td>Yes</td>
<td>Yes, you may also use the WellCare subscriber ID</td>
</tr>
</tbody>
</table>

Health plans preferred drug list, prior authorization criteria, benefit design, and reimbursement rates:

Each health plan sets their own procedures, including preferred drug list, prior authorization criteria, benefit design, and reimbursement rates.
Will Medicaid cover prescriptions for members that the health plans do not?

No, Medicaid will not provide a “wrap-around” benefit for medications not covered or approved by the health plan. Each health plan will set its own processes for determining medical necessity and appeals.

Who to call to request a PA:

<table>
<thead>
<tr>
<th>Amerigroup Community Care</th>
<th>CareSource</th>
<th>Peach State Health Plan</th>
<th>WellCare of Georgia</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (800) 454-3730</td>
<td>1 (855) 202-1058</td>
<td>1 (866) 399-0929</td>
<td>1 (866) 231-1821</td>
</tr>
<tr>
<td></td>
<td>1 (866) 930-0019</td>
<td>(fax)</td>
<td>1 (866) 455-6558</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(fax)</td>
<td></td>
</tr>
</tbody>
</table>
APPENDIX I

Information for Providers Serving Medicaid Members in the Georgia Families 360°.SM Program

Georgia Families 360°.SM, the state’s managed care program for children, youth, and young adults in Foster Care, children and youth receiving Adoption Assistance, as well as select youth in the juvenile justice system, launched Monday, March 3, 2014. Amerigroup Community Care is the single Care Management Organization (CMO) that will be managing this population.

Amerigroup is responsible, through its provider network, for coordinating all DFCS, DJJ required assessments and medically necessary services for children, youth and young adults who are eligible to participate in the Georgia Families 360°.SM Program. Amerigroup will coordinate all medical/dental/trauma assessments for youth upon entry into foster care or juvenile justice (and as required periodically).

Georgia Families 360°.SM Every member in Georgia Families 360° is assigned a Care Coordinator who works closely with them to ensure access to care and ensure that appropriate, timely, and trauma informed care is provided for acute conditions as well as ongoing preventive care. This ensures that all medical, dental, and behavioral health issues are addressed. Members also have a medical and dental home to promote consistency and continuity of care. The medical and dental homes coordinate care and serve as a place where the child is known over time by providers who can provide holistic care. DFCS, DJJ, foster parents, adoptive parents and other caregivers are involved in the ongoing health care plans to ensure that the physical and behavioral health needs of these populations are met.

Electronic Health Records (EHRs) are being used to enhance effective delivery of care. The EHRs can be accessed by Amerigroup, physicians in the Amerigroup provider network, and DCH sister agencies, including the DFCS, regardless of where the child lives, even if the child experiences multiple placements. Ombudsman and advocacy staff are in place at both DCH and Amerigroup to support caregivers and members, assisting them in navigating the health care system. Additionally, medication management programs are in place to focus on appropriate monitoring of the use of psychototropic medications, to include ADD/ADHD as well as other behavioral health prescribed medications.

Providers can obtain additional information by contacting the Provider Service Line at 1-800-454-3730 or by contacting their Provider Relations representative.

To learn more about DCH and its dedication to A Healthy Georgia, visit www.dch.georgia.gov
APPENDIX J

Preventive Oral Health: Fluoride Varnish

Fluoride varnish acts to retard, arrest, and reverse the caries process. The teeth absorb the fluoride varnish, strengthening the enamel and helping prevent cavities. It is not a substitute for fluoridated water or toothpaste.

Once teeth are present, the application of fluoride varnish is required and may be applied every 3-6 months in the primary care or dental office for children between the ages of 6 months and 5 years.


Indications for fluoride use are noted in the 2014 AAP clinical report “Fluoride Use in Caries Prevention in the Primary Care Setting”


Documentation: Evidence that fluoride varnish was applied once between the ages of 6 months and 5 years OR evidence that the provider addressed the fluoride varnish requirement and/or its importance with the parent.

D1206 - Current Dental Terminology (CDT) Code

Effective January 1, 2015, the application of topical fluoride varnish by a physician or other qualified health care professional may be billed with the new CPT code 99188. This applies to providers enrolled in and filing claims under GA Medicaid programs 430, 431, and 740. Only providers enrolled in and filing claims under GA Medicaid programs 430, 431, 450, and 740 may bill Code D1206 Fluoride Varnish (eff. 1/1/2010).

Note:
- Dentists: under category of service 450
- Physicians: under category of service 430
- Physician Assistants (PA): under category of service 431
- Nurse Practitioners: under category of service 740

Providers may not bill for an Evaluation and Management (E/M) visit in addition to billing for the application of fluoride varnish, if the sole purpose of the visit was to apply the fluoride varnish. In this instance, the provider may bill for the fluoride varnish code only.

For more information including the payment rate for this service, please see the Part II Policies and Procedures Manual for Dental Services.
RESOURCES (not mandatory to use):

| Smiles for Life Oral Health Risk Assessment Tool: |
| Caries risk assessments: |
| ADA Caries Risk Assessment Form (Age 0-6) |
| ADA Caries Risk Assessment Form (Age >6) |

Smiles for Life Online trainings:
Child Oral Health (Course 2)
Caries Risk Assessment, Fluoride Varnish and Counseling (Course 6) (Course 6)

American Academy of Pediatric Dentistry (AAPD): http://www.aapd.org
Parent Handouts: 'For The Dental Patient' by the ADA freely available for download and photocopy at http://www.ada.org/993.aspx

*Patients at risk for caries include those with: insufficient sources of dietary fluoride; high carbohydrate diets; caretakers who transmit decay-causing bacteria to children via their saliva; areas of tooth decalcification; reduced salivary flow; and poor oral hygiene. AAP training course also includes “children from low socioeconomic and ethnocultural groups.”
APPENDIX K

EPSDT HIPAA Referral Code Examples

1. Child has come in for an EPSDT Interperiodic Hearing Screen and the provider finds that the child has an ear infection. The provider treats the child for the ear infection at the time of the interperiodic visit and requests a follow up appointment with him in two weeks. What EPSDT referral code should be documented?
   A. EPSDT Referral Code: S2

2. Child has come in for an EPSDT Screen and has experienced complications with diabetes since birth. The provider treats the child for the diabetes complications at the time of the preventive health visit and does not request a follow up appointment. What EPSDT referral code should be documented?
   A. EPSDT Referral Code: NU

3. Child has come in for an EPSDT Screen and during the screen, the mother informs the provider that the child has behavior problems. The provider refers the child for further diagnostic testing within two weeks with a Diagnostic and Behavioral Center. What EPSDT referral code should be documented?
   A. EPSDT Referral Code: ST

4. Child has come in for EPSDT Screen and the provider finds that the child has some developmental problems. The provider refers the child for further diagnostic testing with a Developmental and Behavioral Center. Mom refuses the Developmental and Behavioral appointment. What EPSDT referral code should be documented?
   A. EPSDT Referral Code: AV
Effective May 1, 2015, paper claims are no longer accepted by DXC. As part of the Georgia Paperless Initiative, providers are required to submit CMS 1500 claims electronically over the GAMMIS web portal. For more information regarding the Paperless Initiative, please access the web portal and review all related Banner Messages.
New CMS 1500 Field Locator Instructions

The following table outlines the revised changes on the above CMS 1500 claim form version 02/12:

<table>
<thead>
<tr>
<th>FLD Location</th>
<th>NEW Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Header</td>
<td>Replaced 1500 rectangular symbol with black and white two-dimensional QR Code (Quick Response Code)</td>
</tr>
<tr>
<td>Header</td>
<td>Added “(NUCC)” after “APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE.”</td>
</tr>
<tr>
<td>Header</td>
<td>Replaced “08/05” with “02/12”</td>
</tr>
<tr>
<td>Item Number 1</td>
<td>Changed “TRICARE CHAMPUS” to “TRICARE” and changed (Sponsor’s SSN)” to “(ID#/DoD#).”</td>
</tr>
<tr>
<td>Item Number 1</td>
<td>Changed “(SSN or ID)” to “(ID#)” under “GROUP HEALTH PLAN”</td>
</tr>
<tr>
<td>Item Number 1</td>
<td>Changed “(SSN)” to “(ID#)” under “FECA BLK LUNG.”</td>
</tr>
<tr>
<td>Item Number 1</td>
<td>Changed “(ID)” to “(ID#)” under “OTHER.”</td>
</tr>
<tr>
<td>Item Number 8</td>
<td>Deleted “PATIENT STATUS” and content of field. Changed title to “RESERVED FOR NUCC USE.”</td>
</tr>
<tr>
<td>Item Number 9b</td>
<td>Deleted “OTHER INSURED’s DATE OF BIRTH, SEX.” Changed title to “RESERVED FOR NUCC USE.”</td>
</tr>
<tr>
<td>Item Number 9c</td>
<td>Deleted “EMPLOYER’S NAME OR SCHOOL.” Changed title to “RESERVED FOR NUCC USE.”</td>
</tr>
<tr>
<td>Item Number 10d</td>
<td>Changed title from “RESERVED FOR LOCAL USE” to “CLAIM CODES (Designated by NUCC).” Field 10d is being changed to receive Worker’s Compensation codes or Condition codes approved by NUCC. FOR DCH/DXC: FLD 10d on the OLD Form CMS 1500 Claim (08/05) will no longer support receiving the Medicare provider ID.</td>
</tr>
<tr>
<td>Item Number 11b</td>
<td>Deleted “EMPLOYER’S NAME OR SCHOOL.” Changed title to “OTHER CLAIM ID (Designated by NUCC).” Added dotted line in the left-hand side of the field to accommodate a 2-byte qualifier.</td>
</tr>
<tr>
<td>Item Number 11d</td>
<td>Changed “If yes, return to and complete Item 9 a-d” to “If yes, complete items 9, 9a, and 9d.” (Is there another Health Benefit Plan?)</td>
</tr>
<tr>
<td>Item Number 14</td>
<td>Changed title to “DATE OF CURRENT ILLNESS, INJURY, OR PREGNANCY (LMP).” Removed the arrow and text in the right-hand side of the field. Added “QUAL.” with a dotted line to accommodate a 3-byte qualifier. “FOR DCH/DXC: Use Qualifiers: 431 (onset of current illness); 484 (LMP); or 453 (Estimated Delivery Date).”</td>
</tr>
<tr>
<td>Item Number 15</td>
<td>Changed title from “IF PATIENT HAS HAD SAME OR SIMILAR ILLNESS. GIVE FIRST DATE” to “OTHER DATE.” Added “QUALIFIER.” with two dotted lines to accommodate a 3-byte qualifier: 454 (Initial Treatment); 304 (Latest Visit or Consultation); 453 (Acute Manifestation of a Chronic Condition); 439 (Accident); 455 (Last X-ray); 471</td>
</tr>
<tr>
<td>FLD Location</td>
<td>NEW Change</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>(Prescription): 090 (Report Start [Assumed Care Date]): 091 (Report End [Relinquished Care Date]): 444 (First Visit or Consultation).</td>
<td></td>
</tr>
<tr>
<td>Item Number 17</td>
<td>Added a dotted line in the left-hand side of the field to accommodate a 2-byte qualifier – Used by Medicare for identifiers for provider roles: Ordering, Referring and Supervising. For DCH/DXC: Use the following Ordering Provider, Referring, Supervising Qualifiers (effective 4/01/2014): Ordering = DK; Referring = DN or Supervising = DQ.</td>
</tr>
<tr>
<td>Item Number 19</td>
<td>Changed title from “RESERVED FOR LOCAL USE” to “ADDITIONAL CLAIM INFORMATION (Designated by NUCC).” For DCH/DXC: Remove the Health Check logic from field 19 and add it in field 24H.</td>
</tr>
<tr>
<td>Item Number 21</td>
<td>Changed instruction after title (Diagnosis or Nature of Illness or Injury) from “(Relate Items 1, 2, 3 or 4 to Item 24E by Line)” to “Relate A-L to service line below (24E).”</td>
</tr>
<tr>
<td>Item Number 21</td>
<td>Removed arrow pointing to 24E (Diagnosis Pointer).</td>
</tr>
<tr>
<td>Item Number 21</td>
<td>Added “ICD Indicator.” and two dotted lines in the upper right-hand corner of the field to accommodate a 1-byte indicator. Use the highest level of code specificity in FLD Locator 21. Diagnosis Code ICD Indicator - new logic to validate acceptable values (0, 9). ICD-9 diagnoses (CM) codes = value 9; or ICD -10 diagnoses (CM) codes = value 0. (Do not bill ICD 10 code sets before October 1, 2015.)</td>
</tr>
<tr>
<td>Item Number 21</td>
<td>Added 8 additional lines for diagnosis codes. Evenly space the diagnosis code lines within the field.</td>
</tr>
<tr>
<td>Item Number 21</td>
<td>Changed labels of the diagnosis code lines to alpha characters (A-L).</td>
</tr>
<tr>
<td>Item Number 21</td>
<td>Removed the period within the diagnosis code lines</td>
</tr>
<tr>
<td>Item Number 22</td>
<td>Changed title from “MEDICAID RESUBMISSION” to “RESUBMISSION.” The submission codes are: 7 (Replacement of prior claim) 8 (Void/cancel of prior claim)</td>
</tr>
<tr>
<td>Item Numbers 24A – 24G (Supplemental Information)</td>
<td>The supplemental information is to be placed in the shaded section of 24A through 24G as defined in each Item Number. For DCH/DXC: Item numbers 24A &amp; 24G are used to capture Hemophilia drug units. 24H (EPSDT/Family Planning).</td>
</tr>
<tr>
<td>Item Number 30</td>
<td>Deleted “BALANCED DUE.” Changed title to “RESERVED FOR NUCC USE.”</td>
</tr>
<tr>
<td>Footer</td>
<td>Changed “APPROVED OMB-0938-0999 FORM CMS-1500 (08/05)” to “APPROVED OMB-0938-1197 FORM 1500 (02/12).”</td>
</tr>
</tbody>
</table>
Completion of the Health Insurance Claim Form for EPSDT Services
Billed by Fee-for-Service Providers

Review these helpful tips for completing the Health Insurance Claim Form (CMS-1500) for EPSDT Services. See Appendix K for EPSDT HIPAA Referral Code Examples.

Item 9  Other Insured’s Name
Leave blank. EPSDT preventive health screenings are exempt from third party liability. Even if the member has other insurance, you may file Medicaid first for preventive health services.

Item 21  Diagnosis
Enter the applicable ICD indicator to identify which version of ICD codes is being reported. Enter the indicator between the vertical, dotted lines in the upper right-hand portion of the field.

Enter the codes to identify the patient’s diagnosis and/or condition. List no more than twelve (12) diagnosis codes. Relate lines A-L to the lines of service in 24E by the letter of the line.

Item 24A  Dates of Service (DOS)
The “From” and “To” DOS will always be the same. Since there is only one DOS, enter the date under “From.” Leave “To” blank or re-enter “From” date.

Item 24B  Place of Service (POS)
Enter POS code 99 for all preventive health services and interperiodic visits.

Item 24C  EMG (emergency)
Leave blank for “No”.

Item 24D  HCPCS Code and Modifier
Enter procedure code and the EP modifier, plus any additional modifiers as applicable.

Item 24E  Diagnosis Pointer
Enter the diagnosis code reference letter (pointer) to relate to the DOS and the procedures performed to the primary diagnosis. When multiple services are performed, the primary reference letter for each service should be listed first, other applicable services should follow. Do not use commas between letters.

Item 24H  HIPAA EPSDT Referral Codes
- If EPSDT screening resulted in an EPSDT referral, enter the appropriate referral code:
  - ✓ Document AV, S2, or ST in the shaded area of box 24H
- If EPSDT screening did not result in an EPSDT referral:
  - ✓ Document NU in the shaded area of box 24H
- A “Y” for Yes or “N” for No is not entered with the referral code in the shaded area or in the unshaded area of box 24H.
### CMS-1500 Health Claim Form – SAMPLE

**SAMPLE EPSDT CLAIM**

9-month preventive visit

---

**Health Insurance Claim Form**

- **MEDicaid Number**: Doe, Mary J.
- **Date**: 12/25/2014
- **Address**: 123 Any Street, Anytown, GA
- **Phone**: (404) 123-4567

**Diagnoses and Procedures**:

- **Diagnosis Code**: Z00.121 or Z00.129
- **Procedure Code**: 99391 EP 25
- **Procedure Code**: 96110 EP
- **Procedure Code**: 90460 EP
- **Procedure Code**: 90744 EP
- **Procedure Code**: 90713 EP

**Note**: This is a sample form for demonstration purposes. Actual claims may vary.
SAMPLE EPSDT CLAIM
Age: 10 months
9-month Catch-Up preventive visit
**CMS-1500 Health Claim Form – SAMPLE**

**SAMPLE EPSDT CLAIM**

12-month preventive visit

<table>
<thead>
<tr>
<th>Line</th>
<th>Description</th>
<th>Code</th>
<th>Quantity</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Preventive Visit</td>
<td>99392</td>
<td>10 01 15</td>
<td>EP 25</td>
</tr>
<tr>
<td>2</td>
<td>Preventive Visit</td>
<td>99212</td>
<td>10 01 15</td>
<td>EP 25</td>
</tr>
<tr>
<td>3</td>
<td>Preventive Visit</td>
<td>90480</td>
<td>10 01 15</td>
<td>EP A</td>
</tr>
<tr>
<td>4</td>
<td>Preventive Visit</td>
<td>90744</td>
<td>10 01 15</td>
<td>EP C</td>
</tr>
<tr>
<td>5</td>
<td>Preventive Visit</td>
<td>90710</td>
<td>10 01 15</td>
<td>EP C</td>
</tr>
</tbody>
</table>
SAMPLE EPSDT CLAIM
Preventive visit with Immunization Administration Codes and EPSDT Referral Code
SAMPLE EPSDT CLAIM
19 year old – Preventive
with Immunization Administration Codes
and EPSDT Referral Code
APPENDIX M

Resources for Children in Georgia

Georgia Public Health Programs

Programs for Children with Disabilities or Special Health Care Needs:

**Babies Can’t Wait Program (Birth – 3 years)**
2 Peachtree Street, NW
11th floor
Atlanta, GA 30303
[http://dph.georgia.gov/Babies-Cant-Wait](http://dph.georgia.gov/Babies-Cant-Wait)
404-657-2850
888-651-8224

**Children’s Medical Services (Birth – 21 years)**
2 Peachtree Street, NW
11th floor
Atlanta, GA 30303
[http://dph.georgia.gov/CMS](http://dph.georgia.gov/CMS)
404-657-2850

**Children 1st Program**
2 Peachtree Street, NW
11th floor
Atlanta, GA 30303
404-657-2850

**Women, Infants, and Children (WIC)**
2 Peachtree Street, NW
10th floor
Atlanta, GA 30303
[https://dph.georgia.gov/WIC](https://dph.georgia.gov/WIC)
1-800-228-9173
Georgia Families

For members in Medicaid or PeachCare for Kids®

Most Medicaid and PeachCare for Kids members must enroll in the Georgia Families managed care program and choose a health plan and a provider.


1-888-GA-ENROLL (1-888-423-6765)

PeachCare for Kids®

CHIP Program

(PeachCare for Kids offers free to low cost health insurance, inclusive of the EPSDT benefit, to uninsured, eligible children living in Georgia)

P.O. Box 2583
Atlanta, GA 30301-2583
www.PeachCare.org
1-877-GA-PEACH (1-877-427-3224)

Vaccines for Children (VFC) Program

GA Department of Public Health Immunization Program
2 Peachtree St NW, 13-276
Atlanta, GA 30303
https://dph.georgia.gov/vaccines-children-program
(800) 848-3868
(404) 657-5013/ 5015
DPH-gavfc@dph.ga.gov
Georgia Department of Education (GaDOE)

Ask DOE Manager
2054 Twin Towers East
205 Jesse Hill Jr. Drive SE
Atlanta, GA 30334
(404) 656-2800
(800) 311-3627 (GA)
(404) 651-8737 (fax)
askdoe@doe.k12.ga.us

Special Education

Division for Special Education Services and Supports
Georgia Department of Education
1870 Twin Towers East
Atlanta, GA 30334-9048
(404) 656-3963
Web: www.doe.k12.ga.us

Programs for Children with Disabilities: Ages 3 through 7

Young Children/619 Coordinator
Division for Special Education Services and Supports
Georgia Department of Education
1870 Twin Towers East
Atlanta, GA 30334-5060
(404) 657-9965
Web: www.doe.k12.ga.us

Division of Family & Children Services (DFCS)

http://dfcs.dhs.georgia.gov
1.800.georgia (1.800.436.7442)
678.georgia (678.436.7442) – Atlanta area

DFCS Office of Constituent Services
(404) 657-3433
- Child Welfare Online Contact Form
  complete online contact form for issues related to Adoptions, Child Protective Services, Foster Care or any other Child Welfare issue.
Child Protective Services / Child Abuse & Neglect
1-855-GACHILD / 1-855-422-4453
(404) 657-3400

Medicaid
(877) 423-4746

Food Stamps
(877) 423-4746

Energy Assistance
(877) 423-4746

Temporary Assistance for Needy Families
(877) 423-4746

Department of Behavioral Health and Developmental Disabilities (DBHDD)
Two Peachtree Street, NW
24th Floor
Atlanta, GA 30303
404-657-2252
http://dbhdd.georgia.gov

Other Resources:

Parent-To-Parent of Georgia
Parent to Parent of Georgia offers a variety of services to Georgia residents ages birth to 26 years and their families impacted by disabilities or special healthcare needs.

3070 Presidential Parkway, Suite 130
Atlanta, GA 30340
(770) 451-5484
(800) 229-2038
Web: http://p2pga.org

Healthy Mothers, Healthy Babies Powerline
Source for healthcare referrals and information
2300 Henderson Mill Road
Suite 410
Atlanta, GA 30345
(770) 451-0020
(770) 451-2466
(800) 300-9003
(800) 822-2539
thecoalition@hmhbga.org
www.hmhbga.org
APPENDIX N

General Claims Submission Policy for Ordering, Prescribing, or Referring (OPR) Providers

The Affordable Care Act (ACA) requires physicians and other eligible practitioners who order, prescribe and refer items or services for Medicaid beneficiaries to be enrolled in the GA Medicaid Program. As a result, CMS expanded the claim editing requirements in Section 1833(q) of the Social Security Act and the providers’ definitions in sections 1861-r and 1842(b)(18)C. Therefore, claims for services that are ordered, prescribed or referred must indicate who the ordering, prescribing or referring (OPR) practitioner is. The Department will utilize an enrolled OPR provider identification number for this purpose. Any OPR physicians or other eligible practitioners who are NOT already enrolled in Medicaid as participating (i.e. billing) must enroll separately as OPR. The National Provider Identifier (NPI) of the OPR provider must be included on the claim submitted by the participating, i.e. rendering provider. If the NPI of the OPR provider noted on the Georgia Medicaid claim is associated with a provider who is not enrolled in the Georgia Medicaid program, the claim will not be paid.

Effective 4/1/2014, DCH will begin editing claims submitted through the web, EDI, and on CMS 1500 forms for the presence of an ordering, prescribing or referring provider as required by program policy. The edit will be informational until 6/1/2014. Effective 6/1/2014, the ordering, prescribing or referring provider will become a mandatory field and claims that do not contain the information as required by policy will begin to deny.

For the New CMS-1500 claim form:
Enter qualifiers to indicate if the claim has an ordering, prescribing or referring to the left of the dotted line in box 17 (Ordering = DK; Referring = DN or Supervising = DQ).

For claims entered via the web:
Claims headers were updated to accept ordering or referring Provider ID and name for Dental and Institutional claims and the referring provider’s name for Professional claims. The claim detail was updated to accept an ordering or referring provider ID and name. Utilize the “ordering” provider field for claims that require a prescribing physician.

For claims transmitted via EDI:
The 837 D, I and P companion guides were updated to specifically point out the provider loops that capture the rendering, ordering, prescribing, referring and service facility provider information that is now used to transmit OPR information.
APPENDIX 0

Screening Tools

The CRAFFT Screening Interview

Begin: “I’m going to ask you a few questions that I ask all my patients. Please be honest. I will keep your answers confidential.”

Part A
During the PAST 12 MONTHS, did you:

1. Drink any alcohol (more than a few sips)?
   (Do not count sips of alcohol taken during family or religious events.)
   No □ Yes □

2. Smoke any marijuana or hashish?
   No □ Yes □

3. Use anything else to get high?
   (“anything else” includes illegal drugs, over the counter and prescription drugs, and things that you sniff or “huff”)
   No □ Yes □

For clinic use only: Did the patient answer “yes” to any questions in Part A?

No □ Yes □

Ask CAR question only, then stop
Ask all 6 CRAFFT questions

Part B

1. Have you ever ridden in a CAR driven by someone (including yourself) who was “high” or had been using alcohol or drugs?
   No □ Yes □

2. Do you ever use alcohol or drugs to RELAX, feel better about yourself, or fit in?
   No □ Yes □

3. Do you ever use alcohol or drugs while you are by yourself, or ALONE?
   No □ Yes □

4. Do you ever FORGET things you did while using alcohol or drugs?
   No □ Yes □

5. Do your FAMILY or FRIENDS ever tell you that you should cut down on your drinking or drug use?
   No □ Yes □

6. Have you ever gotten into TROUBLE while you were using alcohol or drugs?
   No □ Yes □

CONFIDENTIALITY NOTICE:
The information recorded on this page may be protected by special federal confidentiality rules (42 CFR Part 2), which prohibit disclosure of this information unless authorized by specific written consent. A general authorization for release of medical information is NOT sufficient for this purpose.

© CHILDREN’S HOSPITAL BOSTON, 2009. ALL RIGHTS RESERVED.
Reproduced with permission from the Center for Adolescent Substance Abuse Research, CeASAR, Children’s Hospital Boston. (www.ceasar.org)
## Screening Tools

### Patient Health Questionnaire-2 (PHQ-2)

**PHQ-2**

<table>
<thead>
<tr>
<th>Over the past two weeks, how often have you been bothered by any of the following problems?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Little interest or pleasure in doing things.</td>
</tr>
<tr>
<td>0 = Not at all</td>
</tr>
<tr>
<td>1 = Several days</td>
</tr>
<tr>
<td>2 = More than half the days</td>
</tr>
<tr>
<td>3 = Nearly every day</td>
</tr>
<tr>
<td>Feeling down, depressed, or hopeless.</td>
</tr>
<tr>
<td>0 = Not at all</td>
</tr>
<tr>
<td>1 = Several days</td>
</tr>
<tr>
<td>2 = More than half the days</td>
</tr>
<tr>
<td>3 = Nearly every day</td>
</tr>
</tbody>
</table>

Total point score: ________________

**Score interpretation:**

<table>
<thead>
<tr>
<th>PHQ-2 score</th>
<th>Probability of major depressive disorder (%)</th>
<th>Probability of any depressive disorder (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>15.4</td>
<td>36.9</td>
</tr>
<tr>
<td>2</td>
<td>21.1</td>
<td>48.3</td>
</tr>
<tr>
<td>3</td>
<td>38.4</td>
<td>75.0</td>
</tr>
<tr>
<td>4</td>
<td>45.5</td>
<td>81.2</td>
</tr>
<tr>
<td>5</td>
<td>56.4</td>
<td>84.6</td>
</tr>
<tr>
<td>6</td>
<td>78.6</td>
<td>92.9</td>
</tr>
</tbody>
</table>

**Figure 1.** Patient Health Questionnaire-2 (PHQ-2). This questionnaire is used as the initial screening test for major depressive episode.

APPENDIX P
2016 Policy Revisions Record

Part II Policies and Procedures Manual for EPSDT (Health Check) Services

<table>
<thead>
<tr>
<th>REVISION DATE</th>
<th>SECTION &amp; PAGE</th>
<th>REVISION DESCRIPTION</th>
<th>REVISION TYPE</th>
<th>CITATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>01/01/16</td>
<td>902</td>
<td>Revised AAP BF Periodicity Schedule</td>
<td>M</td>
<td>AAP Bright Futures (BF)</td>
</tr>
<tr>
<td>01/01/16</td>
<td>1003.3</td>
<td>Depression Screenings and Alcohol/SA Risk Assessments (96127) – added</td>
<td>A</td>
<td>N/A</td>
</tr>
<tr>
<td>01/01/16</td>
<td>1003.16</td>
<td>Incontinence Products - added</td>
<td>A</td>
<td>N/A</td>
</tr>
<tr>
<td>01/01/16</td>
<td>Appendix C-2</td>
<td>Vaccine product codes: 90634 - Hepatitis A – removed 90655 – Influenza - added</td>
<td>D</td>
<td>N/A</td>
</tr>
</tbody>
</table>
| 01/01/16      | Appendix R     | • Deleted BF Periodicity Schedule  
• Added upcoming 4/16 EPSDT Updates | D             | A        |
| 04/01/16      | Introduction   | Added brief emotional/behavioral assessments to services reimbursed under Health Check | M             | N/A      |
| 04/01/16      | 902 p. IX-1-3  | Revised AAP BF Periodicity Schedule (copyright 2016, updated 10/15) | A             | AAP BF   |
| 04/01/16      | 902.1 #7, #25, #26 p. IX-4-7 | Updated BF Footnotes:  
• Visual Acuity, Oral Health  
• Fluoride Varnish | M             | AAP BF   |
| 04/01/16      | 902.2 D.1., p. IX-9 E.4 & 5, p. IX-12-13 G.1.b., p. IX-14-15 G.8., p. IX-18 I., p. IX-19 | Updated Screening Components  
• Vision- routine screening at age 18 changed to risk assessment.  
• Clarifications to Alcohol/Substance Abuse Risk Assessment & Depression Screening  
• Critical Congenital Heart Disease (CCHD) Screening – updated  
• Cervical Dysplasia / Pap Test – updated  
• Fluoride Varnish –added | M             | AAP BF   |
| 04/01/16      | 904 Table A p. IX-23 & 23 | 99384 & 99394 – ICD-10 Z00.00 & Z00.01 for ages 15-17 years | M             | ICD-10 coding guidelines |
| 04/01/16      | Immunization Schedules IX-30 - 32 | 2016 Immunizations Schedules posted | M             | CDC      |
| 04/01/16      | 1003.3 p. X-2 & 3 | Brief Emotional / Behavioral Assessment (96127) – updated | M             | N/A      |
## APPENDIX P

### 2016 Policy Revisions Record

Part II Policies and Procedures Manual for EPSDT (Health Check) Services

<table>
<thead>
<tr>
<th>REVISION DATE</th>
<th>SECTION &amp; PAGE</th>
<th>REVISION DESCRIPTION</th>
<th>REVISION TYPE</th>
<th>CITATION</th>
</tr>
</thead>
</table>
| 04/01/16      | 1003. p. 5-7   | • School-based Telemedicine Services for LEAs (Q3014) – updated  
• Fluoride Varnish – added  
• NCCI-MUE limits – added  
• Other Reimbursement Rates - added | M A A A | N/A |
| 04/01/16      | Appendix C-2   | Minor updates to vaccine procedure code descriptions:  
90620, 90621, 90632, 90633, 90644, 90647, 90648, 90649, 90650, 90651, 90655, 90656, 90657, 90658, 90670, 90672, 90680, 90681, 90685, 90686, 90687, 90688, 90696, 90698, 90714, 90716, 90732, 90734, 90744, 90746, 90474  
90670 – clarified age restriction (6 weeks to 17 years)  
90733 - added for ages 19-20 years | M 2016 HCPCS | N/A |
| 04/01/16      | Appendix H     | updates to CMO PBM, BIN# and PCN for AMG & WC | M | N/A |
| 04/01/16      | Appendix J     | Fluoride varnish - revised | M | N/A |
| 04/01/16      | Appendix R     | Removed upcoming 4/2016 EPSDT Updates | D | N/A |
| 07/01/16      | 902.2, p. IX-7 | Bright Futures helpful materials – updated hyperlink | M | N/A |
| 07/01/16      | 902.2, D.2, p. IX-10 | EHDI Program - updated hyperlink and info | M | N/A |
| 07/01/16      | 902.2, E.3, 902.2, E.4, 902.2, E.5. p. IX-12 & 13 | MCHAT tool - updated hyperlink  
CRAFFT tool - added hyperlink  
PHQ-2 tool - updated hyperlink | M A M | N/A |
## APPENDIX P

### 2016 Policy Revisions Record

Part II Policies and Procedures Manual for EPSDT (Health Check) Services

<table>
<thead>
<tr>
<th>REVISION DATE</th>
<th>SECTION &amp; PAGE</th>
<th>REVISION DESCRIPTION</th>
<th>REVISION TYPE</th>
<th>CITATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>07/01/16</td>
<td>902.2, G.1.a. &amp; b. 902.2, G.2 p. IX-14 &amp; 15</td>
<td>Georgia NBS Program - added hyperlink and minor info GRITS - added hyperlink</td>
<td>A</td>
<td>N/A</td>
</tr>
<tr>
<td>07/01/16</td>
<td>Tables A, C p. IX-22, 27</td>
<td>Minor revision for clarification related to modifiers</td>
<td>M</td>
<td>N/A</td>
</tr>
<tr>
<td>07/01/16</td>
<td>Appendix A p. A-1- 4</td>
<td>Minor revisions Posted the HB76 FY2016 PCP Increased Rates (Implementation of rates is pending. Refer to Banner Message dated 6-17-2016)</td>
<td>M</td>
<td>A</td>
</tr>
<tr>
<td>07/01/16</td>
<td>Appendix F p. F-2 - 4</td>
<td>Counseling for Nutrition and Physical Activity – added info related to HEDIS requirements</td>
<td>A</td>
<td>HEDIS</td>
</tr>
<tr>
<td>07/01/16</td>
<td>Appendix M</td>
<td>Updated Resources</td>
<td>M</td>
<td>N/A</td>
</tr>
<tr>
<td>10/01/16</td>
<td>902.2 H., p. IX-19</td>
<td>Added clarifications to Oral Health section. Revised the statement to read: “The AAP recommends the establishment of a dental home six months after the first tooth erupts or by 12 months of age (whichever comes first).”</td>
<td>M</td>
<td>AAP Bright Futures (BF)</td>
</tr>
<tr>
<td></td>
<td>902.2 I., p. IX-19</td>
<td>For clarification, deleted the statement “One application of fluoride varnish is required for children between the ages of 6 months and 5 years.” Revised to read, “Once teeth are present, the application of fluoride varnish is required and may be applied every 3-6 months in the primary care or dental office for children between the ages of 6 months and 5 years.”</td>
<td>M</td>
<td>AAP Bright Futures (BF)</td>
</tr>
<tr>
<td></td>
<td>1003. #17. p. X-6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Appendix J p. J-1</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# APPENDIX P

2016 Policy Revisions Record

Part II Policies and Procedures Manual for EPSDT (Health Check) Services

<table>
<thead>
<tr>
<th>REVISION DATE</th>
<th>SECTION &amp; PAGE</th>
<th>REVISION DESCRIPTION</th>
<th>REVISION TYPE</th>
<th>CITATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/01/16</td>
<td>Table A-1 p. IX-24</td>
<td>Posted the HB 751 FY 2017 PCP rate increases for the preventive visits 99381, 99391-99395</td>
<td>A</td>
<td>Legislation – HB 751</td>
</tr>
<tr>
<td></td>
<td>Table B-2 p. IX-26</td>
<td>Posted the HB 751 FY 2017 PCP rate increases for the catch-up preventive visits 99381, 99391, 99392</td>
<td>A</td>
<td>Legislation – HB 751</td>
</tr>
<tr>
<td></td>
<td>Table C-2 p. IX-28</td>
<td>Posted the HB 751 FY 2017 PCP rate increases for the interperiodic visits 99202-99203, 99212-99214</td>
<td>A</td>
<td>Legislation – HB 751</td>
</tr>
<tr>
<td></td>
<td>1003. #20. p. X-7</td>
<td>Posted the HB 751 FY 2017 PCP rate increase for the office consultation code 99244</td>
<td>M</td>
<td>HEDIS</td>
</tr>
<tr>
<td></td>
<td>Appendix C-1 Table C-1b p. C-1</td>
<td>Posted the HB 751 FY 2017 PCP rate increase for the vaccine administration codes 90460, 90471, 90472</td>
<td>M</td>
<td>Policy</td>
</tr>
<tr>
<td>10/01/16</td>
<td>Appendix C-2 p. C-7</td>
<td>90630 (influenza virus vaccine, quadrivalent, intradermal) - added for ages 19-20 years</td>
<td>A</td>
<td>ACIP</td>
</tr>
<tr>
<td>10/01/16</td>
<td>Appendix F p. F-4</td>
<td>Under ICD-10 Codes to Identify Counseling for Physical Activity, ICD-10 diagnosis code Z71.89 (other specified counseling) was deleted.</td>
<td>M</td>
<td>HEDIS</td>
</tr>
<tr>
<td>10/01/16</td>
<td>Appendix H p. H-2</td>
<td>Updated the Georgia Families Regions – “Counties” Column revised</td>
<td>M</td>
<td>Policy</td>
</tr>
<tr>
<td>10/01/16</td>
<td>Appendix H p. H-11</td>
<td>Updated with the new PBM information for Peach State Health Plan</td>
<td>M</td>
<td>Policy</td>
</tr>
</tbody>
</table>
## APPENDIX P

### 2017 Policy Revisions Record

Part II Policies and Procedures Manual for EPSDT (Health Check) Services

<table>
<thead>
<tr>
<th>REVISION DATE</th>
<th>SECTION &amp; PAGE</th>
<th>REVISION DESCRIPTION</th>
<th>REVISION TYPE</th>
<th>CITATION</th>
</tr>
</thead>
</table>
| 01/01/17      | 902.2 H. p. IX-19 | Clarifications to Oral Health:  
- The AAP recommends both the establishment of a dental home and the first dental exam no later than 12 months of age.  
- An oral health risk assessment tool has been developed by the AAP/Bright Futures. | M | AAP Bright Futures (BF) |
| 01/01/17      | Appendix C-2 | The 2017 HCPCS influenza vaccine code description changes will not go into effect until the updates are completed in GAMMIS. | M | HCPCS |
| 01/01/17      | 902 p. IX-1 | The “Mapping of EPSDT Preventive Health ICD-9 Codes to ICD-10 Codes” table was removed from Appendices. Accordingly, all references to the table were removed throughout the manual. | D | N/A |
| 01/01/17      | Appendix Q | The “2016 Policy Revisions Record” was added as Appendix Q. | A | N/A |
| 04/01/17      | 902 p. IX-30-32 | Notification – updated AAP 2017 BF Periodicity Schedule (effective date July 1, 2017) | M | AAP Bright Futures (BF) |
| 04/01/17      | p. IX-30-32 | 2017 Immunization Schedules posted | M | ACIP |
| 04/01/17      | Appendix C-2 | 90670 – age restriction removed. Refer to the ACIP Immunization Schedule for recommended age | M | N/A |
| 04/01/17      | Appendix H | Georgia Families – updated appendix | M | N/A |
| 04/01/17      | Appendix O | Performance Measures - minor updates | M | N/A |
| 04/01/17      | Appendix R | 2017 BF Periodicity Schedule – displays updated schedule and summary of changes | A | AAP Bright Futures (BF) |
## APPENDIX P

### 2017 Policy Revisions Record

#### Part II Policies and Procedures Manual for EPSDT (Health Check) Services

<table>
<thead>
<tr>
<th>REVISION DATE</th>
<th>SECTION &amp; PAGE</th>
<th>REVISION DESCRIPTION</th>
<th>REVISION TYPE</th>
<th>CITATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>07/01/17</td>
<td>Entire Manual</td>
<td>Vendor name change - HPE updated to reflect new name –DXC Technology (DXC)</td>
<td>M</td>
<td>N/A</td>
</tr>
<tr>
<td>07/01/17</td>
<td>902-902.1 p. IX-1 – IX-7</td>
<td>Updated 2017 BF Periodicity Schedule – adoption of new schedule effective July 1, 2017 with revised footnotes. Added new screening BF requirements, and deleted/revised current screening requirements. Revised the minimum standards for screening components in accordance with the updated 2017 BF Periodicity Schedule. Changes to: • Hearing • Tobacco, Alcohol, or Drug Use Assessment • Depression Screening • Maternal Depression Screening • Newborn Blood • Newborn Bilirubin • Dyslipidemia Screening • STIs • HIV • Oral Health Screening tools requirements revised to reflect updated 2017 BF Periodicity Schedule.</td>
<td>M</td>
<td>AAP Bright Futures (BF)</td>
</tr>
<tr>
<td></td>
<td>902.2 p. IX-11 – IX-22</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>903 IX-23</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>07/01/17</td>
<td>902.2, G.4. p. IX-18, 907.2, C. p. IX-40, Appendix A, p. A-5</td>
<td>Blood Lead Test – provided clarification that “All <em>venous</em> sample lead screening tests conducted using any Magellan Diagnostic lead testing system should be laboratory analyzed by a properly accredited laboratory.”</td>
<td>M</td>
<td>FDA, CDC, GA. Dept. of Public Health (DPH)</td>
</tr>
<tr>
<td>07/01/17</td>
<td>1003, #3, p. X-2</td>
<td>Effective July 1, 2017, DCH will allow separate reimbursement for the Autism screening (96110 EP, UA)</td>
<td>A</td>
<td>DCH</td>
</tr>
</tbody>
</table>
# PART II Policies and Procedures Manual for EPSDT (Health Check) Services

## APPENDIX P

### 2017 Policy Revisions Record

<table>
<thead>
<tr>
<th>REVISION DATE</th>
<th>SECTION &amp; PAGE</th>
<th>REVISION DESCRIPTION</th>
<th>REVISION TYPE</th>
<th>CITATION</th>
</tr>
</thead>
</table>
| 07/01/17      | 1003, p. X-2 – X-3, p. X-7 | Billing Requirements revisions:  
- added Autism screening code, modifiers and rate,  
- revised age ranges for brief emotional/behavioral assessments | M | DCH/ AAP Bright Futures (BF) |
| 10/01/17      | 1003, #2 & #3, p. X-2 | 2) Developmental Screenings – included ICD-10 diagnosis codes  
3) Autism Screenings – included ICD-10 diagnosis codes | M | DCH |
| 10/01/17      | Appendix C-2 | Updates to influenza vaccines  
1) 90672 - removed  
2) 90674 – added  
3) 90682 – added (19-20 years) | A, D | DCH |
### 2018 Policy Revisions Record

Part II Policies and Procedures Manual for EPSDT (Health Check) Services

<table>
<thead>
<tr>
<th>REVISION DATE</th>
<th>SECTION &amp; PAGE</th>
<th>REVISION DESCRIPTION</th>
<th>REVISION TYPE</th>
<th>CITATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/1/2018</td>
<td>902.2.E.4. p. IX-14</td>
<td>Tobacco, Alcohol, or Drug Use Assessment: Added clarification to Documentation - Screening tool must be standardized and scorable.</td>
<td>A</td>
<td>DCH</td>
</tr>
<tr>
<td>10/1/2018</td>
<td>902.2.E.6. p. IX-15</td>
<td>Maternal Depression Screening: Added clarification to Documentation - Screening tool must be standardized and scorable.</td>
<td>A</td>
<td>DCH</td>
</tr>
<tr>
<td>10/1/2018</td>
<td>1003.9. p. X-4</td>
<td>Patient-Focused Health Risk Assessment - (96160) updated the guidance in order to allow the 59 modifier to bypass the NCCI PTP edit.</td>
<td>M</td>
<td>DCH</td>
</tr>
<tr>
<td>10/1/2018</td>
<td>1003.10. p. X-4-5</td>
<td>Caregiver-Focused Health Risk Assessment - (96161) updated the guidance in order to allow the 59 modifier to bypass the NCCI PTP edit.</td>
<td>M</td>
<td>DCH</td>
</tr>
<tr>
<td>10/1/2018</td>
<td>1003.23. p. X-9</td>
<td>NCCI PTP Edits - added guidance on NCCI PTP edits</td>
<td>A</td>
<td>DCH</td>
</tr>
<tr>
<td>10/1/2018</td>
<td>1003.23. p. X-9</td>
<td>Q3014 – revised to include EP GT modifiers</td>
<td>M</td>
<td>DCH</td>
</tr>
<tr>
<td>10/1/2018</td>
<td>Appendix C-2 p. C-5</td>
<td>Updated vaccine codes (ages birth through 18 years) in accordance with current VFC supply</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10/1/2018</td>
<td>Appendix C-2 p. C-7</td>
<td>Updated vaccine codes (ages 19 years through 20 years) in accordance with current VFC supply</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10/1/2018</td>
<td>Appendix H</td>
<td>Updated Georgia Families Appendix</td>
<td>M</td>
<td>DCH</td>
</tr>
</tbody>
</table>
## APPENDIX P

### 2018 Policy Revisions Record

Part II Policies and Procedures Manual for EPSDT (Health Check) Services

<table>
<thead>
<tr>
<th>REVISION DATE</th>
<th>SECTION &amp; PAGE</th>
<th>REVISION DESCRIPTION</th>
<th>REVISION TYPE</th>
<th>CITATION</th>
</tr>
</thead>
</table>
| 07/01/18      | 1003, p. X-3-4 | ▶ Revised billing guidance for brief emotional/behavioral assessments (96127)  
▶ New billing guidance for patient focused health risk assessments (96160)  
▶ New billing guidance for maternal depression screenings (96161) | M, A | DCH |
| 07/01/18      | Appendix I     | ▶ Georgia Families 360<sup>SM</sup> Appendix-Revisions to info for providers serving Medicaid members in the Georgia Families 360<sup>SM</sup> Program | M | DCH |
| 04/01/18      | 905, p. IX-37-41 | 2018 Immunization Schedules posted | A | ACIP |
| 04/01/18      | Appendix C-1, Table C-2, p. C-5 | Posted the HB 44 FY 2018 PCP rate increase for the following codes: vaccine administration codes  
▶ 90473 – FFS  
▶ 90474 – FFS, PCK | A | Legislation – HB 44 |
|              | 904, Table C-1, p. IX-32  
904, Table C-2, p. IX-33 | interperiodic visit codes  
▶ 99201 – FFS  
▶ 99211 – FFS, PCK | | |
|              | 1003, #21, p. X-8 | office consultation codes  
▶ 99241, 99242, 99243, 99245  
behavior change smoking codes  
▶ 99406, 99407 | | |
|              | 904, Table A-1 p. IX-27  
904, Table B-2, p. IX-30 | preventive visit codes  
99382, 99383, 99384, 99385 | | |
## APPENDIX P

2018 Policy Revisions Record

Part II Policies and Procedures Manual for EPSDT (Health Check) Services

<table>
<thead>
<tr>
<th>REVISION DATE</th>
<th>SECTION &amp; PAGE</th>
<th>REVISION DESCRIPTION</th>
<th>REVISION TYPE</th>
<th>CITATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>04/01/18</td>
<td>Appendix C-2</td>
<td>Added new 2018 HCPCS code 90756 – Influenza virus vaccine, quadrivalent (ccIIIV4), derived from cell cultures, subunit, antibiotic free, 0.5mL dosage, for intramuscular use</td>
<td>A</td>
<td>HCPCS</td>
</tr>
<tr>
<td>04/01/18</td>
<td>Appendix F</td>
<td>Clarifications to Weight Assessment - BMI</td>
<td>M</td>
<td>N/A</td>
</tr>
<tr>
<td>01/01/18</td>
<td>#6</td>
<td>Maternal Depression – added clarification to recommended tools</td>
<td>M</td>
<td>AAP</td>
</tr>
<tr>
<td>01/01/18</td>
<td>Table C</td>
<td>Updated the hyperlink for the DPH Form 3300 - Certificate of Vision, Hearing, Dental and Nutrition Screening</td>
<td>M</td>
<td>DPH</td>
</tr>
<tr>
<td>01/01/18</td>
<td>Appendix C</td>
<td>Revised descriptions for CPT codes 90620 90621 90651</td>
<td>M</td>
<td>HCPCS 2018</td>
</tr>
</tbody>
</table>
| 01/01/18      | Appendix F     | 1) Documentation for BMI – added the following clarification: “Only evidence of the BMI percentile or BMI percentile plotted on an age-growth chart meet HEDIS criteria.”

2) Under the section containing the notations or examples of documentation that are not compliant with HEDIS requirements for Nutrition, added the following:

   o Documentation related to a member’s “appetite” does not meet criteria. | M            | HEDIS 2018 |
2019 Recommendations for Preventive Pediatric Health Care

(Copyright © 2019 by the AAP, updated March 2019)

The Division will adopt the AAP 2019 Bright Futures “Recommendations for Pediatric Health Care” Periodicity Schedule effective date July 1, 2019.

The schedule is available at https://www.aap.org/en-us/Documents/periodicity_schedule.pdf

The changes implemented in the 2019 schedule include the following footnote revisions. The following is a summary of changes:

BLOOD PRESSURE

• Footnote 6 has been updated to read as follows: "Screening should occur per 'Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents.' Blood pressure measurement in infants and children with specific risk conditions should be performed at visits before age 3 years."

ANEMIA

• Footnote 24 has been updated to read as follows: "Perform risk assessment or screening, as appropriate, per recommendations in the current edition of the AAP Pediatric Nutrition: Policy of the American Academy of Pediatrics (Iron chapter)."

LEAD

• Footnote 25 has been updated to read as follows: "For children at risk of lead exposure, see 'Prevention of Childhood Lead Toxicity' and 'Low Level Lead Exposure Harms Children: A Renewed Call for Primary Prevention'."
2017 Recommendations for Preventive Pediatric Health Care
(Copyright © 2017 by the AAP, updated February 2017)

The Division adopted the AAP 2017 Bright Futures “Recommendations for Pediatric Health Care” Periodicity Schedule effective date July 1, 2017.

The schedule is available at https://www.aap.org/en-us/documents/periodicity_schedule.pdf

The changes implemented in the 2017 schedule include numerous footnote revisions. The following is a summary of changes:

HEARING

- Timing and follow-up of the screening recommendations for hearing during the infancy visits have been delineated. Adolescent risk assessment has changed to screening once during each time period.
- Footnote 8 has been updated to read as follows: “Confirm initial screen was completed, verify results, and follow up, as appropriate. Newborns should be screened, per ‘Year 2007 Position Statement: Principles and Guidelines for Early Hearing Detection and Intervention Programs’ http://pediatrics.aappublications.org/content/120/4/898.full
- Footnote 9 has been added to read as follows: “Verify results as soon as possible, and follow up, as appropriate.”
- Footnote 10 has been added to read as follows: “Screen with audiometry including 6,000 and 8,000 Hz high frequencies once between 11 and 14 years, once between 15 and 17 years, and once between 18 and 21 years. See ‘The Sensitivity of Adolescent Hearing Screens Significantly Improves by Adding High Frequencies’ http://www.jahonline.org/article/S1054-139X(16)00048-3/fulltext

PSYCHOSOCIAL/BEHAVIORAL ASSESSMENT

- Footnote 13 has been added to read as follows: “This assessment should be family centered and may include an assessment of child social-emotional health, caregiver depression, and social determinants of health. See ‘Promoting Optimal Development: Screening for Behavioral and Emotional Problems’ (http://pediatrics.aappublications.org/content/135/2/384) and ‘Poverty and Child Health in the United States’ (http://pediatrics.aappublications.org/content/137/4/e20160339).”

TOBACCO, ALCOHOL, OR DRUG USE ASSESSMENT

- The header was updated to be consistent with recommendations
DEPRESSION SCREENING
- Adolescent depression screening begins routinely at 12 years of age (to be consistent with recommendations of the US Preventive Services Task Force [USPSTF]).

MATERNAL DEPRESSION SCREENING
- Screening for maternal depression at 1-, 2-, 4-, and 6-month visits has been added.
- Footnote 16 was added to read as follows: “Screening should occur per ‘Incorporating Recognition and Management of Perinatal and Postpartum Depression Into Pediatric Practice’ (http://pediatrics.aappublications.org/content/126/5/1032).”

NEWBORN BLOOD
- Timing and follow-up of the newborn blood screening recommendations have been delineated.
- Footnote 19 has been updated to read as follows: “Confirm initial screen was accomplished, verify results, and follow up, as appropriate. The Recommended Uniform Newborn Screening Panel https://www.hrsa.gov/advisory-committees/heritable-disorders/rusp/index.html, as determined by The Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children, and state newborn screening laws/regulations (http://genes-r-us.uthscsa.edu/sites/genes-r-us/files/nbsdisorders.pdf) establish the criteria for and coverage of newborn screening procedures and programs.”
- Footnote 20 has been added to read as follows: “Verify results as soon as possible, and follow up, as appropriate.”

NEWBORN BILIRUBIN
- Screening for bilirubin concentration at the newborn visit has been added.
- Footnote 21 has been added to read as follows: “Confirm initial screening was accomplished, verify results, and follow up, as appropriate. See ‘Hyperbilirubinemia in the Newborn Infant ≥35 Weeks’ Gestation: An Update with Clarifications’ (http://pediatrics.aappublications.org/content/124/4/1193).”

DYSLIPIDEMIA
- Screening for dyslipidemia has been updated to occur once between 9 and 11 years of age, and once between 17 and 21 years of age (to be consistent with guidelines of the National Heart, Lung, and Blood Institute).
SEXUALLY TRANSMITTED INFECTIONS

- Footnote 29 has been updated to read as follows: “Adolescents should be screened for sexually transmitted infections (STIs) per recommendations in the current edition of the AAP Red Book: Report of the Committee on Infectious Diseases.”

HIV

- A subheading has been added for the HIV universal recommendation to avoid confusion with STIs selective screening recommendation.
- Screening for HIV has been updated to occur once between 15 and 18 years of age (to be consistent with recommendations of the USPSTF).
- Footnote 30 has been added to read as follows: “Adolescents should be screened for HIV according to the USPSTF recommendations (http://www.uspreventiveservicestaskforce.org/uspstf/uspshivi.htm) once between the ages of 15 and 18, making every effort to preserve confidentiality of the adolescent. Those at increased risk of HIV infection, including those who are sexually active, participate in injection drug use, or are being tested for other STIs, should be tested for HIV and reassessed annually.”

ORAL HEALTH

- Assessing for a dental home has been updated to occur at the 12-month and 18-month through 6-year visits. A subheading has been added for fluoride supplementation, with a recommendation from the 6-month through 12-month and 18-month through 16-year visits.
- Footnote 32 has been updated to read as follows: “Assess whether the child has a dental home. If no dental home is identified, perform a risk assessment https://www.aap.org/en-us/Documents/oralhealth_RiskAssessmentTool.pdf and refer to a dental home. Recommend brushing with fluoride toothpaste in the proper dosage for age. See ‘Maintaining and Improving the Oral Health of Young Children’ (http://pediatrics.aappublications.org/content/134/6/1224).
- Footnote 33 has been updated to read as follows: “Perform a risk assessment (http://www2.aap.org/oralhealth/docs/RiskAssessmentTool.pdf). See ‘Maintaining and Improving the Oral Health of Young Children’ (http://pediatrics.aappublications.org/content/134/6/1224).”
- Footnote 35 has been added to read as follows: “If primary water source is deficient in fluoride, consider oral fluoride supplementation. See ‘Fluoride Use in Caries Prevention in the Primary Care Setting’ (http://pediatrics.aappublications.org/content/134/3/626).”
APPENDIX S

2018 Immunization Schedules – Summary of Changes

Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger, United States 2018

In October 2017, the Advisory Committee on Immunization Practices (ACIP) approved the 2018 immunization schedule for children and adolescents birth through 18 years, effective February 2018.
The schedule has been approved by the Centers for Disease Control and Prevention (CDC), the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), and the American College of Obstetricians and Gynecologists (ACOG).

The comprehensive summary of the ACIP recommended changes to the schedule can be found in the February 6, 2018 MMWR.

Changes to This Year’s Schedule for Children and Adolescents Aged 18 years and younger

General Schedule
• A table has been added outlining vaccine type, abbreviation, and brand names for vaccines discussed in the child/adolescent immunization schedule.
• The schedule footnotes are presented in a new simplified format. The goal was to remove unnecessary text while preserving all pertinent information and maintaining clarity. This was accomplished by a transition from complete sentences to bullets, removal of unnecessary or redundant language, and formatting changes.
• Manufacturing of MenHibrix (Hib-MenCy) vaccine has been discontinued in the United States and all available doses have expired. Therefore, mention of the vaccine has been removed from the schedule.

Medical Conditions
The medical indications figure (figure 3) changes include:
• The HIV column provides a reference providing additional information regarding HIV laboratory parameters and use of live vaccines.
• Within the pneumococcal row, stippling was added to heart disease/chronic lung disease, chronic liver disease, and diabetes columns to clarify that in some situations children with these conditions may be recommended to receive an additional dose of vaccine.

Hepatitis B (HepB) vaccine
• The Hepatitis B vaccine (HepB) footnote was revised to include information regarding vaccination of <2,000 gram infants born to HBsAg-negative mothers.

Influenza vaccine
• The influenza vaccine footnote has been updated to indicate that LAIV should not be used during the 2017–2018 influenza season. A reference link to the 2017-2018 season influenza recommendations has been added.
Measles, mumps and rubella (MMR) vaccine
- The measles, mumps, and rubella (MMR) footnote was updated to include guidance regarding the use of a 3rd dose of mumps-containing vaccine during a mumps outbreak.

Meningococcal vaccine
- The meningococcal vaccine footnote has been edited to create separate footnotes for MenACWY and MenB vaccines.

Polio vaccine
- The inactivated poliovirus rows of the catch-up schedule have been edited to clarify the catch-up recommendations for children 4 years of age and older.
- The poliovirus vaccine footnote was revised to include updated guidance for persons who received oral polio vaccine as part of their vaccination series.

Rotavirus vaccine
- The maximum ages for the first and last doses of the rotavirus series have been added to the rotavirus vaccine row of the catch-up schedule.

Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States 2018
In October 2017, ACIP approved the 2018 immunization schedule for adults age 19 or older, effective February 2018. The schedule has been approved by the Centers for Disease Control and Prevention (CDC), the American College of Physicians (ACP), the American Academy of Family Physicians (AAFP), the American College of Obstetricians and Gynecologists (ACOG), and the American College of Nurse-Midwives (ACNM). The comprehensive summary of the ACIP recommended changes to the schedule can be found in the February 6, 2018 MMWR.

Changes to This Year’s Schedule for Adults Aged 19 years or older

Tdap or Td vaccines
- “Td/Tdap” has been replaced by “Tdap or Td” on Figures 1 and 2 and the text in the indication bar has been revised to “1 dose Tdap, then Td booster every 10 years.”
APPENDIX S

MMR vaccine
- Administer 1 dose of MMR to adults who previously received ≤2 doses of mumps-containing vaccine and are identified by a public health authority to be at increased risk during a mumps outbreak.
- The text in the indication bar for Figure 1 for MMR has been changed to “1 or 2 doses depending on indication (if born in 1957 or later).”

Zoster vaccines
- Administer 2 doses of recombinant zoster vaccine (RZV) (Shingrix) 2–6 months apart to adults aged 50 years or older regardless of past episode of herpes zoster or receipt of zoster vaccine live (ZVL) (Zostavax).
- Administer 2 doses of RZV 2–6 months apart to adults who previously received ZVL at least 2 months after ZVL.
- For adults aged 60 years or older, administer either RZV or ZVL (RZV is preferred).
- “ZVL” has replaced the term “HZV” (herpes zoster vaccine) that was used in past adult immunization schedules to refer to the live zoster vaccine. A row for RZV was added above the row for ZVL and a dashed line was used to separate RZV and ZVL rows to denote that the 2 zoster vaccines are recommended for the same purpose.

HPV vaccine
- In Figure 1, the text in the indication bars for HPV vaccine for females and males has been revised to “2 or 3 doses depending on age at series initiation.”

MenACWY vaccine
- In figures 1 and 2, the text in the indication bar for MenACWY (serogroups A, C, W, and Y meningococcal vaccine) has been revised to “1 or 2 doses depending on indication, then booster every 5 years if risk remains.”
- MPSV4 (4-valent meningococcal polysaccharide vaccine) is no longer available and has been removed from the adult immunization schedule.
2019 Immunization Schedules Summary of Changes

Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger, United States 2019

At its October 2018 meeting, the Advisory Committee on Immunization Practices (ACIP)* voted to recommend approval of the Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger, United States, 2019. The 2019 child and adolescent immunization schedule summarizes ACIP recommendations, including several changes from the 2018 immunization schedule,† on the cover page, three tables, and notes found on the CDC immunization schedule website (https://www.cdc.gov/vaccines/schedules/index.html). This immunization schedule is recommended by ACIP and approved by the CDC Director, the American Academy of Pediatrics, the American Academy of Family Physicians, and the American College of Obstetricians and Gynecologists. Health care providers are advised to use the tables and the notes together.

For further guidance on the use of each vaccine, including contraindications and precautions, health care providers are referred to the respective ACIP vaccine recommendations at https://www.cdc.gov/vaccines/hcp/acip-recs/index.html. Changes in recommended use of vaccines can occur between annual updates to the child and adolescent immunization schedule. These changes, if made, are available at https://www.cdc.gov/vaccines/acip/recommendations.html.§ Printable versions of the 2019 child and adolescent immunization schedule and ordering instructions are available on the immunization schedule website.

The comprehensive summary of the ACIP recommended changes to the child and adolescent schedule can be found in the February 8, 2019 MMWR. https://www.cdc.gov/mmwr/volumes/68/wr/mm6805a4.htm

Vaccine Changes in the 2019 Immunization Schedule for Children and Adolescents

Vaccine changes in the 2019 immunization schedule for children and adolescents aged ≤18 years include new or revised ACIP recommendations for hepatitis A vaccine (HepA) (2), hepatitis B vaccine (Hep B) (3), influenza vaccine (4), and tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) (5), as well as clarification of the recommendations for inactivated poliovirus vaccines (IPV).

Changes Affecting Multiple Portions of the Schedule

The overall appearance of the 2019 child and adolescent schedule has been updated because of recommendations resulting from a recent evaluation of the child and adolescent immunization schedule. These changes have been applied to all portions of the immunization schedule, including the cover page, routine immunization schedule (Table 1), catch-up schedule (Table 2), medical indications for each vaccine (Table 3), and notes with details for each vaccine.
APPENDIX T

Cover Page. Changes to the cover page are as follows:

- Guidance on how to use the schedule was added to the top of the document.
- Live attenuated influenza vaccine (LAIV) was added to the vaccine table.
- A Helpful Information section, which includes links to the ACIP recommendations, the General Best Practice Guidelines for Immunization, and the Manual for the Surveillance of Vaccine-Preventable Diseases, has been added.

Table 1. Changes to Table 1 (previously known as Figure 1) are as follows:

- A separate row has been added for LAIV.
- A purple bar has been added to the Hepatitis A (HepA) row at age 6–11 months to represent use in infant travelers.
- Within the Tetanus, diphtheria, & acellular pertussis (Tdap: ≥7 yrs) row, the bar for persons aged 13–18 years has been split into a half green and half purple bar to represent catch-up vaccination and use in pregnant adolescents, respectively.

Table 2. Changes to Table 2 (previously known as Figure 2) are as follows:

- Minor changes to the order in which guidance is presented in the *Haemophilus influenzae* type b and Pneumococcal conjugate rows were made. The criteria under which no further doses are needed are now presented first, followed by recommendation for those for whom additional doses are indicated.

Table 3. Changes to Table 3 (previously known as Figure 3) are as follows:

- A new pink color has been added to the legend, which represents “Delay vaccination until after pregnancy if vaccine indicated.” This color is used in the pregnancy column for human papillomavirus vaccine.
- The Contraindicated and Precaution for vaccination boxes in the legend have been defined with narrative text.
- A row for LAIV has been added.
- The Pregnancy cell in the meningococcal B vaccine row has been changed to the orange Precaution for vaccination color.

Notes. The notes (previously known as footnotes) are presented in alphabetical order rather than linked by numerical superscripts as in previous years. Edits have been made throughout the Notes section to harmonize language between the child and adolescent schedule and the adult immunization schedule, where possible. In addition, the following content changes were made:

**Hepatitis A vaccine**

- The HepA note was revised to include information regarding the use of combined HepA-HepB vaccine in persons aged ≥18 years. A section for international travel has been added with recommendations for vaccination of travelers aged 6–11 months and unvaccinated travelers aged ≥12 months. Homelessness also has been added as an indication for HepA vaccination.
Hepatitis B vaccine
- The HepB note was revised to include information regarding the use of CpG-adjuvanted HepB vaccine and combination HepA-HepB vaccine in persons aged $\geq$18 years.

Polio vaccine
- Within the IPV note, a bullet has been added regarding the use of combination vaccines that contain IPV.

Influenza vaccine
- The Influenza vaccines note has been updated to indicate that LAIV can be used during the 2018–19 influenza season. A Special Situations section has been added with information regarding vaccination of persons with a history of egg allergy and circumstances under which LAIV use is not recommended.

Mumps and Meningococcal Outbreaks
- During mumps and meningococcal disease outbreaks, the Additional Information section at the beginning of the notes directs providers to their state or local health department for information regarding vaccination during an outbreak. Therefore, language regarding the use of measles, mumps, and rubella (MMR) vaccine in the setting of a mumps outbreak or the use of meningococcal (groups A, C, W-135, and Y) conjugate (MenACWY) and meningococcal group B (MenB) vaccines in the setting of meningococcal disease outbreaks has been removed from the MMR and meningococcal vaccine notes.

Tdap vaccine
- The Tdap note has been updated to indicate that those persons who received a dose of Tdap or diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) at age 7–10 years inadvertently or as part of the catch-up series should still receive the routine dose of Tdap at age 11–12 years. A link to information regarding use of Tdap/tetanus and diphtheria toxoids (Td) for wound prophylaxis also has been added.

General Schedule
- The schedule cover page has been simplified, providing a shortened title, basic instructions on how to use the schedule and lists routinely recommended vaccines and their standardized abbreviations and trade names.
- Web links are provided for downloading the CDC Vaccine Schedules App, reference materials on vaccine-preventable disease surveillance, reporting postvaccination adverse event to the Vaccine Adverse Event Reporting System, traveler’s vaccines and Vaccine Information Statements (VISs).
- The table providing recommended immunizations by medical condition and other indications distinguishes between precautions, delay and contraindications:
  - Precaution – vaccine might be indicated if benefit of protection outweighs risk of adverse reaction is highlighted in orange
APPENDIX T

- Delay in vaccination – vaccine that should not be given during pregnancy is highlighted in pink
- Contraindicated or use not recommended – vaccine should not be administered because of risk factors for serious adverse reaction is highlighted in red
- The notes in the schedule have been reordered alphabetically by vaccine, providing concise information describing vaccine indications, dosing frequencies and intervals, and other published ACIP recommendations.

**Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States 2019**

In October 2018, the ACIP voted to recommend approval of the Recommended Immunization Schedule for Adults, Aged 19 Years or Older, United States, 2019. The 2019 adult immunization schedule, available at [https://www.cdc.gov/vaccines/schedules](https://www.cdc.gov/vaccines/schedules), summarizes ACIP recommendations in two tables and accompanying notes. The 2019 adult immunization schedule has been approved by the CDC Director, the American College of Physicians, the American Academy of Family Physicians, the American College of Obstetricians and Gynecologists, and the American College of Nurse-Midwives.

For further guidance on the use of vaccines in the adult immunization schedule, health care providers are referred to the respective ACIP vaccine recommendations at [https://www.cdc.gov/vaccines/hcp/acip-recs/index.html](https://www.cdc.gov/vaccines/hcp/acip-recs/index.html). Changes in recommended use of vaccines can occur between annual updates to the adult immunization schedule. These changes, if made, are available at [https://www.cdc.gov/vaccines/acip/recommendations.html](https://www.cdc.gov/vaccines/acip/recommendations.html). Printable versions of the 2019 adult immunization schedule and instructions for ordering printed copies are available at [https://www.cdc.gov/vaccines/schedules/hcp/adult.html#note](https://www.cdc.gov/vaccines/schedules/hcp/adult.html#note).

The comprehensive summary of the ACIP recommended changes to the adult immunization schedule can be found in the February 8, 2019 *MMWR*, [https://www.cdc.gov/mmwr/volumes/68/wr/mm6805a5.htm](https://www.cdc.gov/mmwr/volumes/68/wr/mm6805a5.htm).

**Changes in the 2019 Adult Immunization Schedule: Updated ACIP Recommendations**

**Influenza Vaccination.**
- In June 2018, ACIP updated recommendations on the use of live attenuated influenza vaccine (LAIV) (FluMist Quadrivalent, AstraZeneca) after two influenza seasons (2016–17 and 2017–18), during which use of LAIV was not recommended in the United States (4). For the 2018–19 season, any licensed influenza vaccine that is recommended for age and health status of the patient may be used. LAIV is an option for adults aged ≤49 years, except those who 1) have immunocompromising conditions, including human immunodeficiency virus (HIV) infection; 2) have anatomic or functional asplenia; 3) are pregnant; 4) have close contact with or are caregivers of severely immunocompromised persons in a protected environment; 5) have received influenza antiviral medications in the previous 48 hours; or 6) have a cerebrospinal fluid leak or a cochlear implant. Adults with a history of Guillain-Barré syndrome
within 6 weeks of receipt of a previous dose of influenza vaccine generally should not receive influenza vaccine.

Hepatitis B Vaccination.
- In February 2018, ACIP recommended use of the new single-antigen recombinant hepatitis B vaccine with a novel cytosine-phosphate-guanine 1018 oligodeoxynucleotide adjuvant (Heplisav-B, Dynavax) for prevention of hepatitis B virus infection in adults aged ≥18 years (5). Approved by the Food and Drug Administration in November 2017, Heplisav-B is routinely administered in 2 doses given ≥4 weeks apart. It can be used as a substitute in a 3-dose series with a different hepatitis B vaccine, but a valid 2-dose series requires 2 doses of Heplisav-B with ≥4 weeks between doses. When feasible, a vaccine from the same manufacturer should be used to complete the vaccination series. However, vaccination should not be deferred if the previously administered hepatitis B vaccine is unknown or if a vaccine from the same manufacturer is not available. A pregnant woman with an indication for hepatitis B vaccination should not receive Heplisav-B because no safety data are available on its use during pregnancy.

Hepatitis A Vaccination.
- In October 2018, ACIP recommended adding homelessness as an indication for routine hepatitis A vaccination with a 2-dose series of single-antigen hepatitis A vaccine (Havrix, GlaxoSmithKline; Vaqta, Merck) or a 3-dose series of combination hepatitis A and hepatitis B vaccine (Twinrix, GlaxoSmithKline) (6). Other populations at increased risk for hepatitis A virus infection or severe hepatitis A disease and recommended to receive vaccination include 1) persons with chronic liver disease or clotting factor disorders; 2) travelers in countries with high or intermediate hepatitis A endemicity; 3) persons with close personal contact with an international adoptee in the first 60 days after arrival from a country with high or endemic hepatitis A prevalence; 4) men who have sex with men; 5) persons who use injection or noninjection drugs; and 6) persons who work with hepatitis A virus in a laboratory or with nonhuman primates infected with the virus (7–9). In addition, any person who is not at risk for hepatitis A virus infection but wants protection against it may be vaccinated.

Changes in the 2019 Adult Immunization Schedule: Revised Content, Format, and Graphics

Cover. Recommended Adult Immunization Schedule. The cover page of the 2019 adult immunization schedule has been simplified and contains the following changes:
- Features a shortened title, provides basic instructions on how to use the adult immunization schedule to systematically identify vaccination needs of adults, and lists routinely recommended vaccines and their standardized abbreviations and trade names.
- Includes web links through which health care providers can download the CDC Vaccine Schedules App and access reference materials on surveillance of vaccine-preventable diseases, including case identification and disease outbreak response.
- Simplifies instructions for reporting suspected cases of reportable vaccine-preventable diseases to local or state health departments and for reporting postvaccination adverse
events and serious adverse events to the Vaccine Adverse Event Reporting System; information on the Vaccine Injury Compensation Program; and links to other resources, such as Vaccine Information Statements and recommended vaccines for travelers.

Table 1. Recommended Adult Immunization Schedule by Age Group. Table 1 (previously known as Figure 1) describes routine and catch-up vaccination recommendations for adults by age. ACIP recommends routine annual influenza vaccination for all persons aged ≥6 months who do not have contraindications; 1 annual dose of IIV, RIV, or LAIV that is appropriate for age and health status of the vaccine recipient is recommended. Table 1 contains the following change:

- Lists LAIV separately from inactivated influenza vaccine (IIV) (many branded products) and recombinant influenza vaccine (RIV) (Flublok Quadrivalent, Sanofi Pasteur) for adults aged ≤49 years.

Table 2. Recommended Adult Immunization Schedule by Medical Condition and Other Indications. Table 2 (previously known as Figure 2) describes indications for which vaccines, if not previously administered, should be administered unless noted otherwise. Table 2 contains the following changes:

- Lists LAIV separately from IIV and RIV.
- Contains two new display colors for some vaccines: orange and pink. Orange indicates “Precaution—vaccine might be indicated if benefit of protection outweighs risk of adverse reaction”; pink indicates “Delay vaccination until after pregnancy if vaccine is indicated.”
- Designates the use of LAIV in pregnant women and immunocompromised adults, including those with HIV infection, as “Contraindicated—vaccine should not be administered because of risk for serious adverse reaction” (red). The risk for associated adverse effects from the use of LAIV in adults with functional or anatomic asplenia or complement deficiencies is not known; however, the use of LAIV in this population has also been designated as “Contraindicated” (red). For adults with end-stage renal disease, heart or lung disease, chronic liver disease, or diabetes, the use of LAIV has been given the “Precaution” (orange) designation.
- Designates the use of serogroup B meningococcal vaccine (MenB) (Bexsero, GlaxoSmithKline; Trumenba, Pfizer) in pregnant women as “Precaution” (orange). MenB should be deferred in pregnant women unless they are at increased risk for serogroup B meningococcal disease and the benefits of vaccination are considered to outweigh potential risks (10).
- Maintains the use of meningococcal serogroups A, C, W-135, and Y conjugate vaccine (MenACWY) (Menactra, Sanofi Pasteur; Menveo, GlaxoSmithKline) in pregnant women as “Recommended vaccination for adults with an additional risk factor or another indication” (purple). In contrast to the recommendation to defer administration of MenB vaccine to pregnant women, pregnancy should not preclude the use of MenACWY vaccine if it is otherwise indicated (11).
• Designates the use of human papillomavirus (HPV) vaccine (Gardasil 9, Merck) and recombinant zoster vaccine (RZV) (Shingrix, GlaxoSmithKline) in pregnant women as “Delay until after pregnancy” (pink). The use of HPV vaccine is not recommended for pregnant women (12,13). Pregnant women should consider delaying receipt of RZV, if it is indicated, until after pregnancy (14). Live attenuated zoster vaccine (Zostavax, Merck) is contraindicated during pregnancy (15).

Notes. Recommended Adult Immunization Schedule. Each routinely recommended vaccine for adults in Tables 1 and 2 is accompanied by notes (previously known as footnotes), designed to provide additional information about routine vaccination and recommendations in special situations. The notes contain the following format changes:
• Lists vaccination sections alphabetically (superscript footnote numbers in the former figures [now tables] have been removed).
• Contains concise information describing vaccine indications, dosing frequencies and intervals, and other published ACIP recommendations for each section.
• Includes new recommendations on influenza, hepatitis B, and hepatitis A vaccines in their respective sections.
• Removes recommendations for vaccination in outbreak settings in measles, mumps, and rubella, and meningococcal vaccination notes.

Additional Information

The Recommended Adult Immunization Schedule, United States, 2019, is available at https://www.cdc.gov/vaccines/schedules/hcp/adult.html and in the Annals of Internal Medicine (16). The full ACIP recommendations for each vaccine are also available at https://www.cdc.gov/vaccines/hcp/acip-recs/index.html. All vaccines identified in Tables 1 and 2 (except zoster vaccines) also appear in the Recommended Immunization Schedule for Children and Adolescents, United States, 2019 (3). The notes for vaccines that appear in both the adult immunization schedule and the child and adolescent immunization schedule have been harmonized to the greatest extent possible.